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Malaria
Malaria is a major global health problem with 219 million new cases and 435,000 deaths 
Although an overall decrease in malaria mortality and morbidity has been observed in the 
between 2015-2017 (1). The countries with the highest burden in Africa even had an 
increase in malaria cases in 2017 compared to 2016 (1) (Figure 1). Contributing to the 
increase in incidence are the emergence of drugs resistant parasites (2, 3) and insecticide 
resistant mosquitoes (4-6). 
Figure 1 – Estimated malaria cases (World Malaria Report 2018)
Malaria is caused by Plasmodium parasites that are transmitted to the human host by 
a bite of an infected Anopheles mosquito. The majority of injected sporozoites migrate 
through the skin, enter the blood circulation (7) and travel to the liver. Subsequently, 
the sporozoites invade hepatocytes (liver cells) (8, 9) and start to replicate, resulting 
in thousands of merozoites (10). Depending on the Plasmodium species, the infected 
hepatocytes, called liver schizonts, rupture 6 to 30 days after infection. The merozoites 
are then released into the blood stream and invade erythrocytes (11). In the erythrocytes 
the merozoites mature as part of an asexual life cycle into trophozoites and subsequently 
into schizonts that comprise new merozoites (12). The infected erythrocytes rupture 
after infection (13), depending on the Plasmodium species this may take 24 hours for P. 
knowlesi, 48 hours for P. falciparum, P. ovale and P. vivax and 72 hours for P. malariae. 
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During the erythrocyte rupture the newly formed merozoites are released and can infect 
new erythrocytes. 
A small percentage of the asexual parasites develop into a sexual form, gametocytes (14). If 
these sexual stages are taken up by uninfected Anopheles mosquitoes, the male and female 
gametes can fuse to form zygotes (15). These zygotes become motile, invade the midgut 
wall of the mosquito and develop in oocysts. As the oocysts grow and rupture, sporozoites 
are released and migrate to the salivary glands of the mosquito (15). The mosquitoes then 
become infective and can infect new human individuals (Figure 2). 
Figure 2 – Plasmodium spp. life cycle
Figure reprinted from reference (16) with permission from Springer Nature. 
Of all Plasmodium species that can infect humans, P. falciparum causes the most 
severe disease. P. falciparum infected erythrocytes adhere to the vascular endothelium 
(sequestration) (17, 18) and to uninfected erythrocytes (rosetting) (19). In contrast to 
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infection with P. falciparum, this occurs only to a very limited extent after infection with one 
of the other Plasmodium species (P. vivax; P. ovale; P. malariae; P. knowlesi). Sequestration 
decline in oxygen delivery to the organs, acidosis and multi-organ failure (20). Whereas 
the liver stage is asymptomatic, patients become symptomatic during the blood stage 
infection, experiencing symptoms such as fever, headache and muscle pain. The clinical 
presentation of malaria depends, at least in part, on pre-existent immunity. Malaria 
response and have severe clinical symptoms with a high morbidity and mortality rate 
whereas individuals that experienced previous malaria episodes have a tendency to have 
malaria (21, 23), as they have not developed an immunological memory response against 
Plasmodium parasites. Only after repeated exposure to Plasmodium parasites, clinical 
immunity (parasitaemia without symptoms) will develop (24). This clinical immunity 
wanes quickly in the absence of ongoing exposure to Plasmodium parasites (25). If timely 
the diagnosis of malaria in patients in endemic, low-income countries is often delayed 
(27).
To compare P. falciparum infected patients for research purposes, the World Health 
Organization has determined disease severity criteria, which are now also used in clinical 
P. falciparum parasitaemia with 
one or more of the following criteria; impaired consciousness, acidosis, hypoglycemia, 
renal impairment, anemia, jaundice, pulmonary edema, bleeding shock or parasitaemia 
treated, the mortality among patients with severe malaria is high (28, 29). Treatment 
consists of anti-malarial medication and supportive care in case of organ involvement 
(20, 26). However, due to the increase in resistance to anti-malarial medication, especially 
to the most often prescribed drug, artesunate (2, 3), prevention of malaria is becoming 
now, vaccines have not resulted in sterile immunity (absence of parasitaemia) and further 
malaria infection and vaccination is crucial for the development of improved immunization 
Human Malaria infections (CHMI) model has been developed to study malaria disease in 
a homogenous group of malaria naïve volunteers (30, 31). 
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Controlled human malaria infection models
CHMI studies conducted in malaria naïve volunteers are a powerful tool to examine the 
selected from all candidate vaccines. These studies, with a relatively small sample size, may 
reduce failing large trials in malaria endemic areas and accelerate vaccine development 
(30). In addition to testing of vaccines, CHMI studies can be used to answer multiple 
research questions on e.g. acquisition of immunity, the host response after infection and 
on the pathogenesis of malaria. 
During a CHMI, a small group of healthy malaria naive participants is deliberately infected 
with P. falciparum parasites by either bites of infected mosquitoes or by an intravenous 
inoculum of P. falciparum infected erythrocytes or sporozoites. After infection volunteers 
are intensely monitored and immediately treated with anti-malarial therapy when a 
a highly controlled setting, enable researchers to control infection rates, study distinct 
aspects of malaria and elucidate the mechanisms of protective immunity. In general, 
CHMIs have been conducted using standardized protocols and so far over 3000 healthy 
volunteers have been infected and treated worldwide. The data on parasitaemia during 
infection show that the disease course can be predicted with only a very limited variation in 
prepatent period between study participants (30). Additionally, protocols can be adjusted, 
depending on the study endpoints. To test candidate malaria vaccines, CHMI participants 
the vaccine is considered to be safe, participants can be immunized by multiple doses and 
subsequently challenged with P. falciparum
candidate vaccine. Many candidate vaccines were proposed and tested in the last years, 
but none of those could establish durable protection (32).
Need for a malaria vaccine 
Malaria mortality showed a strong decrease after the year 2000, which has been attributed 
to increased access to antimalarial therapy and prevention of malaria transmission by 
bed net distribution in malaria endemic areas (33, 34), due to increased funding for 
malaria control interventions after the Declaration of the Millennium Development 
Goals. However, this multitude of still ongoing intervention programs, has not resulted 
in a lasting (or further) decrease in malaria prevalence. For many viral diseases (e.g. 
measles), only vaccines proved to be an intervention that achieved a durable reduction 
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of malaria has great clinical impact as asymptomatic malaria increases the susceptibility 
to other infectious diseases (39-41). Furthermore, the eradication of smallpox (42) is a 
clear example that immunization of populations can stop spread of an infectious disease. 
Additionally, vaccination can prevent disease in the individual patient. Development of a 
malaria vaccine has been a research topic for decades (43, 44). An ideal malaria vaccine 
will not only result in personal protection, but also reduces disease on the population 
level. The asymptomatic form of malaria functions as a reservoir for malaria transmission, 
enabling the parasites to spread in the population (45, 46). 
Challenges to overcome
Developing a malaria vaccine has been found to be extremely challenging due to the 
complex multi-stage life cycle of Plasmodium spp. and the interaction of the parasites 
proteins are expressed and therefore candidate vaccines have been grouped according to 
the parasite stage and vaccine targets: 
1. Pre-erythrocytic stage vaccines which elicit an immune response that is targeted to 
sporozoites and the liver stages. 
2. Blood-stage vaccines are targeted to the asexual blood stages; after merozoites are 
released from hepatocytes. 
3. Transmission-blocking vaccines which prevent transmission of sexual parasites from 
humans to mosquitoes (48). 
In addition to the complex life cycle, other complicating factors for vaccine development 
P. falciparum strains and antigenic variation (alteration of surface 
membrane antigens during infection), which enables the parasite to evade the human 
immune response thereby increasing its survival (49-51). The ideal vaccine will expose 
the immune system to multiple conserved antigens expressed during the asymptomatic 
pre-erythrocytic stage, resulting in broad and fully protective immune response which 
prevents the symptomatic blood-stage. However, humans that are exposed to multiple 
antigens during a natural malaria infection, can still get re-infected with Plasmodium spp. 
parasites. Therefore, a malaria vaccine-induced immune response should be stronger, 
areas acquisition of clinical immunity (asymptomatic parasitaemia) develops slowly and 
wanes quickly in the absence of repeated exposure to P. falciparum parasites (25) whereas 
vaccine induced protection should be lasting. Moreover, the lack of sterile protection 
(absence of blood parasitaemia) after a natural infection, due to the induction of immune-
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immune response (54, 55). The incomplete understanding of the host response after a 
natural infection and acquisition of lasting immunity is another hurdle for malaria vaccine 
development. 
Malaria vaccines
The ideal vaccine results in durable sterile protection, and is easy to store and to administer, 
the RTS,S vaccine is the most well-known (55). This pre-erythrocytic subunit vaccine is 
based on the P. falciparum sporozoite surface protein ‘circumsporozoite protein’ (CSP) 
which is fused to hepatitis B virus surface antigen virus-like particles. Although this 
vaccine elicits an immune response that can protect from clinical malaria episodes in 
immunized individuals in endemic areas, lasting sterile protection was not induced (56, 
57). Development of a vaccine that induces sterile protection is favorable as subclinical 
as it remains a competent reservoir for transmission (46). Currently, only studies in 
which healthy volunteers were immunized by P. falciparum while receiving malaria 
prophylaxis reported sterile protection after a homologous challenge (challenge with the 
same strain as used for immunization) (58, 59). These studies showed that induction of 
sterile immunity is possible and that the immune response after development of parasites 
in the liver is essential. However, the strategy of immunization while receiving malaria 
prophylaxis is not feasible and safe on population level in endemic countries. 
Genetically attenuated parasites (GAP)
A promising novel immunization strategy is the administration of genetically attenuated 
development, allows development of the parasite in the liver, but program the parasite to 
die before or during the early blood-stage (60-62). With this approach the immune system 
is exposed to multiple parasite antigens without a symptomatic and pathogenic blood-
stage infection. However, development of a genetically attenuated parasite (GAP) vaccine 
is still in an early stage: while sterile protection in rodent models was shown (63, 64), 
breakthrough infections were observed in a phase 1 trial in humans (65). Multiple newly 
developed GAP vaccines are currently being tested. 
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Transmission blocking vaccines
immunity (66). The interest for this strategy is increasing (67, 68). The transmission of 
parasites from humans to mosquitoes can be interrupted by antibodies targeting proteins 
present on sexual parasite stages or proteins that are expressed by the parasite in the 
midgut of the mosquito, thereby preventing parasite maturation. Vaccines that induce anti-
Pfs25 (Pfs25 is a highly important female gametocyte antigen) have been tested in a CHMI 
in a phase 1 trial focussing on safety, but resulted in systemic adverse events in a subset 
of volunteers possibly due to the adjuvants used (69, 70). Pfs28, Pfs230 and Pfs48/45 
also are under investigation for their transmission blocking capacity (71). However, 
setting by adding antibodies to the infected blood meals before mosquito feeding (72). 
The infection rate of these mosquitoes is than compared to mosquitoes that were fed 
on infected blood without antibodies. To establish a more representative transmission-
blocking model, a CHMI model is currently being developed. In this model, mosquitoes are 
infected by healthy infected volunteers after direct skin feeding (73, 74). However, higher 
transmission rates of mosquitoes are needed to test transmission blocking interventions 
in this model. 
CHMI participants resp
infection 
Although the CHMI studies are proven to be save and well tolerated (75), CHMI participants 
experience malaria symptoms after infection, such as fever, muscle pain, headache, nausea 
and fatigue. Whereas in some of the study participants these symptoms are mild, others 
are also observed in standard laboratory parameters: a decrease in thrombocyte count, 
which is a common manifestation during malaria disease, is not observed in all CHMI 
participants (76, 77), nor are liver function abnormalities (73) and pathological processes 
like endothelial cell activation and coagulation (78).
Add-on studies in a CHMI cohort showed that onset of malaria symptoms, such as fever 
(82) and enhances the phagocytosis of merozoites and infected red blood cells (83), the 
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upregulation of MHC class I and II (84) and in the induction of cellular memory responses 
upregulation in only a subset of CHMI participants is not yet known. To counteract the 
only in a subset of CHMI participants (80). Thus, the heterogeneity in immune response 
between the host immune responses to a P. falciparum infection in persons that previously 
have not been infected with P. falciparum.
Consequences and importance of understanding the 
heterogeneity in host response
clinical presentation is of importance for several reasons. First, the initial immune 
after immunization in host response between CHMI participants in relation to study 
outcome may give further insight in which cytokines and cellular immune responses are 
the etiology of the heterogeneous immune response in a homogeneous CHMI study group 
is needed for further improvement of malaria vaccines. In addition, this knowledge on 
the early host immune response might lead to the development of immune-modulating 
symptoms, may identify risk factors for the development of severe malaria. 
Aims and outline of the thesis
The work described in this thesis can be grouped into two sections with the following 
aims: i. testing a novel immunization strategy for malaria vaccination and optimizing 
the current CHMI transmission model in order to test transmission blocking vaccines, ii. 
immune response after a P. falciparum infection.
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Part I: Clinical malaria vaccine development
Chapter 2 
a genetically attenuated parasite (GAP) is tested for safety and protective immunity. The 
Plasmodium berghei is considered a safe immunization as it 
may infect human liver cells, but cannot replicate in human erythrocytes. The engineered 
GAP contain the highly immunogenic CSP-protein of P. falciparum. In Chapter 3 the CHMI 
model is optimized for testing transmission blocking interventions that interrupt the 
transmission of P. falciparum parasites from humans to mosquitoes. 
Part II: Heterogeneity in host response after Plasmodium spp. infection 
In Chapter 4
clinical malaria in endemic areas is reviewed. Recommendations are made for parameters 
that can predict the host immune response and are frequently proposed as biomarkers and 
therapeutic targets during malaria. In Chapter 5 we compare liver function abnormalities 
during malaria between clinical patients and CHMI participants. In addition, we correlate 
Chapter 6, pro- and anti-
in Chapter 7 the activity of immune cells at baseline is investigated by determination of 
thesis and further perspectives are summarized and discussed in Chapter 8. 
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Abstract
Background  
Successful vaccines have been developed using a non-pathogenic counterpart of the 
causative micro-organism of choice. The non-pathogenicity of the rodent Plasmodium 
berghei (Pb) parasite in humans prompted us to evaluate its potential as a platform 
for vaccination against human infection by P. falciparum (Pf). We hypothesized that 
the genetic insertion of the leading protein target for clinical development of a malaria 
vaccine, Pf circumsporozoite protein (CSP), in its natural pre-erythrocytic environment, 
would enhance Pb’s capacity to induce protective immunity against Pf infection. 
Methods  
Hence, we recently generated a transgenic Pb sporozoite immunization platform expressing 
PfCSP (PbVac), and we now report the clinical evaluation of its biological activity against 
Controlled Human Malaria Infection (CHMI). 
Results 
PbVac is safe and well-tolerated, when administered 
by a total of ~300 Pb
in patency (2.2 days, p= 0.03) and decreased parasite density were observed after 
immunization corresponding to an estimated 95% reduction in Pf liver parasite burden 
p=0.010]. PbVac elicits dose-dependent cross-species 
cellular immune responses, as well as functional PfCSP-dependent antibody responses 
Pf sporozoite invasion of liver cells. 
Conclusion 
This translational research study demonstrates that PbVac immunization elicits a 
Pf parasite, and 
establishes the clinical validation of a new paradigm in malaria vaccination.
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Introduction
Malaria, a disease caused by Plasmodium (P.) parasites, remains a severe public health 
burden. Despite tremendous progress made over the last decade as a result of scaled-up 
progress has slowed down over recent years. Malaria still caused ~435.000 deaths in 2017 
(1). Besides its direct implications on human health, malaria is a substantial contributor 
most important tools for prevention and potential eradication of malaria. The clinical 
(2). Most vaccine candidates so far have shown modest protection or even failed due 
to the complex biology of malaria parasites and required immune responses (3). The 
circumsporozoite protein (CSP) of P. falciparum (Pf), the predominant antigen on the 
surface of sporozoites, is currently the leading protein target for clinical development 
of pre-erythrocytic subunit malaria vaccines. Encouraging, but moderate, protection has 
been obtained with the PfCSP-based RTS,S/AS01e (RTS,S) vaccine (4, 5). RTS,S has been 
associated with up to 87 percent protection in CHMI and delays patency in non-protected 
volunteers (6); further, it reduces the number of cases of malaria by 39 and severe malaria 
against malaria when used in combination with other malaria control interventions, and 
is currently undergoing pilot implementation in various African countries. However, it is 
A promising alternative approach are whole-parasite vaccine strategies which are based 
on attenuated Pf sporozoites, However, these novel strategies are still in relatively early 
during Controlled Human Malaria Infections (CHMI) in malaria-naïve adults (10, 11). 
not heterologous (18), protection against Pf infection was also achieved by immunization 
using a combination of chemoprophylaxis and sporozoites (CPS). More recently, the 
evaluation of novel cross-strain or cross-species approaches that might provide protection 
against genetically diverse human Plasmodium strains.
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The concept of cross-species vaccination relies on immunization with the non-pathogenic 
counterpart of the causative micro-organism of disease. The origins of this concept are 
usually attributed to Sir Edward Jenner, who is claimed to have pioneered the use of a 
bovine poxvirus to prevent smallpox (20), although Jenner’s role in this discovery is the 
matter of some controversy (21). Nevertheless, the idea of cross-species vaccination has 
Ankara (MVA) virus and other poxviruses against smallpox (reviewed in (22), the bovine 
bacillus Calmette–Guérin (BCG) vaccine against human tuberculosis (reviewed in (23)), 
or the selection of rhesus and bovine rotavirus strains to create human rotavirus vaccines 
Plasmodium species has 
been reported in multiple animal studies (25-30), and in clinical studies carried out in the 
last century as part of an experimental neurosyphilis treatment (31, 32). Live attenuated 
sporozoite-based cross-species immunity is thought to be dependent on both cellular- 
and antibody-based responses (30). Experimental evidence indicates that Pf sporozoites 
can protect mice from a P. berghei (Pb) infection (28), and inoculations of P. malariae in 
humans reduce parasitaemia and symptoms of a subsequent Pf infection (31, 32). 
While the expression of correctly folded Pf proteins in heterologous systems can be 
challenging, Pb parasites have recently emerged as an alternative solution for their 
transmission-blocking candidate antigen Pfs48/45 (33, 34). Thus, we hypothesized 
that PfCSP’s protective ability against Pf could be qualitatively enhanced compared to 
recombinant subunit CSP vaccine candidates, through its expression in a more native-
like conformation, and in its natural pre-erythrocytic environment. This, coupled with 
Plasmodium species, and the 
non-pathogenic nature of Pb parasites (35), prompted the generation of a transgenic Pb 
sporozoite expressing PfCSP (PbVac). Pre-clinical studies established the proof-of-principle 
of PbVac immunization through the validation of an array of core premises, including 
the demonstration of (i) its ability to infect and develop inside human liver cells; (ii) its 
inability to develop in human red blood cells (RBCs), (iii) its high cellular cross-species 
immunogenicity; and (iv) its ability to induce functional antibodies that block infection 
of human hepatocytes by Pf sporozoites (35). Additional pre-clinical demonstration of 
PbVac’s safety for human use paved the way to the evaluation of this vaccine candidate in 
a clinical setting (36).
of Pb
against Pf CHMI. We showed that PbVac is safe and well-tolerated, and induces cross-
species cellular immune responses and functional PfCSP-dependent antibody responses, 
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Pf sporozoite invasion of liver cells. Sterile protection against 
Pf
PbVac and establish the clinical validation of a new approach to malaria vaccination. 
Materials and Methods
Study design
This study was a multicenter Phase I/IIa open label, dose escalation trial in malaria-naïve 
healthy participants to assess safety and tolerability of PbVac (Phase 1) and to determine the 
PbVac against CHMI (Phase 2). The study protocol 
was approved by the Dutch Central Committee on Research Involving Human Subjects 
(CCMO, NL60019.091.16), the Western Institutional Review Board (WIRB, 20170356), and 
Pb
to the Radboud University Medical Centre (IM-MV 15-010), Erasmus Medical Centre (IM-
MV 16-008) and Harbour Hospital (IM-MV 16-010). The trial was conducted according to 
the principles outlined in the Declaration of Helsinki and Good Clinical Practice standards, 
In Phase 1, eighteen participants were divided in 3 groups and exposed to bites of 5 (n=3), 
25 (n=3) or 75 (n=12) PbVac-infected mosquitoes. Study subjects of all groups were 
followed once daily on an outpatient basis from day 1 to 10 and every other day on day 12 
to 20 after exposure. During the visits, blood was drawn for routine haematological and 
biochemical analysis, peripheral Giemsa-stained thick blood smears, and retrospective 
real-time quantitative polymerase chain reaction (Pb18S qPCR) analysis. Signs and 
symptoms were recorded by a physician and graded as follows: grade 1 (no interference 
with daily activities), grade 2 (interferes with normal activity) or grade 3 (prevents 
normal activity). Participants of group 1 and 2 were treated with a curative regimen of 
atovaquone/proguanil (Malarone®, GlaxoSmithKline) on day 28, and received an end 
of study visit on day 100 after immunization. Participants of group 3 received three 
additional immunizations with 75 PbVac-infected mosquitoes after Phase 1 at four, four, 
and eight weeks intervals (Phase 2). Three weeks after the last immunization all twelve 
immunized participants, including six infectivity controls, were subjected to a standard 
CHMI with 5 P. falciparum (strain NF54)-infected mosquito bites (37). All participants 
were monitored once daily on an outpatient basis from day 6 to 21 for symptoms and 
signs of malaria, and blood was drawn for routine laboratory tests and for Pf18S qPCR 
analysis, as previously described (38). Participants were treated with a curative regimen 
of atovaquone/proguanil (Malarone®, GlaxoSmithKline) after a single positive qPCR 
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Trial Protocol, included as Supplementary Information.
Study participants and eligibility criteria
All 57 volunteers that underwent screening signed an informed consent form after 
the nature and possible consequences of the studies have been explained. Four of the 
volunteers included withdrew their informed consent because of change of job and 
relocation from the area of the study center and, therefore, 4 back-up volunteers were 
enrolled in the study. A total of 33 participants were excluded after screening. Twenty-
four healthy malaria-naïve males and non-pregnant females (aged 18 to 35 years) were 
recruited at the Harbour Hospital, Rotterdam, after signing informed consent. Extensive 
screening was performed before inclusion in the Erasmus Medical Centre, Rotterdam, 
as previously described (39). The complete screening procedures, including the list of 
inclusion and exclusion criteria, can be found in the clinical trial protocol document, as 
Sample collections
Blood collections for separation and cryopreservation of plasma and peripheral blood 
mononuclear cells (PBMCs) were performed at the beginning of the trial and the day 
before each immunization or CHMI using sodium citrate BD Vacutainer® Mononuclear 
Cell Preparation Tubes (CPT). Further details are provided in the Clinical Trial Protocol, 
included as Supplementary Information.
Objectives and end point measures
The primary objectives of the study were to assess safety and tolerability of PbVac and to 
PbVac immunization against CHMI. The endpoints 
were determined by frequency and magnitude of adverse events, as well as by the presence 
of parasitemia after exposure to PbVac as assessed by thick blood smear. The primary 
endpoint of Phase 2 was to determine the time to parasitemia after CHMI as detected 
by 18S qPCR. Secondary endpoints were to determine the immunogenicity of PbVac as 
(IFA), as well as the composition and function of immune responses after exposure to 
Pb
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Production and administration of PbVac
The generation and characterization of Pb
sporozoites of rodent P. berghei parasites (Pb) expressing PfCSP has been previously 
a Pfcs expression cassette was generated using the ‘gene insertion/marker out’ (GIMO) 
technology. Correct integration of the construct into the genome of transgenic parasites 
(PFG)-separated chromosomes. 
PbVac parasite detection by quantitative PCR
Retrospective PbVac parasite detection on whole blood samples was performed by the 
use of a qPCR with P. berghei
standard curve consisting of ten-fold serial dilutions from 106 to 1 PbVac sporozoite was 
included in all qPCR assays.
Estimation of Pf liver burden reduction
Liver burden reduction calculation was estimated by back-calculating the initial number 
the logarithms of estimated concentration in controls and immunized individuals with a 
two-sample T-test. Back-calculations were performed based on a published mathematical 
are released at 6.87 days after inoculation; 2) the time between parasite generation is 
1.84 days; and 3) asexual parasite numbers increase with a factor of 11.8 per parasite 
generation. Back-calculation was performed using the highest measured parasite 
concentration for each subject, which yielded the most conservative estimate of the 
greater than zero, or a composite estimate based on all concentrations above zero in each 
person).
Pre- and post-immunizations (before challenge) IgGs from citrated plasma samples 
were precipitated with a saturated ammonium sulfate solution (Pierce, Thermo Fisher), 
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HiTrap protein G HP columns (GE Healthcare Life Science) and eluted with an amine-
P. falciparum circumsporozoite protein (PfCSP), 
post-immunization IgGs were run several times through a 1ml HiTrap NHS-activated HP 
column coupled to a full length PfCSP (Genova Biotechniques Pvt. Ltd, In Hyderabad, 
India), as previously described (42). Anti-PfCSP IgGs were eluted from the column with 
 PfCSP fraction 
and non- Pf
measured by the bicinchoninic acid (BCA) assay (Pierce, Thermo Fisher) following the 
manufacturer’s indications.
Anti-P. falciparum circumsporozoite protein enzyme-linked immunosorbent 
assay
The reactivity of the IgGs from citrated plasma samples at indicated time points and the 
PfCSP (Genova Biotechniques Pvt. 
Ltd.) or the repeat region of PfCSP with the amino acid sequence (NANP)4NVDPC using 
PfCSP. The plates were blocked (0,05% Tween20/1x PBS (PBST) with 5 % milk) for 1h at 
room temperature (RT). Plasma samples were diluted 1:50 in 1% milk PBST and a four-
pre and post anti-Pf
ml in duplicates. After 3h incubation at RT, plates were washed three times with washing 
solution (PBST) and incubated for 1h at RT with the secondary antibody, goat anti-human 
IgG coupled to horseradish peroxidase (HRP) (1:3000, Jackson Immuno research). After 
six washes the reaction was developed with tetra-methyl-benzidine (TMB) followed by 
the addition of 0,2M sulfuric acid to stop the reaction and Absorbance was measured at 
reader. Data was analyzed in relation to a plasma pool from 100 Tanzanian hyper-immune 
adults living in a highly malaria-endemic area (HIT). The plasma pool was diluted 1:200 
in 1% milk PBST and a 7 point 1:2 dilution curve generated. Analysis was performed using 
Auditable Data Analysis and Management System for ELISA (ADAMSEL FPL v1.1) and the 
data were expressed as arbitrary units (AU), as described elsewhere (18, 42).
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In vitro sporozoite invasion inhibition assay 
The ability of the induced antibodies to inhibit sporozoite invasion was assessed in 
vitro using the human hepatoma cell line HC-04 (MRA-965, deposited by Jetsumon 
4 cells/well) were seeded onto rat tail collagen 
or post-immunization or anti-PfCSP depleted IgGs were pre-incubated at 6 mg/ml with 
PfNF54, PbVac or PbWT salivary gland-dissected sporozoites with 10% heat-inactivated 
human serum (HIHS). Sporozoites were also incubated with PBS to determine the 
MRA-183A) as invasion inhibition control. In addition, to neutralize possible anti-PfCSP 
PfCSP protein was added to the 
depleted samples and to the 2A10 control. After 30 minutes on ice, 5x104 sporozoites were 
seeded in triplicates onto HC-04 cells. The plates were centrifuged for 10 minutes at 3000 
rpm with low brake and incubated for 3h at 37°C in 5% C02. Cells were then washed 
with PBS (Gibco) to eliminate non-invading sporozoites and trypsinized (0.05% Trypsin-
ethylenediamine tetraacetic acid (EDTA); Gibco) for 5 minutes at 37°C to obtain a single 
cell suspension. 10% HIHS/PBS was added at 1:1 ratio to neutralize the trypsin. Cells were 
transferred to a V-bottom 96-well plate, washed with PBS (Gibco) and centrifuged at 1700 
rpm for 4 minutes at 4°C. Subsequently, a cell viability dye (1:2,000; Fixable viability 
30 minutes at 4°C and stained to detect intracellular and invading sporozoites with a 
(FITC)) for 30 minutes at 4°C. Cells were then washed with 2% fetal bovine serum (FBS)/
using Gallios (Beckman Coulter) and the analysis with FlowJo software (version 10.0.8, 
Tree Star). 
In vitro complement deposition and membrane-compromised sporozoite 
assay
P. falciparum (NF54) sporozoites were seeded onto 
V-bottom 96-well plates (5x104 sporozoites /well; Costar). Infected salivary glands were 
washed with PBS and centrifuged at 3200 g for 5 minutes at RT. The supernatant was 
carefully removed and the sporozoites were then incubated in duplicate with 10 mg/ml of 
pre- or post-immunization IgGs and 10 % fresh human serum (NHS, active complement), 
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minutes at 37°C, the complement was inactivated with 10 mM EDTA/PBS for 5 minutes at 
PfCSP 
antibody (1:10000; 3SP2-dylight 650) and the anti-C3b complement protein deposition 
(1:500; C3-FITC Cappel, MP Biomedicals) for 30 minutes at 4°C. The samples were 
were acquired with Gallios (Beckman Coulter) and analyzed with the FlowJo software 
(version 10.0.8, Tree Star). 
PfNF54, PbVac or PbWT sporozoites were thawed and washed with PBS by centrifuging at 
13,200 rpm (16,900g) for 15 minutes at 4ºC. Sporozoites were labeled by incubating with 
in PBS (containing 25-50x103 parasites) in a U-bottom 96-well plate. After a 30-minute 
incubation at 4ºC the plate was centrifuged (10 minutes at 3900g and 4ºC) and the 
(Biolegend) antibodies were added to the wells for 30 minutes at 4ºC. Sporozoites were 
TM X-20 (BD 
Biosciences). Data was analyzed using FlowJo v10.5.3 (FlowJo, LLC). 
Ex vivo phenotyping of peripheral blood mononuclear cells
The impact of Pb
cytometry. PBMCs were thawed and rested overnight at 37ºC in complete RPMI (RPMI-1640 
streptomycin, 10 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) and 1x 
Minimum Essential Medium (MEM) non-essential aminoacids, all from Gibco, Thermo 
6 PBMCs were incubated with FVD for 15 minutes at RT, washed 
with PBS containing 2% FBS and stained with the following anti-human antibodies: CD4 
(MEM-188), CD14 (HCD14), all from Biolegend, eBioscience or Beckman Coulter. Cells 
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5x105 events on a BD LSRFortessaTM X-20 (BD Biosciences). After exclusion of dead cells 
(based on positive FVD staining) and doublets (based on FSC-A and FSC-H parameters) 
the following populations were assessed: CD4+ T cells (CD3+CD4+CD8neg negCD56neg), 
CD8+ T cells (CD3+CD4negCD8+ negCD56neg + + 2 
T cells (CD3+ + 2
+), NKT cells (CD3+ negCD56+), NK cells (CD3negCD56+) and 
monocytes (FSChighSSChighCD3negCD14+). Data was analyzed using FlowJo v10.5.3 (FlowJo, 
LLC).
Serum cytokine and chemokine analysis
bead-based LEGENDplexTM, (Biolegend) assay, following the manufacturer’s instructions. 
10). Flow cytometry data were obtained on a Gallios (Beckman Coulter) apparatus and 
analyzed with the FlowJo software (version 10.0.8, Tree Star). 
Measurement of in vitro T cell responses by intracellular cytokine staining 
assay
The cellular responses of immunized volunteers to PfNF54, PbVac or PbWT sporozoites or 
to PfCSP were assessed using an intracellular cytokine staining assay. 1x106 thawed PBMCs 
5 
PfNF54, PbVac or PbWT sporozoites, or with media 
alone as a negative control, for 22h at 37ºC. For PfCSP stimulation, PBMCs were rested 
PfCSP (Genova Biotechniques 
alone as a negative control. Stimulation with 10 ng/ml PMA (Sigma) and 500 ng/mL 
ionomycin (Sigma) for 5h was used as positive control. In all stimulation conditions 10 
were incubated with FVD, washed with PBS containing 2% FCS and surface-stained with 
antibodies for 30 minutes at 4ºC. Finally, cells were washed and resuspended in PBS with 
2% FCS, and approximately 5x105 events were acquired on a BD LSRFortessaTM X-20 (BD 
Biosciences). Data was analyzed using FlowJo v10.5.3 (FlowJo, LLC). Results are presented 
as the frequency of cytokine-producing cells in the stimulated condition minus in the 
respective negative control.
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Analysis of heterogeneity of individual immune responses
To analyze the heterogeneity of individual responses to immunization, a Z-score was 
calculated for the magnitude of the cellular and humoral immune responses measured for 
each volunteer in each assay, by subtracting the population mean prior to immunization 
responses of each volunteer before CHMI with the mean values of each parameter prior to 
immunization for the entire group, and enables ranking the volunteers according to their 
responses, for each immune response parameter assessed.
Statistics
Statistical analysis was performed using GraphPad Prism software (version 5, GraphPad 
Software Inc., California, USA) and Microsoft Excel (version 16.16.8). All volunteers 
exposed to PbVac were included in the intention-to-treat analysis. All safety data 
were descriptive to characterize safety and appearance of parasitemia (‘breakthrough’ 
infection). After challenge infection, the prepatent period to P. falciparum positivity 
positive qPCR were compared between groups by applying the Kolmogorov-Smirnov non-
parametric test. Liver burden reduction calculation was estimated as described above. 
the immunization groups were analyzed by applying the Wilcoxon matched-pairs signed 




Twenty-four volunteers were enrolled in the study from May 2017 to January 2018, of 
which 3 volunteers participated in group 1, 3 in group 2 and 12 in group 3, receiving 5, 25, 
and 75 PbVac-infected mosquito bites, respectively. Group 3 participants received a total 
of ~300 (4x~75 at 4-, 4- and 8-week intervals) PbVac-infected mosquito bites prior to Pf 
CHMI by 5 mosquito bites. Six volunteers (group 4) served as non-immunized controls 
for Pf CHMI (Fig. 1). All 24 study volunteers (100%) completed all immunizations and/or 
challenge as scheduled per group. CHMI was administered to 12 immunized participants 
(group 3) and 6 controls (group 4) on 30 January 2018. Baseline characteristics are shown 
in Table S1. 
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Safety and tolerability 
Immunization phase: Immunizations were well-tolerated in all study groups without 
breakthrough infections, as measured by thick smear and retrospective Pb quantitative 
PCR (qPCR) analyses of samples collected daily for 10 days after parasite administration, 
during Phase 1 of the trial, and on days 1 and 8 after immunization, during Phase 2 of the 
trial. Only mild to moderate (grade 1 and 2) adverse events, and no grade 3 or serious 
adverse events, were recorded (Table S2
events between study groups, while local reactions related to the mosquito bites were more 
 
BMI=Body Mass Index, ECG=Electrocardiogram.  
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frequent in groups 2 and 3. The most commonly reported systemic adverse events were 
headache (7/18 participants), nausea (5/18 participants) and malaise (3/18 participants). 
A total of only eight (grade 1 or 2) laboratory abnormalities were observed including 
decreases in leukocyte, lymphocyte, and platelet counts, and increases in bilirubin, AST/
ALT, and creatinine concentrations (Table S3).
Challenge phase: Approximately 92% (11/12) of the participants of group 3 and 100% of 
group 4 reported mild to moderate adverse events (Table S2) including headache (6/12 
in group 3, 6/6 in group 4), nausea (1/12 in group 3, 4/6 in group 4) and malaise (1/12 in 
group 3, 2/6 in group 4). The total number of adverse events per participant of groups 3 
P=0.040) in the immunized subjects than in controls.
While sterile protection against a NF54 P. falciparum challenge was not observed, 
PbVac-
immunized subjects (9.9 ± 2.0 days), compared to controls (7.7 ± 1.6 days) (P=0.026, 
Kolmogorov-Smirnov test), as detected by qPCR (Fig. 2A). Furthermore, there was 
immunized volunteers compared to the control group (p=0.04, Kolmogorov-Smirnov 
test) (Fig. 2B). Collectively, this corresponds to an estimated 95% average reduction in 
parasite liver load (CI 56%, 99%; p=0.010, two-sample T-test for logarithm of estimated 
Fig. 2C).
Humoral immune responses
Antibody responses to the candidate vaccine were measured in subjects by IFA against 
PbVac sporozoites, as well as against the wild type Pb (PbWT) and PfCSP vaccine 
components. Marked increases in PbVac sporozoite recognition were observed for both 
IgG (5.9-fold, P<0.01, Fig. 3A) and IgM (3.14-fold, P<0.01, Fig. S1A) after immunization. 
Similar results, albeit of lower magnitude, were obtained for Pb
IgG and IgM (2.6-fold, Fig. 3B; 2.8-fold, Fig. S1B, respectively) and for PfCSP (4.2-fold, 
Fig. 3C; 2.16-fold, Fig. S1C). 
We subsequently assessed antibody binding and functionality against Pf, by IFA, 
sporozoite membrane integrity and sporozoite liver invasion inhibition assays (Fig. 3D-
F). Immunization with PbVac increased the concentration of both IgG and IgM targeting 
Pf sporozoites (3.5-fold, P<0.01, Fig. 3D; 1.71-fold, P=0.03, Fig. S1D, respectively). Of 
note, the capacity of plasma IgG to bind Pf sporozoites directly correlated with the titers 
of circulating anti-PfCSP antibodies (Fig. S1E Fig. S1F) 
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enhanced C3 complement protein deposition on Pf sporozoites (4.3-fold, P<0.01, Fig. 
S1G), resulting in a strong decrease in Pf sporozoite viability (Fig. 3E). 
Pf sporozoite invasion of HC-04 cells by a 
median of 61.1% (P<0.01). Depletion of anti-Pf
Pf sporozoite invasion (Fig. 3F)
on Pf sporozoites (Fig. S1G). The titers of IgG against PfCSP, the binding capacity of IgG to 
Pf sporozoites, and the enhancement of Pf sporozoite lysis, correlated with the cumulative 
number of PbVac mosquito bites (Fig. 3G-I, respectively and Table S4). The combined 
data suggest that induced antibodies were capable of inhibiting Pf sporozoite viability 
and functionality in a dose-dependent manner. However, these in vitro
correlate with the delayed pre-patency nor with the reduced parasite liver load.  
Cellular immune responses
Given the largely exploratory nature of the study, a wide-range analysis of cellular immune 
responses was performed. Peripheral blood mononuclear cells (PBMCs) sampled before 
Figure 2 – PbVac
(A) Prepatent period for non-immunized controls (white circles) and immunized volunteers (green 
circles), presented as the number of days until parasitemia was at least 100 Pf parasites/ml of blood, 
as measured by qPCR; (B) Pf (C) Pf parasitemia curves following 
CHMI; (D) Pf parasites exiting the liver. Comparisons 
between controls and immunized volunteers in A) and B) were assessed by employing the 
error. The shaded area below the dashed line in B) and C) denotes parasitemia values below the 
100 Pf
represent geometric mean ± standard error. Vxx denotes volunteer number.
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Figure 3 – Humoral responses elicited by PbVac
(A-B) Plasma IgG binding to PbVac spz (A) and PbWT (B) spz in samples collected pre-immunization 
values are for binding at a 1/1,000 dilution; (C) Plasma IgG reactivity against full length PfCSP as 
measured by ELISA, normalized to a pool of sera from 100 hyperimmune Tanzanians (HIT), which 
was set at 100 arbitrary units (AU). (D) Binding of plasma IgG to Pf spz. MFI values are for binding 
at a 1/1,000 dilution; (E) Viable Pf 
was assessed as a surrogate for induced Pf spz lysis; (F) Inhibition of Pf spz invasion of HC04 cells 
depleted or not of Pf PfCSP-depleted – light green circles) (G-I) Correlation 
between the cumulative number of mosquito bites and anti-PfCSP antibody titers (G), binding 
capacity to Pf spz (H) and induction of Pf
employing the Wilcoxon matched-pairs signed rank test and correlations using the non-parametric 
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+ T (10, 16, 
43), CD8+
(Fig. S2). An increased frequency of CD8+
unrelated to trial outcome (Table S5). Of note, an increase in circulating NKT cells was 
found prior to CHMI (at C-1, Fig. S2), which associated with the increase in pre-patent 
period and the decrease in parasite density (Table S5).
Fig. S3). However, a clear association was found 
PbVac 
1 (MCP1/CCL2) (Table S6). Such changes also appear to associate with the observed 
Table S7). For example, serum 
+ T and NKT cells. As expected, 
changes in the MCP1/CCL2 chemokine are closely linked to variations in the frequency of 
circulating monocytes, and are accompanied by alterations in other cytokines involved in 
Table S7).
Next, PBMCs were incubated with PbVac or PbWT sporozoites, or with recombinant 
Pf
increases were observed in the frequency of PbVac- and PbWT-, but not Pf
P=0.002 and P=0.001, respectively) or C-1 
(P=0.002 and P=0.007, respectively) (Fig 4A-C). Similarly, PbVac- (P=0.009 for C-1), and 
PbWT- (P=0.034 for I1+14), but not Pf + (Fig. S4-C) and CD8+ (Fig. 4D-
F
frequent after immunization (P=0.016 and P=0.042, for C-1, respectively). Interestingly, 
the frequency of CD4+
both PbVac (Fig. S4D, S4E) and PbWT (Fig. S4F, S4G) 
Collectively, these data show that the genetic introduction of Pf
on the cellular responses induced by immunization with PbVac. In contrast, the PbWT 
but no correlation was found between cytokine production by any of the cell populations 
analyzed and the clinical outcome. The combined data suggest the existence of a 
multifaceted response to Pb
combination of cellular and humoral immune responses.
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Figure 4 – Cellular immunogenicity of PbVac
(A-C)
and before CHMI (C(-1) – green circles) following stimulation with PbVac spz (A) PbWT spz (B) or 
PfCSP recombinant protein (C); (D-F) Percentage of CD8+ T cells producing any combination of 
PbVac spz (D), 
PbWT spz (E) or Pf
mean ± standard deviation. Vxx denotes volunteer number.
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Cross-species cytokine responses
Finally we studied cytokine responses to Pf in PBMCs from volunteers receiving 5, 25 and 75 
PbVac infected-mosquito bites (Fig. 5A,B, S5A-C)
increased at the highest PbVac dosage in total PBMC (Fig. 5A), and CD8+ T cells (Fig. 5B), 
but not in CD4+ Fig. S5A). 
Nonetheless, CD4+
increased after immunization (P=0.012) (Fig. S5B
association between the frequency of cytokine-producing cells and either an increase in 
pre-patency time or a reduction in liver load of immunized subjects. Our results show that 
PbVac immunization elicits dose-dependent cross-species cytokine responses against Pf, 
suggesting that a higher Pb
Figure 5 – Cross-species cytokine responses
(A) Pf spz in peripheral 
blood samples collected pre-immunization (I1(-1)) and 14 days after immunization (I1(+14)) with 5 
(I1(+14d)) with 75 mosquito bites and before CHMI (C(-1)); (B) Percentage of CD8+ T cells producing 
Pf
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Discussion 
Whole-sporozoite immunization constitutes a promising approach to the much-desired 
goal to control and eliminate malaria (49). PbVac, a Pb parasite that expresses the 
PfCSP antigen under the control of the UIS4 pre-erythrocytic stage promoter, belongs 
to a novel class of whole-sporozoite malaria vaccination approaches based on the use 
Plasmodium parasites expressing target antigens of their 
human counterparts (35). Pb
Plasmodium parasite 
expressing inserted heterologous antigens, evaluated in a clinical study. We show that 
administration of PbVac by mosquito bites to healthy volunteers is safe and well-tolerated, 
Pf 
challenge, that appears to be associated with components of both humoral and cellular 
immune responses. 
vaccination (50, 51). In fact, anti-CSP antibodies have been shown to inhibit Pf sporozoite 
infectivity in vitro (52, 53) and in vivo (54) and their protective role is clearly shown 
in the context of the subunit vaccine RTS,S (55, 56). Here, we show that PbVac’s PfCSP 
for complement activation, to mediate Pf sporozoite lysis, and to inhibit Pf sporozoite 
invasion of hepatic cells in vitro. The genetic insertion of PfCSP onto the rodent Pb platform 
enhanced the functionality of PbVac-induced immune responses, possibly contributing to 
Our results also suggest a contribution of PbVac-elicited cellular immune responses to the 
clinical outcome. In RAS and CPS vaccination, an increase in the frequency of Pf
CD4+ and CD8+ 
+ T cells associates with sterile immunity in CHMI studies in healthy US/European 
volunteers (10, 43, 45, 46, 57, 58). In the present study, a marked expansion of not only CD8+ 
+ T cells, but also NKT cells, was observed post-immunization. Conversely, 
decreased frequencies of circulating monocytes were observed after vaccination and 
appear to be linked to early changes not only in MCP1/CCL2 signaling but also in IL-18, an 
inducer of MCP1 production (59, 60). These observations suggest a possible recruitment of 
monocytes to the liver, where they may contribute to the development of protective tissue-
resident immune responses (61-64). Finally, increased frequencies of IFN -producing 
lymphocytes and of CD8+ T cells producing any combination of IFN
observed upon PBMC stimulation with either PbWT or Pf sporozoites, but not with PfCSP. 
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Collectively, and in agreement with our pre-clinical data (35), these results suggest that 
PbVac immunization elicits functional PfCSP-based antibody responses, as well as cross-
species, PbWT backbone-dependent, cellular immune responses against Pf.
To directly compare the responses of each volunteer with the mean values of each 
parameter for the entire group prior to immunization, a Z-score was calculated for the 
magnitude of the cellular and humoral immune responses measured for each volunteer 
(Fig. S6). An analysis of the individual immune responses to immunization, reveals a 
marked heterogeneity in the magnitude of these responses, with some volunteers 
developing a predominantly humoral response, and others favoring a cellular immune 
response (Fig. S6). This heterogeneity is not unexpected and has been observed not 
only in malaria vaccination trials of whole-sporozoite vaccines delivered by mosquito 
bite, but also in other malaria vaccination trials (65). However, our analysis shows 
that all individuals display a response to PbVac in at least one of the immune response 
parameters assessed. For example, v70, the volunteer which showed the smallest increase 
in prepatency period and the lowest reduction of liver load following CHMI, appears 
to be one of the volunteers with the lowest cellular immune responses against either 
PbVac (Fig.S6A) or Pf sporozoites (Fig.S6B), but developed a robust functional humoral 
immunity, capable of inhibiting Pf sporozoite invasion of HC04 cells (Fig.S6C). On the 
contrary, v65 is among the top responders of the group in terms of cellular immune 
responses against either PbVac or Pf sporozoites, but his/her humoral immune responses 
against Pf sporozoites rank as the lowest of the group. Overall, this analysis highlights the 
heterogeneity of individual immune responses as well as the lack of a direct correlation 
between the clinical outcome and a single immune response parameter. A similar absence 
of clear correlates of protection have been noted for RTS,S (55, 56), as well as for whole-
sporozoite immunizations (10, 58), likely due to the multi-factorial and complex nature 
of the immune signature. Finally, the association observed between the early plasma 
amounts of the MCP1/CCL2 cytokine, as well as changes in frequency of circulating NKT 
cells, and the outcome of CHMI warrant further investigation.
Our results show a proportionality between humoral / cellular immune responses and 
the cumulative number of immunizing bites, as previously determined following RAS and 
CPS immunizations (10, 43). In fact, in early clinical studies of Pf RAS vaccination by 
mosquito bite, sterile protection was only achieved when volunteers underwent a mean 
of 9 immunizations and >1000 immunizing bites before CHMI (66). In the present study, 
the total number of immunizing bites was substantially lower (4 immunizations with 
~75 immunizing bites each, for a total of ~300 bites). Therefore, we hypothesize that 
sterile protection against Pf challenge, following PbVac immunization may be achieved 
with an increase in the number of sporozoites administered. Since markedly increasing 
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the dose of parasites used for immunization through increasing the number of mosquito 
bites appears impractical, achieving this goal will potentially require the inoculation of 
sporozoites through the injection of sporozoites by intravenous route. This method is 
chemoattenuated vaccine candidates (10, 11, 45, 46). Such an endeavor poses several 
challenges, chief among which is the requirement for a GMP-compliant sterile Pb/PbVac 
production system, an absolute requisite for the intravenous administration of such 
parasites to humans.
Whole-sporozoite vaccines against malaria still require relatively high doses of sporozoites 
to elicit sterile immunity, demanding the production of large numbers of infected mosquitoes 
reared in highly specialized facilities, with a consequent impact on the cost-of-goods. This 
is particularly relevant in the case of Pf-based vaccines, whose production commands 
PbVac administration in the present study warrants the exploration of Pb as one possible 
alternative platform for whole-sporozoite vaccination. Besides its inherent safety, Pb-
Pf-based vaccination, with potential advantages 
over the latter in terms of cross-species immunization. In fact, we have previously shown 
not only that Pb infectivity of human primary hepatocytes appears to be higher than that 
of Pf, but also that >24,000 in silico-predicted CD8+ T cell epitopes, encoded in >60% of 
both the Pf and the Pb proteins, are shared between the two parasite species (35). One 
may further speculate that, given the co-evolution of humans and Pf parasites, immune 
evasion mechanisms may be at play during immunization with the latter that may be 
absent in the case of Pb-based immunization. On the other hand, whereas the expression 
of Plasmodium proteins in heterologous systems for subunit vaccination is notoriously 
Pb
folded antigens in their native conformation (33). Thus, next-generation Pb-based vaccine 
Plasmodium spp., but also blood stage or transmission-blocking immunogens, as well as 
multiple alleles of an antigen (71). Additionally, the hepatotropic nature of Pb sporozoites 
promotes the exposure of antigens in the liver, where tissue-resident immunity is most 
can be elicited by Pb-based immunization needs to be addressed in further clinical studies. 
Such studies will potentially include both wild-type Pb- and PbVac-immunized volunteers, 
as well as appropriate PfRAS or PfCPS arms for a comparative analysis of protective 
PbVac, even at 
sub-optimal doses, make the Pb-based platform a promising tool for the development of a 
next-generation malaria vaccine.
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PbVac
(A-B) Binding to PbVac spz (A) and PbWT spz (B) of plasma IgM from samples collected pre-
intensity (MFI) values were registered for binding at a 1/1,000 dilution; (C) Plasma IgG reactivity 
against the repeat sequence of PfCSP as measured by ELISA, normalized to a pool of sera from 100 
hyperimmune Tanzanians (HIT), which was set at 100 arbitrary units (AU). (D) Binding of plasma 
IgM to Pf spz; (E) Correlation between binding of plasma IgGs from samples collected prior to CHMI 
to Pf spz and the titers of anti-PfCSP whole protein antibodies for the same samples determined 
by ELISA; (F) Correlation between plasma IgG binding to Pf
for samples collected before CHMI; (G) C3b complement deposition in Pf spz pre-incubated with 
Pf PfCSP-depleted – light green 
Supplementary data 
  |  Chapter 
Figure S2 – Frequency of sub-families of circulating immune cells
Fold change in the frequency of sub-families of circulating immune cells between samples collected 
circles) and before CHMI (C(-1) – green circles). Frequency of sub-families were calculated as a 
to 75th percentiles and whiskers represent the range.
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Figure S3 – PbVac 
administration
Fold change in the serum concentration of various cytokines and chemokines between samples 
percentiles and whiskers represent the range.
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Figure S4 – Polyfunctionality of CD4+ T cell-produced cytokines
(A-C) Percentage of CD4+
immunization (I1(+14d) – grey circles) and before CHMI (C(-1) – green circles) following stimulation 
with PbVac spz (A) or surrogates for the PbVac components, PbWT spz (B) and PfCSP (C). 
  |  
Continued Figure S4 – Polyfunctionality of CD4+ T cell-produced cytokines
(D-H) Comparative changes (D and F) and overall relative cytokine proportions within CD4+ T cells 
with PbVac spz (D and E) or PbWT spz (F and G). In (D and F), left panels show the percentage of 
polyfunctional CD4+ T cells in the various peripheral blood samples collected and the right panels 
show the percentage of mono-functional CD4+ T cells. Pie charts in (E and G) are colored for each 
cytokine combination as indicated below (D and F), respectively, and represent the total populations 
In (C, D and F), bars represent the mean ± standard deviation. Vxx denotes volunteer number.
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Figure S5 – Polyfunctionality of cross-species cytokine responses
(A) + T cells following stimulation with Pf spz in peripheral 
blood samples collected pre-immunization (I1(-1)) and 14 days after immunization (I1(+14)) with 5 
(I1(+14d)) with 75 mosquito bites and before CHMI (C(-1)); (B and C) Comparative changes (B) 
and overall relative proportion within CD4+
each combination of cytokines produced upon stimulation with Pf spz. In (B), left panels show the 
percentage of polyfunctional CD4+ T cells in the various peripheral blood samples collected and 
the right panels show the percentage of mono-functional CD4+ T cells. Pie charts in (C) are colored 
for each cytokine combination as indicated below (B) and represent the total population of cells 
the mean ± standard deviation.
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Figure S6 – Analysis of heterogeneity of individual responses to immunization
Individual cellular immune responses to PbVac (A) or to Pf (B), and humoral immune responses 
against Pf (C) were globally scored for each volunteer by comparing their immune responses with 
the entire group’s mean values prior to immunization.
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 Group 1 Group 2 Group 3 Group 4
No. of participants 3 3 12 6
Gender (no. of participants, %)
Female 3 (100) 1 (33) 7 (58) 4 (67) 
Male - 2 (67) 5 (42) 2 (33) 
Race
Caucasian 2 3 10 6 
Asian 0 0 1 0
Other 1 0 1 0
Age (median (range)) 21.1 (18-23) 26.1 (21-30) 21.5 (19-26) 22.5 (21-26) 
Table S1 – Baseline characteristics
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Number of mosquito bites Days to parasitemia 1st generation parasites
I1 (+14) C (-1) I1 (+14) C (-1) I1 (+14) C (-1)
r P value r P value r P value r P value r P value r P value 
CD4 T cells (%) -0.409 0.179 -0.225 0.473 -0.112 0.652 -0.424 0.141 0.411 0.184 0.669 0.020
CD8 T cells (%) -0.453 0.137 -0.463 0.128 0.194 0.543 -0.119 0.647 0.158 0.623 0.480 0.116
-0.032 0.905 0.148 0.643 0.387 0.212 0.360 0.248 -0.235 0.451 -0.349 0.258
0.093 0.771 0.389 0.210 0.353 0.259 0.384 0.217 -0.193 0.537 -0.417 0.174
NKT cells (%) -0.119 0.703 -0.105 0.736 0.277 0.382 0.729 0.009 -0.098 0.754 -0.617 0.035
NK cells (%) 0.274 0.387 0.389 0.210 0.075 0.816 0.395 0.203 -0.182 0.561 -0.518 0.085
Monocytes (%) -0.409 0.179 -0.225 0.473 -0.244 0.388 0.115 0.722 0.039 0.908 -0.245 0.433
cells, total number of mosquito bites after 4 immunizations, and CHMI outcome 
The non-parametric Spearman correlation test was employed to identify potential correlation 
between the changes in circulating immune cells and outcome of PbVac immunization, as represented 
by the increase in pre-patency and the decrease in the number of 1st
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Abstract
Background 
to mosquitoes and to develop models for early-clinical evaluation of transmission-blocking 
interventions. We previously described a controlled human malaria infection protocol for 
induction of gametocytemia in malaria-naïve volunteers by mosquito bite (CHMI-trans) 
(1).  
Methods 
Here, we compared gametocyte production and infectivity in healthy adults following CHMI 
initiated by either Plasmodium falciparum (Pf)- infected mosquito bite or intravenous 
blood-stage inoculation of Pf-infected-erythrocytes. Participants received (sub) curative 
treatments with gametocyte-permissive piperaquine or sulfadoxine-pyrimethamine. 
Results 
Blood-stage inoculation induced higher gametocyte densities than mosquito bite 
inoculation, which was predicted by PfAP2-G transcript levels – indicative of gametocyte 
commitment – and resulted in Pf-positive mosquito infections in 9/12 participants 
compared to 0/12 participants after mosquito bite inoculation. 
Conclusion 
This direct comparison establishes the CHMI-transmission model with intravenous 
administration of asexual parasites as a tool for early-clinical evaluation of interventions 
that aim to interrupt Pf-transmission.
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Introduction
Plasmodium transmission to mosquitoes depends on the presence of mature male and 
female gametocytes in the peripheral blood. Gametocyte formation is triggered by 
activation and expression of PfAP2-G (2, 3). Following maturation in the bone marrow 
and spleen (4), mature gametocytes are released into the circulation where they can be 
ingested by blood-feeding mosquitoes, thus propagating infection. Gametocyte density is 
a key determinant of Plasmodium transmission to mosquitoes (5). 
Malaria elimination strategies depend on a clear understanding of human to mosquito 
transmission-blocking interventions (TBIs) are required. Recently, we developed a 
controlled human malaria infection model (CHMI-trans) that permitted safe induction of 
mature gametocytes in malaria-naïve volunteers by Pf-infected mosquito bite, but failed 
be used as an outcome measure (1). Here, we have demonstrated in a direct comparison, 
that the mosquito-bite (MB) CHMI-trans model can be improved by instead initiating 
infections with intravenous inoculation of Pf-infected erythrocytes, so called induced 
blood stage malaria (IBSM) (8). We evaluated the induction of infectious gametocytes 
value of PfAP2-G transcripts for gametocyte development and determined the sample size 
requirements for evaluation of TBIs using the improved CHMI-trans study design. 
Methods
Study design, ethics approval and registration
This randomized, open-label, single center trial was conducted at the Radboud university 
medical center (Nijmegen, the Netherlands) between May and November 2018. Screening 
procedures and eligibility criteria were described earlier (1). All participants were between 
number NL63552.000.17) was approved by the central committee for research involving 
human subjects (CCMO), and the Western Institutional Review Board (WIRB), and 
00040005-40.
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Study procedures
24 participants were enrolled in two time-separated cohorts/groups. Within each group, 
participants were randomly assigned to one of two treatment arms (Table 1). In group 
Pf 3D7-infected mosquitoes (MB) (1); In group 
2 (IBSM), n=12 were infected by intravenous injection with ~2800 Pf 3D7-infected 
erythrocytes (8). Once parasitemia was detected by 18S qPCR (9) at a density of 5,000 
parasites/mL in the MB group, or on day 8 post-inoculation in the IBSM group, treatment 
was initiated with low-dose piperaquine (LD-PQP 480 mg; T1). If asexual parasitemia 
exceeded 1,500 parasites/mL by qPCR after T1 and before day 21 after inoculation, 
participants received a second subcurative treatment with LD-PQP 480 mg (T2) to extend 
asexual parasitemia and allow induction of gametocytes. On day 21 post-inoculation or 
upon recrudescence after T2, participants were curatively treated with either 960mg 
PQP or 1000mg/50mg SP (T3) (Table 1
with a three-day regimen of 1000mg/400mg atovaquone/proguanil (Malarone) per day 
starting on day 36 post-inoculation or upon recrudescence after curative treatment (T3). 
Female and male gametocytes were assessed by quantitative reverse-transcriptase PCR 
(qRT-PCR) for CCp4 (female) and PfMGET (male) mRNA (10) with a threshold of 5 
gametocytes/mL for positivity (1). PfAP2-G (2) and SBP-1 (8, 11) qRT-PCR was performed 
  MB IBSM
 Arm 1 Arm 2 Arm 3 Arm 4
Subjects (n) 6 6 6 6
Infection method Mosquito Mosquito Blood-stage Blood-stage
Treatment 1 LD-PIP LD-PIP LD-PIP LD-PIP
Treatment 2 LD-PIP LD-PIP LD-PIP LD-PIP
Treatment 3 PIP SP PIP SP
Sex  
     Female 3/6 (50%) 4/6 (66.7%) 4/6 (66.7%) 4/6 (66.7%)
Age  
Median 24.5 (18-30) 22.5 (19-26) 25.5 (20-29) 20.0 (19-26)
BMI (kg/m2)  
Median
22.2 (20.8-
29.3) 24.2 (22.7-26.9) 20.4 (18.1-22.8) 24.7 (20.8-27.7)
Hemoglobin (mmol/L) 8.8 (8.0-9.7) 8.2 (7.6-9.9) 8.8 (7.6-10.0) 8.7 (7.7-9.4)
Table 1 – Baseline characteristics
Values between brackets represent range (min-max). MB; mosquito bite inoculation, IBSM; induced 
blood stage malaria. LD-PIP; piperaquine 480mg, PIP; piperaquine 960mg, SP; sulfadoxine-
pyrimethamine 1000mg/50mg.
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PfAP2-G:SBP-1 expressed as an indication of the 
proportion of sexually committed ring-stage parasites (12). Infectivity of gametocytes to 
mosquitoes was assessed on days 21, 24 and 29 post-inoculation for all gametocyte positive 
individuals by direct skin feeding assays (DFA), direct membrane feeding assay with 
whole blood (DMFA), following serum replacement (MFA-SR), or following enrichment 
for gametocytes by magnetic-activated cell sorting (MFA-MACS) (13). Mosquitoes were 
dissected on day 7-9 post-feeding and microscopically examined for oocysts following 
staining with mercurochrome.
Study outcomes
Primary outcomes were the prevalence of gametocytes and the frequency and severity 
gametocytes by CCp4 qRT-PCR at any of the daily measurements from day 15 after MB 
inoculation or day 10 after IBSM inoculation. Secondary outcomes were gametocyte 
dynamics, commitment and maturation; and infectiousness to Anopheles stephensi 
mosquitoes. 
Statistical analysis
Based on preliminary data, we anticipated that >95% of individuals would develop 
gametocytes (1). The CHMI-trans approach was considered unsuitable if <50% of 
individuals would develop mature gametocytes. Therefore, we powered the trial to meet 
per inoculation group of whom 11 would become gametocytemic, would mean we can 
estimate the proportion of gametocytemic individuals with a lower limit of the 99% 
would infect at least one mosquito (8). Within each inoculation group of 12 individuals, 
we thus expected 8 or 9 transmitting individuals, resulting in a lower limit of the 95% 
Statistical analyses were performed using GraphPad Prism 5 and SPSS version 25.0 (SPSS 
Inc, Chicago, IL, USA). The non-parametric Mann-Whitney U test was used for comparison 
variables the Fisher’s exact test was used. 
Correlations were assessed using non-parametric Spearman’s rho. To obtain an estimate of 
the proportion of male gametocytes weighted for gametocyte density, for each individual 
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the sum of observed male gametocytes across time-points was divided by the sum of all 
gametocytes. Each individual thus provided one weighted proportion; the median of these 
proportions was calculated per inoculation group. The proportion of infected mosquitoes 
prior to treatment and after treatment was compared between treatment groups using 
Generalized Estimating Equations (GEE), adjusting for correlations between mosquitoes 
feeding on the same donor and using robust standard errors; outcomes were presented 
future TBI studies, mosquito infection data from DFAs in the current study and a previous 
study using IBSM and treatment with LD-PQP on day 8 post-challenge (8), were used, 
assuming three DFAs per individual and 30 examined mosquitoes per assay. The Bayesian 
statistical model takes into account variation between individuals, within individuals and 
between days of sampling. Power estimates were based on 4000 simulations per trial 
design, accounting for uncertainty estimated transmission probability. 
Results
From a total of 41 screened volunteers, 24 healthy adults (Table 1; Figure 1) were enrolled 
and randomly assigned to experimental malaria infection with P. falciparum 3D7 parasites 
by MB or IBSM. To treat asexual parasite infection, participants received subcurative 
treatment with piperaquine (LD-PQP, 480 mg) that was administered a second time upon 
parasite recrudescence (n=6 from MB; n=5 from IBSM). Within each of the two inoculation 
groups (MB or IBSM), participants were randomized to receive curative treatment with 
either PQP (960mg) or sulfadoxine-pyrimethamine (SP, 1000mg/50mg), resulting in four 
study arms. 
All participants completed the study and developed qPCR-detected asexual parasitemia 
6.5 to 16.5 days after the MB inoculation or 4 to 5 days after IBSM. Peak parasite densities 
ranged from 2,428-53,203 parasites/mL after MB infection compared to 3,262-271,790 
parasites/mL after IBSM (p=0.478) (Table 2, Figure 2A and 2B). Female gametocytes 
were detected in 23/24 participants and male gametocytes in 18/24 participants by qRT-
PCR targeting CCp4 and PfMGET, respectively (10). All other participants had detectable 
appearance was 13.9 days (range: 10.0-20.0 days) for MB and 9.2 days (range 8.0-11.0 
days) for IBSM for female gametocytes (p<0.001), and 17.3 days (range 10.5-22.0 days) 
for MB and 9.3 days (range 8.0-11.0 days) for IBSM for male gametocytes (Table 2, Figure 
2; p<0.001). Gametocyte sex-ratio was female-biased; the median proportion of male 
gametocytes was 0.20 (IQR 0.14-0.50) for the MB group and 0.31 (IQR 0.22 – 0.51) for the 
IBSM group (p=0.142) (Figure 2C and 2D). 
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Forty-one individuals were screened for eligibility, of whom 24 were included and divided over 4 
study arms. All participants received LD-PQP on day 8 (IBSM group) or when treatment criteria 
were met (MB group). Participants received a second treatment with LD-PQP (T2) if recrudescence 
occurred. Due to thrombocytopenia 1 participant received T1 7.5 days post-inoculation and a 
with atovaquone/proguanil was initiated on day 27. Two IBSM participants developed asexual 
recrudescence after T1 and both received T3 directly (20.5 days post inoculation). All remaining 
with atovaquone/proguanil 36 days post inoculation. LD-PQP; low dose piperaquine 480mg. PQP; 
treatment, T2; second subcurative treatment, T3; curative treatment.
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The median peak total gametocyte density was 1304 gametocytes/mL (IQR: 308-1607) in 
the IBSM group compared to 12 gametocytes/mL (IQR 7-29) in the MB group (p<0.001) 
(Figure 2A, B). Peak gametocyte density strongly correlated with peak asexual parasitemia 
Figure 
3A); in a linear regression model, peak asexual parasite density for MB (ß=0.800; 95% 
CI 0.458-1.142, p<0.001) and IBSM (ß=1.472; 1.125-1.819, p<0.001) groups were both 
strongly predictive of gametocyte density without evidence of interaction. The ratio of 
PfAP2-G transcripts to ring-stage SBP-1 transcripts, as an indicator of sexually committed 
p=0.002) (Figure 3B). 
In direct feeding assays (DFA), where mosquitoes directly fed on the skin of participants, 
75% (9/12) of the IBSM group infected at least one mosquito compared to 0% (0/12) of the 
MB group (p<0.001) (Figure 4A). The median percentage of infected mosquitoes was 5% 
(range 3-20%) with 1-2 oocysts (Figure 4B); mosquito infection prevalence was strongly 
Supplementary 
Figure 1). Direct membrane feeding assays (DMFA) on venous blood and membrane 
feeding assays where participants plasma was replaced with malaria-naïve serum (MFA-
SR) resulted in lower mosquito infection rates (Supplemental Information). In MFA’s that 
 MB IBSM p-value
Time to T1 (days) 12.25 (7.5-19.50) 8 N.A.
Number of participants receiving T2 
(% (n)) 50 (6) 42 (5) NS
Time between T1-T2 (days) 2.00 (1.75-6.50) 6.25 (4.25-12.50) 0.024
Peak parasite density (pf/mL) 32,807 (2,428-53,203) 27,700 (3,262-271,790) 0.478
Peak gametocyte density (gct/mL) 11.8 (2.5-727.9) 1,304 (179-3,826) <0.001
Area under the curve (AUC)
Total parasitaemia 37,654 (4,260-103,994) 38,639 (3,067-303,669) 0.977
Gametocytaemia 99 (16.6-5,330) 11,043 (1,643-37,326) <0.001
Day of gametocyte detection after 
infection (days) 21.0 (20.0-27.0) 14.0 (13.0-16.0) <0.001
Time to gametocyte detection* (days) 14.0 (10.0-20.0) 9.0 (8.0-11.0) <0.001
CCp4 PfMGET 
subcurative treatment, T2; second subcurative treatment. Presented data are median values with 
range between brackets.
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inoculation
(A/B) Black lines represent median of 18S qPCR asexual parasitemia, grey lines represent individual 
participant data. Red lines represent median gametocytemia, pink lines represent individual 
participant data (sum of CCp4 and PfMGET qRT-PCR). (C/D) Dark pink lines represent median 
female gametocytemia, light pink lines represent individual participant data (CCp4 qRT-PCR) 
represent individual participant data (PfMGET qRT-PCR).
commitment and subsequent gametocyte density
Blue dots represent data from mosquito bite inoculation; green dots represent data from blood-
stage inoculation. (A) Correlation between peak asexual parasitemia and peak gametocytemia after 
0.024), blood-stage inoculation 0.77; 0.003. (B) Correlation between peak gametocytemia and the 
ratio of PfAP2-G transcripts over ring-stage asexual transcripts SBP-1
0.001).
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used gametocytes enriched by magnetic-activated cell sorting (MFA-MACS), samples from 
100% (12/12) of participants in the IBSM group, and 8% (1/12) of the MB group infected 
mosquitoes (p<0.001) (Figure 4A; 4B) with a strong correlation between the original 
Prior to curative treatment (T3), the proportion of infected mosquitoes by DFA was 
or SP (OR 0.743; 95% CI 0.113-4.868; p=0.756 after adjustment for correlation between 
mosquitoes feeding on the same participant). However, following curative treatment, the 
proportion of infected mosquitoes was considerably lower after SP treatment (0.28%; 
1/363) compared to PQP treatment (4.46%; 16/359) (Figure 4C, and 4D; OR 0.059; 95% 
CI 0.0074-0.478). When considering IBSM participants treated with PQP only, 83% (5/6) 
of participants were infectious to mosquitoes by DFA. Using this optimum procedure –
IBSM inoculation followed by PQP treatment – we explored the suitability of the CHMI-
transmission model with its current performance for future early-clinical testing of TBIs. 
Sample size estimates indicated that 7, 10 or 15 participants would be required per study 
90% or 80%, respectively (Figure 5).
Study procedures were well tolerated in all participants; possible and probable related 
adverse events are listed in Supplementary Table 1. No serious adverse events occurred. 
Laboratory abnormalities are shown in Supplementary Table 2 and returned to baseline 
before the end of study. 
Discussion
Gametocytes develop from their asexual progenitors, and asexual parasite density is a 
strong determinant of subsequent gametocyte density in malaria-naïve volunteers (1, 
8). However, in this study, we found considerably higher gametocyte densities following 
IBSM compared to MB inoculation despite a similar asexual parasite burden. A higher 
ratio of PfAP2-G:SPB-1 transcripts – indicative of gametocyte commitment (2, 14) – was 
in vivo 
evidence that PfAP2-G transcripts may serve as a correlate of gametocyte formation (2, 
12, 15). The reasons behind this apparent higher sexual commitment after IBSM remain 
elusive. We observed a strong association between duration of asexual parasitemia prior 
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Figure 4 – Transmission to Anopheles mosquitoes by Direct Skin Feeding or by Membrane 
Feeding of venous blood samples
A total of 71 direct feeding assays (DFA) were conducted (median: 31 examined mosquitoes per 
experiment; IQR: 28 - 32); alongside 71 direct membrane feeding assays (DMFA) (exactly 25 examined 
mosquitoes per experiment), and 71 DMFA experiments following gametocyte concentration by 
magnetic-activated cell sorting (MFA-MACS; median: 18 mosquitoes examined per experiment; 
IQR: 16-19). (A) Total of proportion of individuals infectious to mosquitoes by DFA, DMFA, and 
(B) Number of oocysts per mosquito 
in DFA, DMFA, and MFA-MACS feeding experiments. (C/D) Proportion of infected mosquitoes per 
individual per time-point by curative treatment group (PQP or SP) in DFA and MFA-MACS. Day 21 is 
pre-treatment, day 24 and day 29 are post treatment. PQP = Individuals that received piperaquine 
as a curative treatment, SP = Individuals that received sulfadoxine-pyrimethamine as a curative 
treatment. 
analysis to MB infections (Supplementary Figure 3
We aimed to maximize asexual parasite burden (i.e. the area under the curve of asexual 
parasite density versus time) by adding a second subcurative treatment with piperaquine. 
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previous study using a single subcurative treatment (p=0.02) (1) (Supplementary Figure 
2A). However, the group size was too small to determine if this resulted in a meaningful 
increase in gametocyte density or infectivity to mosquitoes. 
Our work supports the use of PQP over SP for CHMI-trans studies. Whilst treatment with 
SP previously showed promise in our model (1), current data strongly suggest SP may 
data that indicate high and transmissible gametocytemia after SP treatment (19, 20). This 
Further improvements of CHMI-trans may be conceivable, for example by using clinical 
isolates or parasite lines with intrinsically or inducible higher gametocyte commitment (12, 
21). However, in its current form, our protocol involving IBSM with piperaquine treatment 
allows early-clinical testing of highly potent transmission blocking interventions achieving 
– 
similar to CHMI models for pre-erythrocytic and erythrocytic malaria vaccines (23). 
Figure 5 – 
transmission blocking interventions
Sample size calculations were performed using all available data from the current study (n=6) 
and the CHMI transmission trial conducted in Brisbane (n=12) (8). Three mosquito feeding 
time-points per person were assumed. Power estimates are based on 4000 simulations per trial 
design, accounting for uncertainty estimated transmission probability. Line-types indicate vaccine 
volunteers per arm, respectively (80% power; p-value <0.05).
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In conclusion, we report major improvements over our earlier mosquito bite CHMI-trans 
transmission study that allows the safe induction of transmissible gametocyte densities. 
The presented model thus paves the way for early-clinical evaluation of transmission-
blocking interventions that are deemed crucial for successful malaria elimination. 
We also thank Daphne Smit and Annemieke Jansens for their assistance and project 
support during the trial. We thank the following individuals for their assistance during 
the trial: Wouter Graumans, Roel Heutink, Rianne Stoter, Laura Pelser, Jolanda Klaassen, 
Astrid Pouwelsen, and Jacqueline Kuhnen for the mosquito infection and dissection work, 
Foekje Stelma, and all the thick smear microscopists for reading many smears. This trial 
was supported mainly with funds from PATH’s Malaria Vaccine Initiative. KL and KAC and 
TB are supported by a fellowship from the European Research Council (ERC-2014-StG 
639776 to TB). Finally and foremost, we would like to thank the study volunteers who 
participated in this trial. The funder, PATH’s Malaria Vaccine Initiative, was involved in 
the study design, analysis and interpretation of the data, the preparation of the report, 
but not data collection. IJR, MA, GdJ, KC, RWS and TB had full access to all study data with 
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Supplemental Information
AP2-G PCR
Total nucleic acid was RQ1 DNaseI digested (Promega) and cDNA was synthesized using 
the High Capacity cDNA Reverse Transcription Kit (Applied Biosystems) following the 
manufacturers protocol. 2 ul of cDNA was run in a total reaction volume of 20 ul of GoTaq 
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Supplemental Results
Membrane feeding assays after serum replacement
As an exploratory objective, a total of 24 DMFA experiments were conducted where 
volunteer plasma was replaced with malaria-naïve serum (MFA-SR; exactly 25 mosquitoes 
examined per experiment). MFA-SR experiments were conducted only on day 24 post 
inoculation for both inoculation routes. MFA-SR resulted in 67% (8/12) infectious 
individuals and 12% (35/298) infected mosquitoes in the IBSM group. These results were 
considerably lower than the infection rates after MFA-MACS where 100% (12/12), 67% 
(8/12) and 58% (7/12) of individuals were infectious, with 51% (109/215), 34% (75/218) 
and 41% (74/182) infected mosquitoes on day 21, day 24 and day 29 post inoculation 
respectively. No measurable transmission was observed after MFA-SR in the MB group.
gametocyte density
Only data from study arm 4 (N=6) that IBSM inoculated and received piperaquine as a curative 
treatment was included. (A) DFA; direct skin feeding assays. (B) MFA-MACS; membrane feeding 
assay following enrichment for gametocytes by magnetic-activated cell sorting. (C) DMFA; direct 
membrane feeding assay. (D) MFA-SR; membrane feeding assay following serum replacement.
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Trans1; participants of our previous trial (1) and Trans 2; this current studies.
estimation of commitment ratio 
(A) Data from 2 CHMI studies using mosquito bite inoculation only (black dots) (1). (B) All data 
of A, including data from the blood-stage inoculation (red dots). The period of asexual parasitemia 
was calculated from the moment of inoculation (day 0) until day of treatment for participants of the 
blood-stage inoculation, and day 6.5 (the estimated moment of parasites entering the bloodstream) 
after mosquito bite inoculation until day of treatment. The gametocyte commitment rate is estimated 
by dividing the peak gametocyte by the peak of asexual parasites.
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Supplementary Figure 4 – Individual parasite curves
Grey lines represent individual 18S qPCR asexual parasitemia. Red lines represent total 
gametocytemia (sum of CCp4 and PfMGET qRT-PCR). Pink lines represent female gametocytemia 
(CCp4 qRT-PCR). Blue line represents male gametocytemia (PfMGET qRT-PCR).
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Abstract
Background
Levels of both Angiopoietin-1 (Ang-1) and Angiopoietin-2 (Ang-2) correlate with malaria 
disease severity and are proposed as biomarkers and possible therapeutic targets. To 
establish their role in malaria, a systematic review was performed of the literature on 
Ang-1 and Ang-2 with regard to their potential as biomarkers in malaria and discuss their 
possible place in adjuvant treatment regimens. 
Methods
Ten electronic databases were systematically searched to identify studies investigating 
Ang-1 and Ang-2 in human and murine malaria in both clinical and experimental settings. 
Information about the predictive value of Ang-1 and Ang-2 for disease severity and their 
regulatory changes in interventional studies were extracted. 
Results
579 studies were screened; 26 were included for analysis. In all 5 studies that determined 
in P. falciparum malaria, a decline in Ang-1 and an increase of Ang-2 levels was associated 
with increasing disease severity. All 9 studies that determined angiopoietin levels in 
P. falciparum patients to study their ability as biomarkers, could distinguish between 
with Ang-2 as marker, found an AUROC in a range of 0.71-0.83, which performed as well 
or better than lactate. Prophylactic administration of FTY720, rosiglitazone or inhalation 
of nitric oxide (NO) during malaria disease in mice resulted in an increase in Ang-1, a 
decrease in Ang-2 and an increased survival. For rosiglitazone a decrease in Ang-2/Ang-1 
ratio was observed after post-infection treatment in mice and humans with malaria, but 
Conclusion
Both Ang-1 and Ang-2 levels correlate with and can distinguish between malaria disease 
severity states within the group of malaria infected patients. However, distinct comparisons 
of disease severity states were made in distinct studies and not all distinctions made, 
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Background: Possible role of Angiopoietin-1 (Ang-1) 
and Angiopoietin-2 (Ang-2) in malaria
General aspects of malaria and endothelial cell activation
Even though many disease control interventions have been implemented, malaria remains 
a major health problem with an estimated 214 million cases and 438.000 deaths worldwide 
in 2015 (1). Most of these malaria deaths were caused by P. falciparum, one of the six 
Plasmodium species (P. cynomolgi, P. falciparum, P. knowlesi, P. malariae, P. ovale, P. vivax) 
that can infect humans. The high pathogenicity of P. falciparum is in part related to the 
expression of P. falciparum erythrocyte membrane protein-1 (PfEMP-1) on the membranes 
of infected erythrocytes. The infected erythrocytes with PfEMP-1 on the membrane adhere 
to the vascular endothelium of vital organs. This process is called sequestration and will 
uninfected erythrocytes and adherence of uninfected erythrocytes to infected erythrocytes, 
which is called rosetting (2), extensive sequestration will lead to a decline in oxygen 
delivery to the organs. Without treatment, the lack of oxygen will result in acidosis and 
may eventually lead to death in untreated cases, especially in non-immune individuals. Of 
the non-falciparum species, P. vivax, which may run a relatively benign course compared 
to P. falciparum, is most important and can also cause severe malaria and result in death. 
The pathogenesis of P. vivax P. falciparum infection and is still poorly 
understood. P. vivax infects only young erythrocytes – reticulocytes – which can also 
adhere to the vascular endothelium, but showed 10 times less cytoadhesion compared to 
P. falciparum infected erythrocytes in vitro
the species: P. vivax showed a stronger response than P. falciparum did (4). Whether 
cytoadherence in P. vivax
role the cytokine response plays in the pathogenesis remains unclear.
Endothelial cell activation
Endothelial cell activation is crucial in the pathogenesis of P. falciparum infection as 
PfEMP-1 on the erythrocyte membranes interacts with several cytoadherence receptors 
upregulated during malaria infection (5). Activation of endothelial cells is complex and 
endothelial cells have anticoagulant properties due to expression of several proteins, such 
as protein C and thrombomodulin. On the other hand, after activation by e.g. thrombin 
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Factor (vWF), Ang-2, I-CAM, V-CAM and E-selectin (5, 11). Endothelial cell activation 
occurs not only during malaria but also during many other infectious diseases, such 
as bacterial sepsis (12) and dengue haemorrhagic fever (13, 14). To study endothelial 
cell activation during infectious diseases, expression levels of multiple endothelial-cell 
activation markers have been determined and were found to be increased, including the 
vascular growth factors Ang-1 and Ang-2, which were extensively studied during systemic 
malaria has also been investigated. 
Ang-1, Ang-2 and endothelial cell activation
Ang-1 and Ang-2 are ligands of the Tie-2 receptor, which is expressed on endothelial cells 
and regulates endothelial quiescence during normal physiological conditions. Ang-1 is 
constitutively produced and excreted into the blood by pericytes and smooth muscle cells 
and it is also stored in platelets. Ang-1 binds to the Tie-2 receptor, thereby acting as an 
agonist. Upon Ang-1/Tie-2 interaction, the most important downstream signalling event 
is protein kinase B phosphorylation by phosphoinositide-3-kinase resulting in an anti-
Ang-2 is produced in endothelial cells and pre-stored in the Weibel-Palade bodies (WPB) 
together with vWF. Upon activation of endothelial cells, exocytosis of the WPB is induced 
and their content is released into the bloodstream (21). The increased Ang-2/Ang-1 ratio 
causes a replacement of the Ang-1-Tie-2 interaction by an Ang-2-Tie-2 interaction. In the 
presence of Ang-1, Ang-2 acts as a functional antagonist and the Ang-2-Tie-2 interaction 
Ang-1 (see Figure 1). Therefore, Ang-2 release and binding to Tie-2 receptors further 
(22). 
contributes to the increased Ang-2/Ang-1 ratio. The underlying mechanisms of the Ang-1 
role of Ang-1 is protective during malaria and the role of Ang-2 may be harmful.
Ang-1 and Ang-2 are likely to play a role early in malaria pathogenesis
During malaria a decrease in Ang-1 and increase in Ang-2 concentration have been 
observed (15). It is not known whether the decrease of Ang-1 and increase of Ang-2 are 
the result of the endothelium activation status or that the altered levels also contribute 
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to endothelium activation. However, during the initial processes that lead to pathology in 
malaria, Ang-1 and Ang-2 might play a role as i) Ang-1 and Ang-2 levels strongly correlate 
with disease severity and mortality (15), ii) in sepsis, which shares many similarities with 
released rapidly upon activation of endothelial cells as it is pre-stored in WPBs (21). After 
Because of the correlation of Ang-1 and Ang-2 levels with disease severity and mortality, 
Ang-1 and Ang-2 have been evaluated as biomarkers for malaria disease severity in multiple 
around the world. To gain more insight in their role during malaria, the current literature 
concerning the use of Ang-1 and Ang-2 as biomarker in a clinical setting is here reviewed 
systematically. Furthermore, the role of Ang-1 and Ang-2 as potential therapeutic targets 
in malaria is evaluated as they might play a causative role in the pathogenesis. 
receptor
Ang-2 is pre-stored in the Weibel-Palade bodies in endothelial cells and is released upon endothelial 
cell activation. Ang-2 replaces Ang-1 by binding the Tie-2 receptor, preventing its activation and 
Ang-1. Abbreviations: Ang-1, angiopoietin-1; Ang-2, angiopoietin-2; ICAM-1, E-selectin, VCAM-
1, adhesion molecules; PfEMP-1, Plasmodium falciparum erythrocyte membrane protein 1; WPB, 
Weibel-Palade body.
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Methods 
Literature search and inclusion criteria
A broad systematic literature-search strategy was created combining synonyms for 
angiopoietin with synonyms for malaria or Plasmodium. In Embase, Medline and CInahl 
thesaurus terms were used together with words in title and/or abstract. In the other 
databases only titles and/or abstracts were searched. The databases Embase.com, Medline 
(Ovid), Cochrane Central registry of trials, Web of Science, Scopus, cinahl (EBSCOhost), 
Pubmed as supplied by publisher (for the most recent not yet indexed articles), lilacs, 
scielo, ProQuest and Google scholar (an additional search), were searched without data 
limit, from inception lastly on 15 June 2016 ( ). Based on the titles and 
abstracts, potentially relevant articles were selected by two independent reviewers (GMdJ, 
JJS) for full text screening. Articles in English meeting the inclusion criteria were included 
( ). In case of disagreement between the reviewers, a third independent 
reviewer was consulted (JJvH). 
Reported studies were included if Ang-1 and/or Ang-2 protein or mRNA levels were 
Plasmodium 
infection. Through tracking the citations in selected articles, no additional articles were 
found.
Data extraction
The selected articles were grouped, depending on the study aim, into: i) studies performed 
in non-pregnant humans and ii) interventional studies. The aim of studies in group i 
was to correlate Ang-1 and Ang-2 levels with disease severity and in group ii
adjuvant therapy next to antimalarial treatment.
For the articles of group i, information was extracted on the Plasmodium species, the 
study population, the Ang-1 and/or Ang-2 protein and/or mRNA levels or the Ang-2/Ang-
1 ratio in various disease states, and information about the associations of Ang-1 and 
Ang-2 levels with other variables. In the studies included in group ii, data was extracted 
regarding study subject, mice species or population characteristics, details of the studied 
intervention, Ang-1, Ang-2 protein or mRNA levels and the Ang-2/Ang-1 ratio.
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Results
Characteristics of included studies 
26 studies assessing Ang-1 and/or Ang-2 protein and/or mRNA levels in human and/or 
Plasmodium
22 studies were performed in humans only, of which 5 included children and adults in 
Asia and Canada as a single group ( ), 6 studies included adults only and 
were performed in Asia and Brazil ( ), 8 studies included children only 
and were all performed in only African countries ( ) and 1 study included 
a separate group of children and adult (25) ( ). 3 studies provided 
data on mice only ( ). 1 interventional study combined results of studies 
in mice and humans (26) ( ). 
In 9 studies a discriminative value of Ang-1, Ang-2 levels or the Ang-2/Ang-1 ratio for 
disease severity was reported (25, 27-35) ( ). 4 studies determined the 
Ang-1 and/or the Ang-2 level in humans after start of antimalarial treatment (29, 34, 36, 
survival and on Ang-1 and/or Ang-2 levels in mice (38-40), 2 in humans (41, 42) and 1 in 
both humans and mice (43) during Plasmodium species infection ( ). 1 
study used a mouse model with one deleted Ang-1 allele (43) ( ). 
Aim i: Ang-1 and Ang-2 levels as biomarkers for malaria disease severity
Ang-1 is decreased and Ang-2 is increased during Plasmodium species infection in 
non-pregnant humans 
In 10 out of 11 studies comparing healthy controls with either uncomplicated (25, 32, 34, 
35, 37, 44-46), severe (34, 35, 44, 46, 47) or cerebral P. falciparum malaria (25, 32, 37, 
45, 46) or uncomplicated (44, 48) or severe (44) P. vivax malaria, a similar pattern in 
changes was observed for Ang-1 and Ang-2 levels: a decrease of Ang-1 (25, 32), an increase 
of Ang-2 (25, 32, 34, 35, 37, 44-48) and consequently an increase of the Ang-2/Ang-1 ratio 
(25, 32) ( ). Adults and children, living either in endemic areas or 
travellers in non-endemic areas all showed these similar changes. However, 1 study (36) 
out of 3 (25, 32, 36) that determined the Ang-1 levels in P. falciparum malaria found an 
increase in Ang-1 compared with the levels in healthy controls opposed to a decline in the 
P. vivax 
infected patients compared to P. falciparum infected patients in Indonesia, independent 
concentration was observed in P. vivax compared to P. falciparum infected travellers in 
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Canada (49). Barber et al (44) determined also the Ang-2 levels in both uncomplicated 
P. vivax malaria (median pg/ml (IQR)) (4557 (3463-6197)) and P. falciparum malaria 
(3230 (2123-5243)) and in severe P. vivax malaria (8857 (6547-9734)) and P. falciparum 
malaria (8371 (3963-13463). However, this study did not statistically compare the levels 
between the P. vivax and P. falciparum malaria, although Ang-2 seems to be higher in P. 
vivax infected patients especially when the higher parasitaemia of P. falciparum infected 
patients is taken into account. 
disease severity states: lower Ang-1 and higher Ang-2 concentrations were observed in 
severe disease compared to uncomplicated disease in both P. falciparum (25, 28-30, 32, 
34, 44-46) and P. vivax malaria (31, 44) and in non-survivors compared to survivors 
infected with P. falciparum (25, 27, 30, 32-35, 41, 47) ( ). 
Furthermore, an elevated Ang-2 concentration was associated with respiratory distress 
(50), impaired consciousness (50), acute kidney injury (33, 47), multi-organ failure (47), 
anaemia (33), jaundice (33), hypoglycaemia (33), pure cerebral malaria (cerebral malaria 
patients without the other complications of severe malaria according to WHO 2000 
criteria) (33) and higher Ang-1 levels were associated with a higher platelet count in P. 
falciparum and P. vivax infections. (31, 33, 51).
Ang-1 increases and Ang-2 decreases after start antimalarial treatment in survivors
An increase in Ang-1 and a decrease in Ang-2 levels in survivors compared to non-
survivors was observed after the start of treatment in both children (29) and adults (34, 
36) ( ) and one study found an average Ang-2 decrease of 2.7 ng/ml 
over a 24 hour period in survivors (34). Moxon et al (37) found a nearly two-fold decline 
with severe malaria 28 days after the start of treatment. However, 28 days after treatment 
in healthy controls. This lack of decrease to baseline levels might be caused by a 50% loss 
control and patients after treatment. 
Ang-1 and Ang-2 levels have a varying discriminative power for distinguishing 
disease severity states in humans
Uncomplicated P. falciparum malaria can rapidly progress into life-threatening disease due 
to the exponential increase in parasite biomass and sequestration of infected erythrocytes, 
which may lead to organ failure. The currently used biomarkers for disease severity, have 
a limited predictive value to identify those patients that will rapidly progress towards 
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complicated disease (52). Several new markers have been proposed and investigated 
(53) as prognostic parameters for severe malaria, including Ang-1 and Ang-2. In distinct 
studies Ang-1, Ang-2 and the Ang-2/Ang-1 ratio were used to investigate whether they 
27-35) ( ).
The Ang-1 concentration was found to be the best discriminator between uncomplicated 
of 85% (95% CI 76-92) ( ). As expected the more the disease severity 
malaria) the better they could be distinguished (25, 28, 29, 32) ( ). 
Since cerebral malaria is a complication of Plasmodium falciparum malaria and therefore 
a manifestation of severe malaria, distinguishing cerebral malaria from other forms of 
concentration for fatal outcome was found to be as well as plasma lactate in Vietnamese 
adults with severe malaria (33) and in Malawian children with cerebral malaria (27), and 
even better in Indonesian adults with severe malaria (34) ( ). In order to 
increase the discriminative power, two studies used a combination of markers (27, 30). 
Incorporating the i) Ang-2 concentration or ii) the Ang-1, Ang-2 and Tie-2 concentrations 
in a clinical model, comprising age, body condition score, respiratory distress and severe 
survival or fatal outcome compared to the clinical model alone (c-index (95% CI), p-value) 
(i: 0.78 (0.68-0.82), 0.02; ii: 0.79 (0.72-0.84), 0.03) (27). The combination of Ang-2 with 
survivors from non-survivors) (30). 
In addition to the use as biomarker for disease severity in humans infected with Plasmodium 
species, the Ang-1 and Ang-2 concentration may also be used for distinguishing cerebral 
malaria from other diseases involving the central nervous system (CNS) in critically ill 
(95% CI 73-94), respectively ( ) (29).
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Ang-1 and Ang-2 levels do not correlate with parasitaemia, sequestration and 
erythrocyte rosetting
Assuming that Ang-1 and Ang-2 concentrations and parasitaemia, parasite biomass, 
correlation between them may be anticipated. However, no correlation was found between 
concentrations of Ang-1 and Ang-2 or Ang-2/Ang-1 ratio and sequestration in cerebral 
malaria in brain autopsies (33), microvascular obstruction measured with an Orthogonal 
Polarization Spectral device in the rectal mucosa (47) or rosetting as determined by IgG 
antibody levels to the infected erythrocyte surface of ex vivo isolates and corrected for 
disease severity (50). Parasite biomass as measured by PfHRP2 was correlated with Ang-2 
in P. falciparum (34, 44, 47), but not as measured by PvLDH and pLDH in P. vivax. (44). 
P. 
falciparum (25, 33, 34) infected children and adults. However, 3 studies did observe a 
correlation between Ang-2 and the parasitaemia in P. falciparum and P. vivax infected 
children and adults (28, 44) or the Ang-2/Ang-1 ratio (33). Taken together, the relation 
between Ang-1 and Ang-2 and parasite abundance related markers varies between the 
studies. 
Aim ii: Adjuvant therapy next to antimalarial treatment
Ang-1 and Ang-2 concentrations have both been suggested as adjuvant treatment targets 
in malaria (15, 54), but so far interventional studies in mice models or in humans have not 
been performed. Several studies used Ang-1 and Ang-2 as biomarkers for endothelial cell 
activation after an intervention aiming at another target.
Adjuvant treatment strategies 
In distinct included studies P. berghei-Anka infected mice and/or P. falciparum infected 
humans received next to artesunate either a functional S1P receptor antagonist: FTY720 
or LX2031 (38), a PPAR-  agonist: rosiglitazone (43) or inhaled nitric oxide (40-
endothelium activity (55-57). Rosiglitazone increases CD36-mediated phagocytosis 
cerebral malaria model previously (58, 59). NO inhibits the exocytosis of Weibel-Palade 
bodies (60), organelles in endothelial cells that store both vWF and Ang-2. NO levels and 
cofactors required for NO synthesis are known to be reduced during P. falciparum infection 
(34, 35, 45) and higher NO levels are associated with lower Ang-2 levels (34), whereas 
NO inhibitors positively correlate with Ang-2 (46). Several processes contributing to the 
decreased NO levels during malaria have been studied, such as substrate limitation and 
increase in NO inhibitors (35), but these are beyond the scope of this review.
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Adjuvant treatment in mice
No change in Ang-1 levels have been observed in mice treated with FTY720, 1, 3 or 5 days 
after infection nor an increase in survival in treated mice 3 or 5 days after infection (38). 
The survival rates did also not increase in both prophylactic and post-infection LX2931-
treated mice. However, a higher Ang-1 concentration and survival rate were observed in 
mice receiving prophylactic treatment with either FTY720 or iNO compared to placebo 
treated mice (38) ( ). Survival rates increased also in mice receiving 
adjuvant treatment with rosiglitazone or iNO 3 or 5 days after infection compared to 
artesunate only treated mice (40). Rosiglitazone prevented the decrease in the Ang-1 
concentration that was seen in mice treated with artesunate only (43). The Ang-2/Ang-1 
in mice prophylactically treated with iNO (40) or post-infectiously with rosiglitazone 
compared to mice treated with artesunate only (43). These results demonstrated an 
association between prophylactic therapy, decreased endothelium activation and increased 
survival rates. 
When rosiglitazone was given to P. berghei-Anka infected mice with one Ang-1 allele 
deleted (Ang-1del), production of the Ang-1 levels was 30%-50% compared to wildtype 
mice 5-6 days post-infection (43). An increase in survival was only seen in wildtype mice 
treated with rosiglitazone and not in the Ang-1del mice treated with rosiglitazone (43). 
This emphasizes that proper Ang-1 production apparently increases survival in a direct or 
indirect way, and therefore, a role of Ang-1 in the pathogenesis during malaria is likely. 
Adjuvant treatment in humans
iNO as adjuvant therapy for severe malaria and rosiglitazone for uncomplicated malaria 
was also studied in humans. In a total of 272 Ugandan children adjuvant iNO was given 
placebo groups was found in either study. In rosiglitazone treated patients the Ang-2/
None of the patients died or was admitted to intensive care in both the treatment and 
control group. 
Discussion
The role of Ang-1 and Ang-2 as biomarkers and possible therapeutic targets in severe 
malaria are evaluated in this systematic review. Decreased Ang-1 and increased Ang-2 
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concentrations seem to be valuable as biomarker for disease severity and survival. The 
future therapeutic targets are promising, but further studies are warranted. Nonetheless, 
some discussion points before use as biomarkers or therapeutic targets remain. 
Ang-1 and Ang-2 as biomarkers for disease severity
Uncomplicated malaria vs. severe malaria and cerebral malaria 
The results indicate that the decreased Ang-1 and the increased Ang-2/Ang-1 ratio are 
robust biomarkers to distinguish uncomplicated malaria from cerebral malaria (25, 28, 29, 
32). However, it is easier to distinguishing uncomplicated malaria from cerebral malaria 
P. falciparum with coma (Glasgow coma scale <11, Blantyre coma score <3), or malaria 
with coma persisting >30 min after a seizure). Nevertheless, Ang-1, Ang-2 and the Ang-2/
Ang-1 ratio could be valuable markers if they can identify patients with uncomplicated 
malaria at risk for progressing to severe disease. The AUROC (area under the receiver 
operating characteristic) for distinguishing uncomplicated malaria from severe malaria is 
CI 77-92), respectively (28) ( ). This AUROC is higher than for plasma 
lactate (0.67 (95 CI% 0.57-0.75)) or parasitaemia (0.53 (95% CI 0.45-0.62) as found 
in an endemic area (61) and the sensitivity higher than in nonimmune travellers (67%) 
(62). Although the discriminating power of Ang-1 levels is promising, conclusion should 
be drawn with caution, as only one study in children (N=193) evaluated the AUROC to 
distinguish uncomplicated malaria from severe malaria (28). 
Survivors vs. non-survivors
Ang-1 and Ang-2 levels can be used to distinguish malaria disease severity states, but 
prediction of outcome might be of more clinical value. Several studies that focussed on 
clinical outcome demonstrated that the Ang-2 level predicted mortality as well as or better 
than lactate blood levels in adults and children in Asia and Africa with severe and cerebral 
malaria (27, 33, 34). Additional prospective studies that evaluate Ang-1 and/or Ang-2 
these results.
A marker other than parasitaemia to distinguish cerebral malaria from ‘other diseases with 
involvement of the CNS’ might be useful in patients with parasitaemia, as asymptomatic 
mild parasitaemia is not uncommon in malaria endemic areas (63, 64). Direct and indirect 
ophthalmoscopy can be used for this aim if retinopathy is observed with certain malaria-
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90% for diagnosing cerebral malaria (65). The Ang-1 concentration and the Ang-2/Ang-1 
ratio were found to be good discriminators between ‘cerebral malaria with retinopathy’ 
and ‘other diseases with involvement of the CNS’ ( ). However, ‘cerebral 
malaria with retinopathy’ is already a selected group within the total group of patients 
a marker for cerebral malaria - patients with mild parasitaemia and a non-malaria 
disease that involves the CNS -, were not represented in both studies that investigated the 
capacity of angiopoetin levels to distinguish cerebral malaria from ‘other diseases with 
involvement of the CNS’ as parasitaemia in the latter group was absent. Nevertheless, to 
evaluate whether Ang-1 and/or Ang-2 levels can identify these patients might be of clinical 
value. 
Treatment follow-up 
valuable as treatment regimens may be reconsidered when patients do not properly 
recover. In both humans (29, 34, 36, 37, 42, 43) and mice (38-40, 43) recovery from 
malaria and survival was associated with an increase in Ang-1 and decrease in Ang-2 level 
( ). However, the threshold for an Ang-1 increase or Ang-2 
levels compared with other clinical or laboratory indices, e.g. fever or parasite clearance, 
which would be of interest. 
Variation between studies
Even though Ang-1 and Ang-2 concentrations could discriminate between disease severity 
( ). This variation may be due to: a) host-related factors, such as genetic 
Plasmodium species infection between study populations, b) pathogen-related factors, 
c)
result in delayed diagnosis or delayed start of proper treatment. In addition, the methods 
by which Ang-1 and Ang-2 levels are determined are still further developed and currently 
lack proper standardization. Additional investigations are required before conclusions on 
the varying levels can be drawn. 
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Ang-1 and platelet activation
A lower Ang-1 level was found in healthy controls compared to P. falciparum infected 
patients in 1 study which collected blood in CTAD tubes (36). These tubes contain the 
platelet stabilizing agents citrate, theophylline, adenosine and dipyridamole, which 
together result in a nearly complete block of in vitro platelet activation (66, 67). The 
found a higher level Ang-1 in healthy controls compared to P. falciparum infected patients. 
In addition, other studies that determined Ang-1 in malaria patients found a negative 
correlation between Ang-1 and disease severity. It is remarkable that the only study using 
tubes that avoid in vitro platelet activation found a higher level of Ang-1, which is stored 
in platelets and released upon activation, in patients than in healthy controls. Platelet 
activation may occur in vivo during malaria as induction of coagulation is proven even in 
early malaria (68). To exclude altered Ang-1 levels due to in vitro platelet activation after 
blood collection, platelet-poor specimens are preferred to determine platelet activation 
in vivo. 11-dehydrothromboxane B2 is a breakdown product of thromboxane A2 that is 
produced in vivo by activated platelets. Since 11-dehydrothromboxane B2 is excreted in 
urine, a specimen that is free of platelets, determination of 11-dehydrothromboxane B2 in 
urine samples may estimate in vivo platelet activation most accurately (69). 
Lack of consistent associations between Ang-1, Ang-2 and the parasitaemia in P. falciparum
Even though Ang-1 and Ang-2 concentrations correlate with disease severity, the results 
of the correlation between Ang-1 or Ang-2 concentrations in P. falciparum infection and 
parasitaemia, sequestration or rosetting vary between the studies (25, 28, 33, 34, 44, 47, 
50). The lack of a consistent correlation of the Ang-1 concentration, Ang-2 concentration 
and Ang-2/Ang-1 ratio with parasitaemia may be due to the fact that this parameter is 
parasites are not adequately taken into account. A correlation between PfHRP2, which 
P. falciparum infection and Ang-2 was found in 3 studies 
(34, 44, 47), but sequestration (47) and rosetting corrected for disease severity (50) did 
not correlate with Ang-1 and/or Ang-2 concentrations. The correlation between Ang-2 
with parasite load but not with sequestration and rosetting might be due to a) the fact 
that PfHRP2 levels (34, 44, 47), measuring sequestration with a OPD device (47) and IgG 
antibody levels (50) are all markers that may not estimate their biological phenomena 
similarly, b) a temporal dissociation of the determinations (47), c) loss of correlation due 
to the fact that locally observed phenomena –sequestration and rosetting– were compared 
to a systemic phenomenon –Ang-2 release– (47), or d) the infected erythrocytes may 
activate endothelial cells not by direct, physical contact, but indirectly by inducing other 
endothelial cell activators, such as cytokines (70, 71). Next to the quantity of parasite 
biomass, also the Plasmodium strain and the host response might contribute to the 
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variations in Ang-2 increase. Although it should be noted that an included study (50) 
did not show a relation between Ang-2 and group A-like PfEMP expression if corrected 
in that study. Taken together, the host-response related marker Ang-2 might be a good 
or better biomarker for disease severity and treatment follow-up than pathogen-related 
markers, such as parasite load or parasitaemia. 
Ang-2 in P. vivax vs. P. falciparum malaria
Data on Ang-2 levels in P. vivax and P. falciparum 
studies found a higher Ang-2 level in P. falciparum compared to P. vivax (44, 48) and 1 
study found a higher Ang-2 level in P. vivax compared to P. falciparum (49). However, 
populations: patients in endemic areas (44, 48) versus travellers in non-endemic regions 
(49) and the parasitaemia was not reported in all studies (49). In addition, the blood 
samples of P. vivax and P. falciparum of infected Canadian travellers were processed 
in P. vivax compared to P. falciparum are plausible as P. vivax is known to induce a stronger 
cytokine response (4), which was also shown in an included study in adult in an endemic 
area (48). These cytokines might contribute to endothelial cell activation and therefore 
to Ang-2 release from Weibel-Palade bodies. Interestingly, in P. vivax infected patients 
Ang-2 levels did not correlate with pLDH and PvLDH, which were proposed as markers 
that take both peripheral and hidden parasite load into account. Instead, a correlation was 
found between Ang-2 levels and parasitaemia. This might suggest a cytokine-independent 
endothelial cell activation, as both hidden and peripheral infected erythrocytes should 
contribute to the induction of the cytokine response. On the other hand, pLDH and PvLDH 
are not as well established markers for the parasite biomass in P. vivax infected patients 
(72) as PfHRP2 is in P. falciparum
between P. vivax and P. falciparum malaria and the role of endothelium activation during 
both Plasmodium infections. 
 
Clinical implementation 
states in malaria disease and might predict disease progression, their use in routine clinical 
practice is not possible yet. Malaria disease mainly occurs in resource-poor settings where 
it is not possible to determine Ang-1 or Ang-2 with complex laboratories techniques. If 
Ang-1 and Ang-2 are shown to be robust biomarkers for disease progression, new simple 
rapid-point-of-care tests need to be developed for clinical use, as was done before for 
CRP (73) and for multiple haematological, biochemical and coagulation parameters (74). 
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Furthermore, the clinical consequences of a marker for disease progression are currently 
limited as no adjuvant treatment is available yet next to medication to eradicate the 
parasite. However, development of adjuvant treatment and biomarkers to indicate which 
patients should receive adjuvant treatment go hand in hand and multiple adjuvant 
treatment strategies are currently investigated (as reviewed by (75, 76)). 
The possible role of Ang-1 and Ang-2 in adjuvant treatment regimens for P. 
falciparum malaria
Studies using Ang-1 or Ang-2 as therapeutic target were only performed in sepsis, which 
shares many similarities with severe malaria caused by a P. falciparum infection. Both 
sepsis and malaria are characterized by cytokines release, coagulation alterations and 
endothelial cell activation (15, 18, 23). In sepsis Ang-1 was the mostly studied angiopoietin 
in interventional murine models (as reviewed by (24)). Ang-1 was found to be protective 
in endotoxin-induced shock or hyperoxia-induced lung injury models. However, most 
studies used Ang-1 treatment prior to infection which is not useful in a clinical setting 
for sepsis nor for malaria. Some of the studies giving Ang-1 after development of sepsis 
or acute lung injury found no reduction in mortality while others reported a positive 
P. berghei ANKA infected CB57BL/6 mice, 
which are widely used as a model for human cerebral malaria, do show histopathological 
contribute to the contrasting results in outcome between iNO treated P. berghei ANKA 
infected mice and P. falciparum infected humans. This is supported by the observation 
in human cerebral malaria (as reviewed by (78) ). More investigations on the therapeutic 
conclusions about the therapeutic properties of Ang-1 and/or Ang-2 can be drawn.
 
The complexity of the host response to the Plasmodium species infections possibly plays 
malaria disease in humans and mice the immune system, coagulation system and the 
activity of endothelial cell are all systematically altered. These processes are complex and 
interweaved which each other (see Figure 2). Providing even multi-targeted adjuvant 
treatment with FTY720 or iNO at the moment that these regulatory systems are already 
these feed-forward stimulated processes. Multi-targeted adjuvant treatment such as 
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Ang-2 levels and survival when administered post-infection, may however interfere with 
all the distinct regulatory systems in a way that reduces morbidity and mortality (43) (see 
Figure 2
on the determinants
Coagulation, endothelial cell activation and immune system activation are processes that stimulate 
each other. FTY730, LX2931 and NO inhibit the immune system activation and endothelial cell 
activation. Rosiglitazone inhibits immune system activation, endothelial cell activation and 
upregulates CD36 which result in increased phagocytosis of the infected erythrocytes.
Conclusion
Ang-1 and Ang-2 concentrations correlate with disease severity and survival in malaria 
and showed a good discriminative power to distinguish disease severity states with 
predictive values equal to, or higher than, the currently used biomarkers plasma lactate 
studies and not every distinction has clinical impact. The possible ability of Ang-1 and 
disease and to predict those patients progressing from uncomplicated malaria towards 
severe malaria will have clinical value and should be studied in more detail before it can 
be used in routine practice. 
For further optimization of treatment of patients with severe disease, multi-targeted 
adjuvant treatment regimens are needed. Agents interfering with Ang-1 and or Ang-2 
may be included in such adjuvant therapy as their role as therapeutic target is promising. 
However, it is conceivable that agents interfering with multiple pathways are necessary, 
since multiple regulatory systems are consecutively activated during malaria infection. 
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Additional data
Search performed on 15 June 2016
Database Number of publications Number of publications after 
deduplication
Embase.com 170 166








Google scholar 100 58
Total 579 278
Table 1: Number of publications extracted from the indicated databases
Syntaxis of search strategies
Embase.com 
(angiopoietin/exp OR ‘angiopoietin 1’/exp OR ‘angiopoietin 2’/exp OR ‘angiopoietin 
receptor’/exp OR ‘angiogenic protein’/exp OR ‘angiogenic factor’/exp OR (angiopoietin* 
OR angiogenic* OR angpt* OR ‘ang 1’ OR ‘ang 2’ OR ang1 OR ang2 OR (tie NEAR/3 
(receptor* OR protein*)) OR tek OR tie1 OR tie2 OR (Tyrosine* NEAR/3 kinase* NEAR/3 
immunoglobulin*))) AND (malaria/exp OR Plasmodium/exp OR ‘antimalarial agent’/de 
OR (malaria OR Plasmodium OR antimalari*))
Medline (ovid) 
(exp angiopoietins/ OR exp “Receptors, TIE”/ OR “Angiogenic Proteins”/ OR (angiopoietin* 
OR angpt* OR “ang 1” OR “ang 2” OR ang1 OR ang2 OR (tie ADJ3 (receptor* OR protein*)) 
OR tek OR tie1 OR tie2 OR (Tyrosine* ADJ3 kinase* ADJ3 immunoglobulin*))) AND (exp 
malaria/ OR exp Plasmodium/ OR “Antimalarials”/ OR (malaria OR Plasmodium OR 
antimalari*))
Ang-1 and Ang-2: biomarkers or therapeutic targets?  |  
Cochrane 
((angiopoietin* OR angiogenic* OR angpt* OR ‘ang 1’ OR ‘ang 2’ OR ang1 OR ang2 OR (tie 
NEAR/3 (receptor* OR protein*)) OR tek OR tie1 OR tie2 OR (Tyrosine* NEAR/3 kinase* 
NEAR/3 immunoglobulin*))) AND ((malaria OR Plasmodium OR antimalari*))
Web-of-science 
TS=(((angiopoietin* OR angiogenic* OR angpt* OR “ang 1” OR “ang 2” OR ang1 OR ang2 
OR (tie NEAR/3 (receptor* OR protein*)) OR tek OR tie1 OR tie2 OR (Tyrosine* NEAR/3 
kinase* NEAR/3 immunoglobulin*))) AND ((malaria OR Plasmodium OR antimalari*)))
Scopus 
TITLE-ABS-KEY(((angiopoietin* OR angiogenic* OR angpt* OR “ang 1” OR “ang 2” OR 
ang1 OR ang2 OR (tie W/3 (receptor* OR protein*)) OR tek OR tie1 OR tie2 OR (Tyrosine* 
W/3 kinase* W/3 immunoglobulin*))) AND ((malaria OR Plasmodium OR antimalari*)))
cinahl (ebsco) 
(MH “Angiogenic Proteins” OR (angiopoietin* OR angpt* OR “ang 1” OR “ang 2” OR ang1 
OR ang2 OR (tie N3 (receptor* OR protein*)) OR tek OR tie1 OR tie2 OR (Tyrosine* N3 
kinase* N3 immunoglobulin*))) AND (MH malaria+ OR MH “Antimalarials” OR (malaria 
OR Plasmodium OR antimalari*))
Google scholar 
angiopoietin|angiopoietins|angiogenic|angpt|angpt1|angpt2|angpt3|angpt4|”ang|tie 




(angiopoietin* OR angiogenic OR angpt* OR ang1 OR ang2 OR ang3 OR ang4 OR tie1 
OR tie2 OR “tie receptor” OR “tie protein” OR “Tyrosine kinase immunoglobulin”) AND 
(malaria OR Plasmodium OR antimalaria*)
ProQuest
(ti(angiopoietin* OR angiogenic OR angpt* OR ang1 OR ang2 OR ang3 OR ang4 OR 
tie1 OR tie2 OR “tie receptor” OR “tie protein” OR “Tyrosine kinase immunoglobulin”) 
OR ab(angiopoietin* OR angiogenic OR angpt* OR ang OR tie OR ang1 OR ang2 OR 
ang3 OR ang4 OR tie1 OR tie2 OR “tie receptor” OR “tie protein” OR “Tyrosine kinase 
immunoglobulin”)) AND (ti(malaria OR Plasmodium OR antimalaria*) OR ab(malaria OR 
Plasmodium OR antimalaria*))
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Liver injury in uncomplicated malaria is an 
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Abstract
Background 
Liver injury is a known feature of severe malaria, but is only incidentally investigated 
in uncomplicated disease. In such cases, drug-induced hepatotoxicity is often thought to 
be the primary cause of the observed liver injury, and this can be a major concern in 
antimalaria drug development. We investigated liver function test (LFT) abnormalities 
in patients with imported uncomplicated malaria, and in Controlled Human Malaria 
Infection (CHMI) studies.
Methods 
Clinical and laboratory data from 484 imported malaria cases and 254 CHMI participants 
were obtained from the Rotterdam Malaria Cohort database, and the Radboud University 
Medical Center database (between 2001-2017), respectively. Routine clinical LFTs, clinical 
in 217 patients with imported falciparum malaria upon admission, and from longitudinal 
data of 187 CHMI participants. 
Results 
Upon admission, the proportion of patients with imported uncomplicated malaria and 
elevated liver enzymes was 128/186 (69%). In CHMI, 97/187 (52%) participants showed 
peaked shortly after initiation of treatment, regardless of drug regimen, and returned to 
normal within three to six weeks. Positive associations were found with parasite burden 
and oxidative stress markers (r=0.65, p=0.008, and r=-0.63, p=0.001, respectively).
Conclusion 
This study shows that reversible liver injury is a common feature of uncomplicated 
falciparum 
treatment. The recognition of this phenomenon is of clinical relevance for individual 
patient care as well as clinical development of (new) antimalarial drugs. 
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Introduction
Malaria continues to play a critical role in the global infectious disease burden with 
travelers are also at risk in more than 90 countries worldwide, mainly in Africa, Asia, and 
induced by asexual Plasmodium parasites. Plasmodium falciparum is responsible for most 
malaria-related deaths globally (1). Severity of disease is determined by multiple factors, 
including parasite species and timing of antimalarial treatment (2). The majority of severe 
falciparum malaria manifestations are most likely related to cytoadherence of parasitized 
red blood cells (RBCs) to the vascular endothelium, to each other (platelet-mediated 
agglutination) (3), or to uninfected erythrocytes (rosetting) (4, 5). The subsequent 
sequestration in the microvasculature results in decreased local oxygen supply and a 
disturbed metabolism, eventually leading to vital organ failure.
Hepatic dysfunction and jaundice are common features of severe malaria (6-9). 
Histopathological changes in the liver range from hepatocyte necrosis, granulomatous 
failure and other systemic complications (9, 12, 13). The underlying pathogenesis of liver 
damage is largely unknown. Furthermore, liver involvement has only been incidentally 
investigated in uncomplicated malaria (14-16).
Previously, we regularly observed pronounced elevations in liver function tests (LFTs) 
often shortly upon initiation of curative treatment in patients with imported uncomplicated 
malaria. We hypothesized that liver injury might arise through a mechanism other than 
drug-induced hepatotoxicity, or the substantial sequestration observed in severe disease 
(4, 17). Understanding this clinical feature of uncomplicated malaria could support 
clinicians in drug-related decision making, and in particular drug development, where 
frequency of adverse hepatic reactions is a leading concern. Here, we performed a 
retrospective analysis to determine the frequency of LFT abnormalities in patients with 
imported uncomplicated malaria, and used longitudinal prospective data of controlled 
and pathophysiological basis of liver injury.
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Methods
Study design and population 
Clinical and laboratory data from 484 imported malaria cases and 254 individuals 
participating in 17 CHMI studies were obtained from the Rotterdam Malaria Cohort 
database, and the Radboud University Medical Center database, respectively. The 
Rotterdam Malaria Cohort consists of patients diagnosed with imported malaria who 
presented at the Rotterdam Harbour Hospital or the Erasmus University Medical Center 
between 2002 and 2017. For this study, clinical and laboratory data from patients with 
imported P. falciparum malaria were selected ( ). Patients with a known history of 
liver disease, or concomitant infections at admission were excluded (e.g. hepatitis B, HIV, 
schistosomiasis, urinary tract infections, and respiratory tract infections). Furthermore, 
patients that received antimalarial treatment prior admission were also excluded. Data on 
concomitant medication use other than antimalarial treatment, antipyretic therapy (e.g. 
acetaminophen) or information on (chronic) alcohol intake were not available. Because of 
the retrospective nature of the analysis and use of anonymized data, ethical approval or 
informed consent was not necessary, as stated in the Medical Research involving Human 
Subject Act (WMO).
Healthy malaria-naïve male and female participants aged 18-35 years were recruited for 
the CHMI studies between 2001 and 2016. Extended screening included hematology and 
biochemistry parameters, serology for asexual stages of P. falciparum, and hepatitis B, C 
and HIV, as previously described (16, 18). All study participants provided written informed 
consent at screening visit. All clinical trials were approved by the Radboudumc Committee 
on Research Involving Human Subjects (CMO), the Central Committee on Research 
Involving Human Subjects (CCMO) of the Netherlands, or the Western Institutional 
Review Board (WIRB). The studies were conducted according to the principles outlined 
in the Declaration of Helsinki and Good Clinical Practice standards, and registered at 
ClinicalTrials.gov. Study EHMI-3, conducted in 2001, was not registered in an online 
database such as ClinicalTrials.gov. 
Controlled Human Malaria Infection 
CHMI participants were all challenged by bites of malaria-infected mosquitoes or direct 
venous inoculation of sporozoites/blood stage parasites. The challenges were conducted 
NF135 (Cambodia) (21), and NF166 (Guinea, West Africa) (22). Daily blood sampling 
included parasitological assessment (thick blood smears and qPCR) and/or safety 
laboratory parameters. 
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Laboratory investigations
All clinical laboratory data were assessed by standard hematological and biochemical 
tests on peripheral blood specimens. Biochemical liver tests included: aspartate 
aminotransferase (AST), alanine aminotransferase (ALT), gamma-glutamyl transferase 
Reference laboratory values for AST were <30 or <35 U/L (female or male); ALT <35 or 
(female or male); total bilirubin <17 μmol/L; LD <250 U/L (S2 table). 
based multiplex (Legendplex). For the oxidative stress analysis, TaqMan gene expression 
Assays (Applied Biosystem) were used to measure antioxidant gene expression levels for 
Superoxide dismutases (SOD1 and SOD2), Nitric oxide synthase (NOS3), Catalase (CAT), 
Peroxiredoxin (PRDX1) and Glutathione S-transferase Kappa (GSTK1) from whole blood 
by using qPCR (S1 Material). The cumulative anti-oxidant and cytokine responses were 
determined through transformation of data into a Z-score (each value subtracted by the 
mean of the group and divided by the SD of the group).
Liver function test (LFT) abnormalities were graded using an adaptation of the World Health 
Organization (WHO) Adverse Event Grading System 2003: mild 
2.5x upper limit of normal (ULN)), moderate severe (>5.0XULN) 
absence of WHO criteria 2014(23) for severe P. falciparum malaria on admission or during 
hospitalization. Abnormal bilirubin levels were not included in the incidence or grading of 
LFT abnormalities, since the bilirubin increases found in the imported malaria cases most 
imported malaria. Similarly, lactate dehydrogenase (LD) was not included in the incidence 
or grading of LFT abnormalities, due to its strong relation to haemolysis and low liver 
immune. In short, patients born in a malaria-endemic country living in the Netherlands 
were considered partially immune. Patients that were born and still residing in a malaria-
endemic area were presumed semi-immune. All other patients were considered non-
immune (24). Data on previous episodes of malaria were not available.
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The parasite load was estimated by measuring the area under the curve of parasitaemia 
over time, and computed by GraphPad Prism 5 (2009, San Diego California USA).
Statistical analysis
All data were analyzed with GraphPad Prism 5 or SPSS software version 24 (IBM 
Inc., Chicago, IL, USA). Descriptive analyses are presented as percentages, mean with 
standard deviation, or median with inter-quartile range. Mann Whitney U test was used 
for comparison of non-normal continuous data or independent groups/samples. Chi 
square test or Fisher’s exact test was used for comparison of qualitative variables and 
parameters was assessed by Spearman’s rho. A P-value of < 0.05 was considered as 
Results
The general characteristics on admission of the 217 included patients with imported 
P. falciparum malaria are shown in table 1 and S1 table. On admission day, LFTs were 
increased in 128/186 (69%) of patients with uncomplicated falciparum malaria (table 1) 
and 27/31 (87%) in severe disease (S1 table). In uncomplicated disease, abnormalities 
appeared to be mild in 93/186 (50%), moderate in 26/186 (14%), and severe in 9/186 
(4.8%) of the cases. The median ALT of all uncomplicated malaria patients with LFT 
abnormalities was 48 U/l (range 15-242 U/l, IQR 34-68 U/l), and the median AST was 41 
49-113 U/l), the median ALP was 83 U/l (range 36-265 U/l, IQR 64-101 U/l), the median 
total bilirubin was 22 μmol/l (3-115 μmol/l, IQR 17-43 μmol/l), and the LD was 286 μmol/l (range 52-656 μmol/l, IQR 113-346 μ
were found between ages, gender, or immune status in patients with- or without LFT 
abnormalities. Furthermore, LFT abnormalities appeared in all treatment groups (table 
1). In a sub-group analysis of the malaria cohort, increases in LFT abnormalities were also 
found in 23/50 (46%) of the patients with a Plasmodium vivax infection (S1 table). No 
LFT abnormalities were observed (S1 table).
studies with a total of 254 participants with patent parasitaemia, showed that LFTs were 
elevated in 97/187 (52%) of the participants with LFTs measured during infection (table 
Liver injury during malaria  |  
  No LFT# LFT# p-value 
(n=58) (n=128)
Age 37 (29-50) 39 (30-47) 0.960
Gender 0.390 a
female 18 (31%) 32 (25%)
male 40 (69%) 96 (75%)
Immunity 0.270 a
Unknown 3 (5%) 1 (1%)
Non-immune 27 (47%) 57 (45%)
Partially 26 (45%) 65 (51%)
Semi 2 (3%) 5 (4%)
7.611 (1.582-44.550) 5.466 (1.146-47.100 0.811
AST (U/L) 21 (17-26) 41 (31-63) <0.001
ALT (U/L) 25 (19-30) 48 (34-68) <0.001
30 (20-37) 71 (49-113) <0.001
Alkaline phosphatase (U/L) 65 (57-79) 83 (64-101) <0.001
21 (10-28) 22 (15-31) 0.039
LD (U/L) 275 (196-304) 286 (113-346) 0.181
Haemoglobin (mmol/L) 8.1 (7.4-8.9) 8.7 (7.7-9.4) 0.006
Leukocytes (x109/L) 4.9 (4.0-5.8) 4.9 (3.6-6.4) 0.863
Lymphocytes (x109/L) 0.9 (0.6-1.4) 0.9 (0.6-1.4) 0.998
Thrombocytes (x109/L) 125 (69-174) 87 (56-131) 0.008
CRP (mg/L) 64 (30-116) 106 (56-158) 0.001
95 (81-108) 95 (81-108) 0.400
Urea (mmol/L) 4.9 (3.9-6.2) 5.2 (4.0-6.4) 0.498
Sodium (mmol/L) 136 (133-138) 135 (133-138) 0.578
Potassium (mmol/L) 3.8 (3.5-4.2) 3.7 (3.5-4.0) 0.299
Lactate (mmol/L) 1.3 (1.0-1.5) 1.4 (1.1-1.9) 0.017
Temperature (0C) 37.6 (36.9-38.8) 38.9 (37.5-39.5) 0.001
Treatment 0.532 a
atovaquone/proguanil 50 (86%) 108 (84%)
quinine 4 (7%) 4 (3%)




Mild LFT# n/a 93 (73%)
Moderate LFT# n/a 26 (20%)
Severe LFT# n/a 9 (7%)
All data are presented as median (IQR) or N (%). LFT#= liver function test abnormalities. Statistical 
aChi-square. *Clinical laboratory reference ranges can be found in S2 table.
Table 1 –  malaria 
on admission
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2). In most cases standard LFT measurement time-points were obtained at baseline, 2 days 
post-treatment, and at the end of study. Elevations were primarily limited to ALT/AST 
83/129 (64%) of the CHMI participants when treated at positive thick smear (treatment 
threshold of ~>5 parasites/μ
table 
2). The incidence of LFT elevations was 14/58 (24%) in volunteers treated at positive 
qPCR (treatment threshold of >0.1 parasites/μL), including mild (12/14 (86%)), moderate 
(1/14 (7%)), and severe (1/14 (7%)) elevations (table 2). Among all CHMI participants 
the median peak ALT was 69 U/l (range 13-870 U/l, IQR 46-98 U/l), and median peak 
AST was 52 U/l (range 22-723 U/l, IQR 43-85 U/l) from all sample collection time-points 
peak ALP was 79 U/l (range 17-218 U/l, IQR 67-94 U/l), median peak total bilirubin was 11 μmol/l (range 3-31 μmol/l, IQR 9-15 μmol/l), and median peak LD was 422 μmol/l (range 
170-981 μmol/l, IQR 198-396 μ
2.5xULN) of total bilirubin levels. 
When more frequently assessed over the course of the study (2 CHMI studies, n=34), 
mild LFT elevations became apparent just prior to initiation of treatment ( ). The 
majority of LFT abnormalities exceeded the upper limit of normal on the day of treatment, 
and peaked around 2-6 days after initiation of antimalarials. This corroborates with data 
from EHMI-3 (n=5) where treatment is initiated 48 hours after a positive thick smear. The 
observed abnormalities were transient, normalizing at study end (around day 35–42 after 
challenge infection). Furthermore, a distinct pattern of timing of peak of transaminase 
elevations is found between individuals. Some participants show peak elevations early 
To compare the dynamics of LFT abnormalities between CHMI and imported cases, data 
of 51 patients with imported uncomplicated malaria with multiple LFTs measurements 
were also obtained to analyze the course of LFT elevations ( ). A similar LFT 
pattern was found in both naturally-acquired infections and CHMI participants, where 
LFT elevations peaked after treatment and normalized during follow-up. In contrast to 
CHMI-participants, total bilirubin levels in patients with imported P. falciparum malaria 
were increased on admission day, suggesting a concomitant haemolysis most likely due to 
2-3 log higher parasite densities.
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Figure 1 – Course of liver function test (LFT) levels during CHMI
Multiple LFT measurements of the LSA-3 and CHMI-trans1 study (n=34). LFT sampling time-points 
points prior- and post-treatment. ALT= alanine aminotransferase, AST= aspartate aminotransferase, 
grey individual participants curves per LFT.
CHMI participants with LFT abnormalities presented with a higher parasite load than those 
without LFT abnormalities (p<0.001), although the range was relatively large (figure 
2A). There was a positive association between LFT values and parasite load in the CHMI 
studies (r=0.33, p<0.001) (
uncomplicated P. falciparum infections, a positive association was found between parasite 
density on admission day, and LFT abnormalities (r=0.25, p=0.005).
Clinical laboratory parameters and liver function tests
Analysis of clinical laboratory parameters in CHMI participants showed that lowest platelet, 
leukocyte, and lymphocyte counts, as well as maximum LD levels, independently associated 
with LFT abnormalities (p<0.0001, p=0.01, p<0.0001, p<0.0001, respectively) (figure 3). 
However, prior to treatment these parameters poorly predicted LFT abnormalities.
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might play a role in these abnormalities. In the imported uncomplicated malaria cases, 
C-reactive protein (CRP) was increased on the day of admission in patients with LFT 
abnormalities (p<0.001) (figure 2C
in maximum d-dimer levels in CHMI participants with or without LFT abnormalities 
(p<0.001) ( ). 
(CHMI-trans1, n=16) one day after treatment, showing a positive correlation between 
p=0.039, p=0.049, and p=0.015, 
respectively (S3 table). A strong positive association was also found between the 
A) Parasite load in CHMI without- (no LFT#), and with LFT abnormalities (LFT#). Error bars 
represent median with inter-quartile range. Parasite load as the area under the curve (AUC) 
represents the total parasite exposure over time. B) Association of parasite load and severity of liver 
function abnormalities in x the upper limit of normal of LFTs (xULN of LFTs) in CHMI subjects. 
C) C-reactive protein (CRP) levels of patients with imported uncomplicated P. falciparum malaria 
on admission day. D) Maximum d-dimer levels measured in participants with LFT abnormalities 
(LFT#) in CHMI. D-dimer data are from 6 CHMI studies (n=81) with multiple samples measured 
during challenge infection. Error bars represent the median with inter-quartile range. ***p<0.001.
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18) and LFT abnormalities (r=0.65, p=0.008) ( ). In a second study (EHMI-8B 
( ). 
in the average of anti-oxidant gene expression SOD1 (p=0.03), SOD2 (p=0.001), NOS3 
(p<0.0001), CAT (p<0.0001), and GTSK1 (p<0.0001) and an increase in expression of 
PRDX1 (p=0.007) was observed during the malaria infection (one day after treatment) (S4 
. The cumulative anti-oxidant response of these markers through transformation 
into a Z-score, showed a negative association between the anti-oxidant response and the 
LFT abnormalities (r=-0.63, p=0.001) ( ). All markers normalized by the end of 
the study.
Figure 3 – Clinical laboratory parameters and liver function test (LFT) abnormalities in CHMI
Maximum lactate dehydrogenase (LD), and minimum platelets, leukocytes, and lymphocytes 
measured in CHMI participants without-, and with LFT abnormalities (LFT#). Error bars represent 
the mean with SD. **P=0.004; ***p<0.001. 
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levels and cumulative anti-oxidant gene expression
and the cumulative anti-oxidant gene expression comprises SOD1, SOD2, NOS3, CAT, GTSK1, and 
PRDX1measured on 1 day after treatment (DT+1) in CHMI-trans1. Values are standardized as a 
Z-score. xULN of LFTs = x upper limit of normal range of liver function tests (LFTs). The xULN of 
LFTs values are the peak LFT abnormalities measured from day 2 after treatment and the samples 
available onwards.
Discussion
This study shows that abnormalities in liver function test (LFT) are a relatively frequent 
regimen. These abnormalities are transient in nature, resolving within 3-6 weeks. The 
typical pattern of LFT elevations is primarily limited to ALT/AST elevations, and to a 
markers. Early treatment based on qPCR thresholds can decrease the occurrence and 
severity of LFT abnormalities in CHMI.
Hepatic dysfunction is a well-known feature of severe malaria, contributing to clinically 
uncomplicated malaria, however, has rarely been investigated so far (25). Observational 
studies are often restricted in number and limited to admission samples only(15), 
the relevance in relation to potential clinical implications in uncomplicated disease, which 
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constitutes the vast majority of clinical malaria cases. This study highlights that LFT 
abnormalities can be severe (up to > 20 xULN), but are apparently fully reversible upon 
parasitological cure, corroborating previous reports (25-27). 
The observed liver injury seems to have a hepatocellular basis, as indicated by the 
disproportionate elevation in serum transaminases relative to alkaline phosphatase. 
Peak bilirubin levels precede antimalarial treatment in imported malaria cases but not 
CHMI. This suggests that these elevations are likely due to haemolysis leading from 
higher parasitaemia in these patients compared to CHMI volunteers. Similarly, Woodford 
et al. show that bilirubin elevations in clinical cases peak on admission day, resolving 
early after treatment in contrast to the later occurring peak of transaminases (14). The 
absence of clearly elevated bilirubin levels in CHMI adduces that these events may not 
result in a functional liver impairment, since conjugation of bilirubin occurred normally. 
Serum albumin or clotting factors were not tested in the current study, and therefore, it 
cannot be formally excluded that biosynthetic capacity of the liver may be compromised. 
The absolute increase in serum transaminases is of little prognostic value since the liver 
can recover from most forms of acute injury, due to its large regenerative capacity. In 
dysfunction seems highly unlikely in patients without history of liver disease. 
The potential contribution of infection transformation, from the liver stage to blood stage 
infection, to LFT abnormalities remains uncertain. However, similar LFT abnormalities 
are found CHMI studies with a blood stage challenge, where the liver stage of the 
parasite is circumvented (14). This, together with the observation that no substantial LFT 
abnormalities are found on day 6-7 (day of liver schizont rupture), makes it less likely that 
This study provides evidence that the underlying pathogenesis of liver injury in 
malaria, tissue damage is thought to be at least partly related to decreased oxygen supply and 
disturbed metabolisms due to parasite sequestration in the microvascular capillary system 
(7, 17). However, in CHMI only very low parasite densities are present and sequestration 
d-dimer, CRP, and IFN-y concentrations is a typical hallmark of malaria even at the very 
low density of parasitaemias as observed after CHMI (28, 29). This study shows a clear 
relationship between these parameters and LFT abnormalities in falciparum malaria. 
Together with the timing of LFT abnormalities post treatment, and the presence of low-
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Similarly, lung injury with impaired alveolar-capillary function is described to deteriorate 
killing (30). Histopathology of lung tissue in vivax malaria supports this hypothesis 
with an increase in alveolar-capillary monocytes and pulmonary phagocytic cell activity 
after initiation of treatment (31). An adjacent hypothesis describes platelet sequestration 
leukocyte accumulation (32), which correlates with the observed thrombocytopaenia and 
in other infectious diseases (e.g. extrahepatic bacterial infection and sepsis), it seems to 
predominantly have a cholestatic nature in contrast to uncomplicated malaria (33).
host’s mitochondria in malaria, leading to organ damage (34). The resulting oxidative 
stress as observed in uncomplicated malaria is known to play a role in pathogenesis (35). 
For instance, lipid peroxidation and antioxidant enzyme activity associate with cholestatic 
jaundice in P. vivax patients (36), and oxidative stress causes hepatocyte apoptosis in 
murine malaria models (37, 38). In this study, we show that anti-oxidant gene expression 
is down-regulated for SOD1, SOD2, NOS3, CAT, and GSTK1 during infection, and up-
regulated for PRDX1. This corroborates with data from rodent studies(39, 40) and a 
non-human primate study with P. knowlesi (41), where hepatic superoxide scavenging 
systems, glutathione S-transferase, superoxide dismutase and catalase, decrease during 
the course of a malaria infection. This net result may be reduced clearance of radicals and 
subsequent failure to protect cellular constituents from oxidative damage. 
where they are often interpreted as drug-induced liver injury, particularly in malaria 
drug studies(27, 42). For example, drug-related serious adverse events in a recent 
multicentre trial comparing pyronaridine–artesunate or dihydroartemisinin–piperaquine 
with increased liver enzymes (43). Incorrect attribution of liver injury to an antimalarial 
drug can lead to unnecessary discontinuation or shifts in drug regimens, or impede 
drug development. Given the diversity of drug regimens used, it is unlikely that the 
observed LFT abnormalities in this study are caused by antimalarials. Moreover, no 
marked deterioration of LFTs was observed after a second, higher drug dose (16). Our 
et al., our data does 
not show a clear relation between the severity of abnormalities found, the pattern of 
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Furthermore, the timing, varied and often limited use of supportive medication (such as 
paracetamol, known for dose-dependent hepatotoxicity) in CHMI does not support a clear 
relationship with LFT abnormalities. It seems similarly improbable that the observed 
P. falciparum strains were used 
in CHMI, and the imported falciparum malaria cases were presumably caused by a wide 
diversity of strains. In addition, non-falciparum malaria (e.g. Plasmodium vivax) was also 
shown to increase LFT abnormalities. 
The limitations of this study are related to the retrospective observational nature of some 
of the data. However, the longitudinal CHMI data from healthy participants excludes 
the majority of confounding factors, and provides a much more thorough description of 
malaria cases, patients with sequential sampling data from the latter seem to have similar 
This study shows that liver function test abnormalities are an under-recognized but 
common feature of uncomplicated falciparum malaria. The pathophysiological basis is 
transient liver tissue injury. Given the rapid and spontaneous resolution, and the absence 
of clear functional liver impairment in uncomplicated malaria, these events are unlikely 
to result in permanent subclinical liver damage. Treatment should remain focused on 
fast parasite clearance, and a more expectative approach might be warranted to avert 
unnecessary discontinuation or shifts in antimalarials due to supposed drug-induced liver 
injury. Nevertheless, supportive drugs with hepatotoxic potential should be limited or 
given only with appropriate monitoring, and adjunctive therapy that mediates systemic 
antimalarials should consider the temporal relationship between LFT abnormalities and 
infection. Importantly, unnecessary early abrogation of further clinical development of 
(re)considered. 
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Evidence before this study 
We conducted an online literature search on liver function test (LFT) abnormalities in 
uncomplicated malaria using PubMed for articles published up to May 1st, 2018. Articles 
were searched by title and abstract using the terms “hepatic dysfunction” or “liver injury” 
or “liver function test” or “liver enzymes” or “transaminases”, with either “malaria” or 
“uncomplicated malaria” or “non-severe malaria” without language restrictions. Some 
articles cited in the screened publications were also included. We screened 58 articles, 26 
of which described liver injury in malaria focusing on severe disease. Only four contained 
studies described hepatic adverse reactions in the context of antimalarial drugs. The most 
descriptive study was a recent retrospective study by Woodford et al that provides data on 
LFT dynamics. Ramirez et al described the proportion of LFT abnormalities on admission 
day in a case control study. In these studies, no clear associations were found between 
clinical and demographic factors, and LFT abnormalities in uncomplicated malaria. The 
pathophysiological basis of liver injury has only been described in animals to date. 
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Added value of this study 
This study adds novel insights into clinical relevance, dynamics and pathophysiological 
basis of liver injury. We provide evidence that the underlying pathogenesis of liver injury 
in uncomplicated malaria is unlikely to be related to hepatotoxicity of antimalarials, and 
per se may be 
Implications of all the available evidence 
importance for both drug-related clinical decision making and development of antimalarial 
drugs. Incorrect attribution of liver injury to an antimalarial drug can lead to unnecessary 
discontinuation or shifts in drug regimens; instead, a more expectative approach might 
carefully (re)consider unnecessary early abrogation of promising drugs with supposed 
infection should, however, be limited or given with appropriate monitoring.
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Supplementary data
S1 Material. Oxidative stress analysis
Total nucleic acid was extracted from whole blood by using Magna Pure LC – High 
Performance kit. After RNA evaluation, cDNA was synthesized using the SuperScript® 
according to the manufacturer´s instructions. 
TaqMan gene expression Essays (Applied Biosystem) were used to measure antioxidant 
gene expression levels for Superoxide dismutases (SOD1, # Hs00533490_m1 and SOD2, 
# Hs00167309_m1), Nitric oxide synthase (NOS3, # Hs01574665_m1), Catalase (CAT, 
# Hs00156308_m1), Peroxiredoxin (PRDX1, # Hs00602020_mH) and Glutathione 
S-transferase Kappa (GSTK1, # Hs01114170_m1) on a QuantStudio5 qPCR instrument. The 
TaqMan® GAPDH Assay (CAT # 4485712, Applied Biosystem) was used as endogenous 
2O. Thermal cycling 
condition was 95 °C for 20 s before running 45 thermal cycles (95 °C for 1 s and 60 °C for 
20 s). ThermoFisher Clouds Software was used to obtain the CT values. Gene expression 
was calculated as 2 T = CT of target gene – CT of control gene (GAPDH).
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malaria
Multiple LFT measurements of patients with imported uncomplicated falciparum malaria (n=51). 
transferase, ALP= alkaline phosphatase. Light grey lines are all individual patients used in the 
analysis. Black lines are six representative patients of all patients to ease interpretation. 
Maximum cytokine levels from EHMI-8b as measured during challenge infection. Coloured data 
points represent an individual participant. Error bars represent the mean with SD.
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S4 Figure – Anti-oxidant gene expression during CHMI and liver function test (LFT) 
abnormalities in CHMI-trans1
C-1= day before challenge, DT+1= one day after treatment, C+64= 64 days after challenge. 
rank test. *p<0.05; **P<0.01; ***p<0.0001. AU = Arbitrary Units, gene expression was calculated 
as 2 T T = CT of target gene – CT of control gene (GAPDH). Each individual color data-
(tested by 1way ANOVA).
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Normal range male Normal range female
AST (U/L) <35 <30
ALT (U/L) <45 <35
<55 <40
Alkaline phosphatase (U/L) <115 <100
Bilirubin (total) (μmol/L) <17
LD (U/L) <250









Lactate (mmol/L) (plasma) 0.5-2.2
S2 Table – Clinical laboratory reference ranges
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Abstract
Background 
After a controlled human malaria infection (CHMI), presentation of clinical signs and 
symptoms and host responses is heterogeneous. Transforming growth factor-beta 
activation of haemostasis and endothelial cells and clinical symptoms.
Methods 
endothelial cells were measured in blood samples of 15 volunteers at baseline before CHMI 
and during CHMI at day of treatment. The fold change of the parameters on the day of 
Results 
with concomitant increased concentrations of D-dimer (p = 0.012), Von Willebrand 
platelet count (p = 0.011). In contrast, 6 of 15 volunteers showed sustained or increased 
responders presented with less moderate and severe clinical symptoms than the negative 
concentrations did not correlate with the parasitaemia on day of treatment.
Conclusion
response and downstream clinical symptoms and pathology during CHMI. 
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Introduction
Malaria is still a major health concern with 438,000 deaths worldwide in 2015 (1). 
The parasitic disease is caused by Plasmodium spp. of which P. falciparum is the most 
pathogenic in humans. Contributing to its pathogenicity is adherence and sequestration 
of the infected erythrocytes to the vascular endothelium which can lead to obstruction of 
The host response to P. falciparum in malaria naïve individuals in controlled human malaria 
and severity of clinical symptoms (3). Also, the levels of coagulation- and endothelial 
cytokines increase in a subset of volunteers (3), whereas in others an increase of the 
the hepatic infection phase, or later, once parasites are detected in the blood stream (5). The 
aetiology of the heterogeneous immune response is unknown. Improved understanding of 
the heterogeneity is of interest as this initial immune response is responsible for the early 
with a more rapid increase in number of infected erythrocytes and subsequently shorter 
parasitaemia is not limited to malaria, but also observed during other parasitic diseases 
such as leishmaniasis (7), infection with Toxoplasma gondii (8) and Trypanosoma cruzi 
(9). The role of pro- and immune-modulatory cytokines during more advanced malaria 
cause increased pathology leading to multi-organ dysfunction. In this situation immune-
modulatory cytokines are protective and associated with increased survival (11, 12). 
Although several studies demonstrated heterogeneity in distinct host responses in 
a CHMI (e.g. cytokines response, coagulation, endothelial activation) (3, 4, 13, 14), 
possible relationships between these distinct host responses remain elusive. Therefore, 
activation and coagulation during CHMI.
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Design and methods
Study populations
Details on the underlying CHMI study aim and design, characteristics of volunteers, as 
CHMI study investigated the clinical and parasitological course of malaria after infection 
of healthy, malaria-naïve volunteers with the well characterized P. falciparum NF54 strain 
in comparison to two other strains (NF135.C10 and NF166.C8). The 15 volunteers that 
participated in that CHMI study were divided in 3 groups of 5 volunteers. Each group of 
CHMI volunteers was infected with 1 of the 3 P. falciparum strains by the bites of 5 infected 
mosquitos. Follow-up of CHMI volunteers started 5 days after infection by twice daily thick 
blood-smear analyses and assessment of clinical symptoms, in the morning and evening. 
Anti-malaria treatment with a 3-day curative regimen of Atovaquon/Proguanil 1000/400 
mg (Malarone ®, GlaxoSmithKline), was started as soon as the thick blood-smear became 
positive. To study submicroscopic parasitemia, the presence of P. falciparum in peripheral 
blood was also analysed by quantitative polymerase chain reaction (qPCR) in stored blood 
samples, retrospectively. The Institutional Review Board of the Harbour Hospital and 
the Dutch Central Committee on Research involving Human Subjects approved the study 
protocol, including add-on studies. All CHMI volunteers gave written informed consent 
(NL41004.078.12). 
Sample collection 
Venous blood samples (EDTA-, serum- and trisodium citrate tubes) were collected and 
subsequently processed using standard laboratory procedures. Thick blood-smears were 
immediately prepared from EDTA-blood and subsequently examined. A positive thick 
Laboratory investigations
From all 15 CHMI volunteers, serum and citrate-plasma samples taken on the day before 
positivity), were examined for immunological, haemostasis and endothelial cell activation 
parameters. If a volunteer had a positive thick smear and was treated in the evening (DT), 
no serum and citrate-plasma samples were available as general laboratory investigations 
were performed only once a day. In these cases, the serum and citrate-plasma samples 
collected the next morning were used for analysis. Samples of DT (n=7) and samples of 
the next day (n=8) were combined for analysis. D-dimer was determined in trisodium 
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citrate plasma and the platelet count in EDTA-blood. Von Willebrand Factor (VWF) was 
measured with an in-house ELISA in citrate plasma as described previously (16).
multiplex luminescent magnetic beads (R&D Systems, Inc.; Abingdon, United Kingdom) 
according to the manufacturer’s instructions and analysed with a Luminex XMAP Multiplex 
to the manufacturer’s instructions.
Statistical analysis
Concentrations of the distinct parameters at C-1 and DT were compared with the 
Wilcoxon-Signed Rank test. For correlations, the Spearman’s rho was used. As none of the 
parameters was normally distributed, data were presented as median with interquartile 
range unless stated otherwise. For comparison of concentrations of parameters between 
P. falciparum strains the Kruskal-
Wallis test was used. All analyses were performed with SPSS version 24.0 (SPSS Inc, 
Chicago, IL, USA). 
Results 
The median age of the 15 CHMI volunteers was 22 years (range 18-36), 6 of them were 
female. One day before challenge (C-1) the full blood cell count, glucose concentration 
and renal- and liver function were all in the normal range. All volunteers developed 
parasitaemia after CHMI and received antimalarial treatment upon microscopic detection 
of P. falciparum parasites in a thick blood smear. Retrospective analysis with qPCR showed 
a median parasitaemia of 33 parasites/mL (IQR: 10-62) on DT. 
be divided in two groups; i) 
ii)
sustained and/or positive responders (Figure 1, Table 1
negative responder, based on measurement 2 days after treatment. None of the parameters 
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(Table 2
and sustained responders at baseline (C-1) (not shown), except the absolute lymphocyte 
9/L; IQR 1.7-2.1) in the negative responders 
than in the sustained responders (2.2x109/L; IQR 2.0-2.5) (p=0.026). 
responders responders
p-value
Number of volunteers 9 6 NA
10.8 (6.9-12.3) 6.1 (3.4-9.3) 0.113
6.2 (5.3-8.0) 8.3 (7.8-10.0) 0.043
Age (years) 22 (19-23.5) 20.5 (18.8-24.8) 0.864
Male/female (%) 66/33 50/50 0.622a 
Time towards positive qPCR (days) 6.5 (6.5-7.0) 6.5 (6.5-7.0) 0.689
Time towards positive thick smear, DT (days) 8.5 (7.0-10.5) 7.0 (6.9-9.0) 0.328
mL, qPCR)
1.1 (0.1-14.5) 3.0 (0.5-25.1) 0.456
Parasite count on DT (parasite/mL, qPCR) 18.2 (7.9-57.7) 33.5 (13.2-85.0) 0.689
responders at baseline (C-1). Data shown as median with interquartile range (IQR), Mann-
Whitney test, unless otherwise stated. 
transforming growth factor beta. qPCR; quantitative polymerase chain reaction. aFisher’s exact test
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         C-1        DT P-value          C-1        DT P-value
IL-6 (pg/mL) Below detection 
limit












13.5 (1.9-25.4) 0.028 Below detection 
limit
2.2 (0.3-6.2) 0.109
4.3 (3.9-5.1) 7.9 (5.8-14.0) 0.008 3.7 (2.4-6.4) 4.7 (2.8-15.7) 0.027
Lymphocytes 
(*109/L)
1.9 (1.7-2.1) 0.8 (0.6-1.2) 0.011 2.2 (2.0-2.5) 1.8 (0.9-1.9) 0.028
Platelets (*109/L) 248 (194-263) 165 (141-244) 0.011 196 (170-247) 183 (168-248) 0.917
D-dimer (mg/L) 0.23 (0.19-0.35) 1.57 (0.45-2.04) 0.012 0.22 (0.19-0.26) 0.27 (0.24-0.31) 0.092
12.2 (9.3-13.4) 19.5 (13.1-24.8) 0.017 9.4 (7.7-11.0) 11.1 (6.5-14.1) 0.753
Temperature 
(0C)
36.1 (35.7-36.4) 37.3 (36.9-38.3) 0.028 35.9 (35.6-36.3) 36.5 (36.1-36.7) 0.173
responders
The Wilcoxon signed rank test was used for comparison between C-1 and DT. C-1; 1 day before 
challenge, DT; day of treatment, VWF, Von Willebrand factor. Data shown as median with 
interquartile range (IQR).
Table 2). In both the 
with parasitaemia. However, a negative correlation was observed between parasitaemia 
or on DT) (-0.642; p=0.013). 
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Haemostasis and endothelial cell activation of CHMI volunteers
Endothelial cell activation and coagulation were activated in a subset of volunteers: a 50% 
increase on DT compared to C-1 concentrations was observed in 4 of 15 volunteers for 
negative responders showed increased concentrations of D-dimer and VWF, as well a 
responders was associated with clinical symptoms. We found a higher body temperature 
and more episodes of fever (p=0.036) (Table 3)
on DT (Spearman’s rho 0.757; p=0.002). The number of grade 2 and 3 clinical symptoms 
 However, 
and on DT (Table 1
the distinct P. falciparum strains (NF54, NF135 and NF166, respectively) were observed 
(Fisher’s exact test: p=1.000). 
Discussion 
observed in controlled human malaria infection study (CHMI). Previously it has been 
P. falciparum 
in a subset of volunteers after infection with P. falciparum.
decrease in others. The malaria naïve volunteers infected with P. falciparum with a 
i) a higher degree of endothelial cell activation. 
ii) a higher degree of coagulation activation. iii) a higher body temperature. iv) a higher 
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number of clinical symptoms compared to the volunteers with a sustained or increased 
of endothelial cells and coagulation with relatively more clinical symptoms. The second 
activation and coagulation and less clinical symptoms. As the CHMI volunteers had to be 
treated relatively early after infection compared to malaria patients in endemic areas. the 
malaria would occur.
Both activation of endothelial cells and formation of coagulation products have impact 
endothelial cell activation and coagulation than sustained responders. This shows that 
the early immune-modulatory cytokine response is associated with upstream clinical 
clinical malaria being associated with a lower number of clinical symptoms (12). However. 
might result in impaired ability to control parasite replication during the blood phase. as 
shown in a mouse model (20). Mice infected with a lethal P. yoelii strain had an increase 
in mice infected with a nonlethal P. yoelii strain early during the infection (20). We did 
replication as one cycle takes 44 hours (21). CHMI studies with a longer time to treatment 
can be used for evaluation of cytokine responses on the parasite growth. Interestingly, a 
from the liver. Indeed, IL6 has been shown to block parasite liver-stage development in 
murine malaria models (22).
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P. falciparum infection 
a broad diversity of populations worldwide were found to be predictive for immune 
responsiveness (24) and the lymphocyte/neutrophil ratio predicts cytokine receptor 
immune set-point (23, 24). CHMIs appear to be a valuable tool to elucidate the relation 
between the baseline immune responsiveness and initial host response after infection and 
to evaluate the implication for immunization strategies. 
is stored in platelets and released upon their activation (25). In our study. we cannot 
4 in EDTA-blood or hydroxy thromboxane b2 in urine) (data not shown). In addition. the 
starts to decrease shortly afterwards. as shown before (13). The combined data strongly 
Although our data generally corroborate those from previous studies. conclusions on the 
caution due to the small sample size. In this study 3 groups of volunteers were infected 
with 3 distinct P. falciparum strains. Although the prepatent period was longer and the 
C8 (15), no correlation between prepatent period, parasitaemia and cytokine levels was 
between the groups. As cytokine concentrations are known to correlate with clinical 
and immunomodulatory volunteers over the 3 distinct strains. In addition, previous 
a single strain (NF54). So, there is no indication of a confounding relationship between 
response.
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In conclusion, the host response in malaria naïve volunteers upon infection with P. 
falciparum
response correlates with the extent of endothelial cell activation and coagulation and 
might originate from the immune responsiveness at baseline. CHMIs are highly valuable 
for downstream clinical symptoms and pathology. 
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Abstract
Background
Immune activation status is heterogeneous in the steady-state amongst healthy individuals 
and co-determines host responses to infections. This study investigated the relationship 
during Controlled Human Malaria Infection (CHMI). 
Methods 
Single CHMIs in vitro
producing lymphocytes and regulatory T-cells were determined in blood samples before 
and after infection (n=35), in relation to parasitaemia. Sporozoite immunization studies; 
immunization, in relation to parasite dynamics.
Results 
to show a decline after infection (negative responders) (n=24); in contrast, lower 
(n=11) (p=0.001) (sustained responders). The percentage of regulatory T-cells (Treg) 
induction of Treg correlated positively with the rate of parasite growth (r=0.549; p=0.002). 
in vitro
immunity after sporozoite immunization correlated with higher baseline concentrations 
Conclusion 
Low 
responses after a single infection and slower induction of protective immunity after 
sporozoite immunization in the CHMI model. 
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Introduction
Healthy malaria naïve participants of controlled human malaria infection (CHMI) studies 
show varied severity of clinical symptoms and cytokine dynamics following infection (1). 
and coagulation activation) and inhibition in the rate of parasite growth (4). NK cells and 
infection (2, 5). A second subpopulation of CHMI participants typically displays an increase 
resulting in reduction of pathology e.g. by reducing fever (6) and by hampering the 
peripheral blood during malaria infection are CD14+ monocytes (4). However, other cells, 
infection or immunization. In addition, previous exposure to particular immunogens 
heterologous pathogen (11-13). This was shown when malaria naïve healthy participants 
received BCG-vaccination prior to P. falciparum experimental infection, which resulted 
in an increase in clinical symptoms (e.g. fever) and rapid monocyte activation compared 
to non-vaccinated participants. In addition, in a previous study we demonstrated that 
infection) present with higher baseline lymphocyte counts (1). This may suggest that 
heterogeneous immunity and pathology in CHMI may be co-determined by immune status 
in vitro stimulation with parasitological and clinical responses in the CHMI model. 
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Methods
Study design and approval
Samples were collected from four (A-D) CHMI studies (Study A, NL41004.078.12; 
Study B NL48704.000.14; Study C NL48301.091.14, Study D, 48732.091.14). Participant 
characteristics, clinical, and parasitological course have been described previously (14-
P. 
falciparum parasites by 5 infected mosquito bites. In study B (14, 15), 24 participants were 
allocated over 6 groups and exposed to 1, 2 or 5 bites of P. falciparum infected mosquitoes. 
Only the 20 participants who developed parasitaemia in study B were included in our 
current study. Twice-daily parasitaemia monitoring with thick blood-smear analyses 
(study A) or quantitative polymerase chain reactions (qPCR) (study B) started 5 days 
after infection. Study participants received anti-malaria treatment with a 3-day curative 
regimen of Atovaquon/Proguanil 1000/400 mg (Malarone ®, GlaxoSmithKline) upon a 
positive thick smear (study A) or on 2 consecutive qPCR positive whole blood samples 
with >500 parasites/mL (study B). 
Studies C (n=8) (NCT02080026) and D (n=24) (16) followed the ‘Chemoprophylaxis with 
Sporozoites (CPS)’ immunization protocol. Study participants were immunized three 
or four times (time-intervals between each immunization is 4 weeks) by bites of 15 P. 
falciparum infected mosquitoes while receiving a prophylactic dose of chloroquine (300 
mg once a week). Ten weeks (study C) or fourteen weeks (study D) after discontinuation 
of chloroquine prophylaxis, the subjects were challenged with bites of 5 P. falciparum 
infected mosquitoes. Subjects were checked twice daily for blood parasitaemia as measured 
by qPCR from days 5 to 21 after challenge and treated with Atovaquon/Proguanil at the 
end of study (day 28) or earlier if parasitaemia rose above 100 Pf/ml (17). 
In all four studies, symptoms were monitored and clinical laboratory parameters were 
determined during all control visits. Parasitaemia was measured by qPCR as described 
previously (17). The Institutional Review Board of the Harbour Hospital (Study A and 
B) and Radboudumc (C and D) and the Dutch Central Committee on Research involving 
Human Subjects approved the study protocols and add-on studies. All CHMI participants 
provided written informed consent. 
Sample collection 
From studies A and B, serum samples were collected and stored at -80°C and venous whole 
blood samples were collected in Vacutainer Cell-Preparation Tubes (CPT, Becton Dickinson) 
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on baseline and 2 (Study A) or 3 days (Study B) after start of treatment. Peripheral blood 
mononuclear cells (PBMCs) were isolated and frozen in dimethyl sulfoxide supplemented 
with 10% foetal calf serum and stored in liquid nitrogen. From studies C and D, citrate 
plasma samples were collected in a similar manner one day before immunization 1 (I1-1) 
and one day before the second immunization (I2-1) and stored at -80°C. 
Cytokine measurements (all studies)
manufacturer’s instructions in baseline samples from all 67 participants (study A-D). 
treatment decision (DT), and in studies C and D (CPS immunization) one day before the 
For study B, cryopreserved PBMCs from baseline and three days after treatment were 
thawed and resuspended in RPMI 1640 culture medium (Gibco) supplemented with 2 
mM glutamine, 1mM pyruvate, 50 μg/ML gentamycine and 10% pooled A+ human serum 
(Sanquin, Nijmegen, the Netherlands) and transferred into 96-well round-bottom plates 
(Corning) at a concentration of 5x105 cells in 100 μL/well for stimulation. Forty μg/mL 
brefeldin A (Sigma) and 5.3 μg/mL monensin diluted in 50 μL were added to each well μg/mL and 2μM, respectively) 3-4 hours prior to 
staining. Stimulations were carried out with 1 ng/mL PMA and 1μg/mL iomomycin for 4 
hours at 37°C and 5% CO2. For the stimulation assays, PBMC samples collected at the same 
CHMI time point were examined simultaneously. After stimulation the PBMCs were stained 
for the extracellular markers CD3–APC-eFluor780, CD4–AF647 and CD56-PerCP-Cy5.5. 
PBMCs were then permeabilised with the FoxP3 Fix/Perm Kit (eBioscience) and stained 
a 10-colour Beckman Coulter Gallios and analysed using FlowJo software (version 10.0.8, 
Tree Star). Staining panels and gating strategy are shown in Supplementary data 1 and 2.
Phenotyping of monocyte and Treg populations in CHMI participants
For each participant in studies A and B a sample from baseline and three days after 
treatment was thawed and cells were immediately stained for phenotyping. Samples of 
the same participants of the two time points were tested simultaneously (for colour panels 
and gating strategy see Supplementary data 1 and 2). Staining panels and gating strategy 
are shown in Supplementary data 1 and 2.
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Statistical analysis
The Wilcoxon-Signed Rank test was used for comparison of concentrations of the same 
parameter in one study participant over time. For independent comparison the Mann-
Whitney test was used. For correlations, Spearman’s rho was used. As none of the 
parameters were normally distributed, data were presented as median with interquartile 
range unless stated otherwise. For comparing distributions of parameters between the 
P. falciparum strains the 
Kruskal-Wallis test was used. The Fisher’s exact test was used for categorical data. All 
analyses were performed with SPSS version 24.0 (SPSS Inc, Chicago, IL, USA). 
Results
Volunteer characteristics 
A total of 35/39 CHMI participants across two separate CHMIs (Study A and B) 
developed parasitaemia and were included in this analysis (Table 1). In study C and D 
(CPS immunization studies) 32 participants successfully completed three rounds of 
immunisation with 15 P. falciparum infected mosquitoes under chloroquine prophylaxis. 
Two volunteers from study D were not included in the analysis due to absence of samples. 
parasitaemia under chloroquine prophylaxis. However, after the second immunization 
only 16/30 included participants developed parasitaemia (slow responders) and 14/30 
remained aparasitaemic (fast responders). An overview of the studies and data on 
parasitaemia is listed in Table 1. 
compared to baseline (median 0.6-fold; IQR 0.4-0.8; ‘negative responders’) and remained 
constant or increased in 11 participants (1.6-fold increase; 1.3-2.1; ‘sustained responders’) 
(Figure 1A
responders (5.1 ng/mL; 3.6-8.1) (p=0.0010) (Figure 1A
immune responses, we investigated whether the ability of lymphocytes to produce 
treatment (p=0.033) (Figure 1B).
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Figure 1, red 
dots
Figure 2A, red dots). 
While as a whole the total group of negative responders displayed equal monocyte numbers 
to the sustained responders (Figure 2A), 
(A) 
A and B. . 
(B) 
after in vitro stimulation by PMA/ionomycin. C-1; 1 day before challenge; DT, Day of treatment. NR, 
negative responders; SR, sustained responders; 
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(p=0.0003) (Figure 2B). This suggests that there is a subset of monocytes producing high 
immunity during CHMI
plasma concentrations and the percentage of Treg at baseline (Spearman’s rho: -0.335, 
p=0.049) (Fig 3A). However, an increase in Treg percentage was strongly associated with 
both an increase in parasitaemia over time (parasitaemia on day of treatment compared 
Fig.3B) as well 
as the parasitaemia on the day of treatment (Spearman’s rho: 0.524, p=0.002) (Fig.3C). 
increase in the percentage of Treg over time (2 or 3 days post treatment versus baseline) 
over the same time period (Spearman’s rho: -0.507, p=0.027) (Fig. 3D). The increase of 
Tregs was only observed in a proportion of CHMI participants (17/31); no correlation was 
data suggest a complex interplay between immune cells and cytokines in which immuno-
responses and loss of ability to inhibit parasite growth.
(A) (B)
concentration at baseline are shown in red. NR, negative responders; SR, sustained responders; 
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in CPS immunization
acquisition of protective immunity after CPS immunization. Thirty-two CPS immunized 
volunteers were divided into fast responders and slow responders based on the number 
of immunizations required to become sterilely protected against a homologous challenge 
(median; IQR) (448 pg/ml; 389-589 pg/ml) compared to slow responders (376 pg/ml; 
332-426 pg/ml) (p=0.028) (Fig. 4A
and immuno-modulatory groups as described previously (1). As in studies A and B, the 
(A)
A and B) (p=0.049). (B) Correlation between Treg ratio (post-treatment/baseline) and speed 
increase of parasitaemia ((parasitaemia on day of treatment – parasitaemia at baseline)/time to 
DT)) (spearman’s rho; p value; 0.549; 0.002). (C) Correlation between Treg ratio (post-treatment/
baseline) and parasitaemia on day of treatment (Study A and B). (D) Correlation between Treg ratio 
Treg, regulatory T-cell.
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ml, 396-629 pg/ml) than in sustained responders (381 pg/ml, 313-443 pg/ml) (p=0.009) 
(Fig. 4B
33%) (Fisher’s exact test; p=0.032). The combined data suggest that the immune response 
during immunization correlates with patterns of immune function that are present prior 
Discussion 
In this study the pre-infection immune activation status of individuals was investigated 
Therefore, pre-infection immune activation status of an individual may co-determine the 
therefore, partly explain heterogeneity. In addition, Treg induction was found to correlate 
(A)  
(B)
and D). Dots with the same colour in A and B represent the same CHMI participant I1-1, 1 day before 
immunization 1. NR, negative responders; SR, sustained responders; 
factor-beta.
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the positive correlation between Treg and parasitaemia. T-reg inhibition of Th1 response 
in a higher parasitaemia.
more rapid acquisition of immunity: study participants with sustained or increased 
Such correlations between pre-infection immune status and responses during infection 
may predict whether an individual will develop sterile immunity or the number of 
immunizations needed to reach sterile immunity. 
derived macrophages as the primary producers. Previously, monocytes stimulated with 
P. falciparum
in vivo, as have been suggested 
+CD4+FOXp3+ T-cells). This apparently contradictory 
generation in the thymus (tTreg) but not for Treg induction in the peripheral blood 
(pTreg) (20, 21). Second, low ubiquitination of FOXp3+ Treg is a major driving force for 
FOXp3+ stability, which is linked to suppressive potential of Treg (22) and might explain 
in Treg proportions was not observed in all CHMI participants. Further evaluation of 
responders is of interest for increase understanding of the heterogeneity in host response. 
In previous malaria studies, the presence of Treg with inhibitory properties was associated 
with lack of upregulation of the cytotoxic marker CTLA-4 (23). Others also found that low 
Treg numbers were associated with improved protection after immunization (24). This 
is in line with our observation that the percentage of induced T-reg strongly correlated 
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signature seems necessary for long-term stable commitment (25). Epigenetic signatures 
number of pathogen encounters as well as the type of pathogen encountered (26). For 
example, helminth infections are known to skew the host response towards an immune-
upon Plasmodium spp. infection, and to vaccinations or infections other than malaria (28-
was associated with a high number of immunizations needed to become sterile protected. 
in Plasmodium falciparum 
kinetics (negative and sustained responders), in a total of 67 individuals. This data further 
infection (1, 2). Although these data are in line with previous studies, conclusions should 
be drawn with caution as our study is of observational nature, thus showing correlations 
rather than direct causality. Lastly, the subgrouping of CHMI participants based on their 
upon a malaria infection are therefore rather a scalable than a binary outcome. Further 
add to the current knowledge. However, it is unlikely that a single baseline marker will 
for immune activation status should be evaluated for its predictive value. 
have been shown in rodents, where immune-modulatory compounds (e.g. FTY720, 
rosiglitazone or inhalation of nitric oxide) administered prior to malaria infection resulted 
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related mortality was observed after a BCG-vaccination (12, 13). Further analysis of how 
baseline immune activation status can predict clinical and vaccination outcomes could 
improve understanding and development of vaccination strategies, paving the way for 
Baseline immune activity  |  
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General discussion
Malaria vaccine development has been a highly important research topic for decades, 
as a successful vaccine may decrease the global disease burden. However, the currently 
limitation in knowledge on what kind of immune response will result in sterile and 
durable protection after immunization. For malaria vaccine research, Controlled Human 
Malaria Infection (CHMI) studies are a valuable tool for both i
candidate malaria vaccines and for ii) investigating the host response after infection and 
immunization in a highly controlled setting (1). 
Part I: Clinical malaria vaccine development
Establishment of sterile protection: pre-erythrocytic vaccines 
The possibility to reach protection to P. falciparum was shown after immunization with 
the pre-erythrocytic RTS,S vaccine, which combines the highly conserved P. falciparum 
sporozoite surface protein, Circumsporozoite Protein (CSP), linked to hepatitis B virus 
surface antigen virus-like particles (2). This recombinant protein vaccine induces high 
antibody titers against CSP (3-5), thereby preventing sporozoites to infect hepatocytes. 
Although this vaccine strategy resulted in immunity in a subset of healthy malaria naïve 
volunteers shortly after they were immunized (3-5), this sterile protection was not long 
lasting. During a re-challenge after 5 or 6 months, most volunteers developed parasitaemia 
and had to receive anti-malarial treatment (6, 7). Also, phase III trials in malaria endemic 
areas showed a rapidly waning protective immunity within a year after vaccination (8-
13). As the subunit vaccines did not result in long-lasting anti-malarial immunity, interest 
has risen for whole parasite vaccination, which exposes the immune system to a broader 
array of parasite antigens. Several approaches for attenuation of sporozoites have been 
investigated in order to immunize humans with whole parasites without resulting in 
malaria blood stage infection; e.g. attenuation by co-administration of anti-malaria drugs, 
Chemoprophylaxis and sporozoites
Encouraging results were observed in healthy volunteers whom were 3 times immunized 
by the bites of 15 P. falciparum infected mosquitoes while receiving chloroquine prophylaxis 
(CSP immunization). Upon challenge to the same P. falciparum strain (homologous 
challenge) by 5 infective mosquito bites none of the volunteers developed blood parasitaemia 
(14). Also, the majority of volunteers was still protected against a re-challenge 28 months 
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after the initial immunization, showing that long-lasting sterile protection to P. falciparum 
is possible (15). It is thought that exposure to many antigens of a high number of viable 
P. falciparum sporozoites (16) combined with complete development of liver schizonts is 
required for induction of protective immunity (17-19). However, the CSP-immunization 
strategy is logistically challenging to deliver to a high number of individuals. In addition, 
a high compliance in taking antimalarial medication is essential to prevent breakthrough 
infections, this seems not feasible to execute on population-based level. For these reasons, 
attenuation of parasites without losing immunogenicity has been a major research topic 
during the last decade. 
Radiation-attenuated parasites
Attenuation of parasites can be also established by radiation of live sporozoites, which 
causes random mutations in the DNA. These radiation-attenuated sporozoites (RAS) can 
invade hepatocytes but arrest early during liver stage, and therefore, do not result in blood 
stage malaria. Infection by intravenous administration of radiated sporozoites resulted 
in homologous (20-22) and partly in heterologous (23) protection against falciparum 
individuals, provided disappointing results as 66% of immunized volunteers was not 
protected against malaria (24). Although these studies have an excellent safety record, 
immunogenicity of RAS is suboptimal and high doses of cryopreserved sporozoites are 
needed to be administered intravenously (21). It has been shown that human individuals 
need to be exposed to more than 1,000 bites of P. falciparum-infected and irradiated 
immunization a product with a higher immunogenicity is necessary. 
Plasmodium parasites possible 
and genes essential for liver development can be deleted. Genetically attenuated parasites 
(GAPs) have several advantages over RAS: a) the product has a higher level of homogeneity 
(26), b) GAPs expose the host to a broader antigen repertoire as they can replicate in the 
liver (19, 27), c) a lower number of sporozoites is necessary to induce protective immunity 
after replication in the liver (14, 27, 28), d) repeats of highly immunogenic genes can be 
inserted to induce a robust immune response. Candidate GAP-products are currently under 
development and tested for their infectivity and safety as after administration parasites 
should not emerge from the liver into the blood (26, 29). A GAP candidate in which p52 
and p36 were lacking caused a protective immune response in mice in absence of blood 
parasitaemia (30), but resulted in a breakthrough infection in 1 of the 6 CHMI participants 
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(31). Taken together, despite these encouraging developments, generation of a safe product 
in vulnerable populations is still a not known. Moreover, probably multiple genes need 
additional gene (p52-/p36-/sap1-) could establish complete protective immunity in mice 
and was found to be safe in human as no breakthrough infection occurred (32). 
A novel immunization GAP platform: Plasmodium berghei
Chapter 2 describes a novel approach in which P. berghei with an inserted P. falciparum 
CSP-gene repeat was used for immunization (PbVac). PbVac parasites can invade human 
hepatocytes, but they cannot replicate in human erythrocytes (33) making it a safe method 
of immunization with viable parasites (34). Although four immunizations with PbVac did 
not result in protection during a CHMI in healthy malaria naïve volunteers, a delay of 2.2 
days in patency and a decrease of 95% in parasite liver burden was observed. Further 
analysis showed a dose-dependent cellular immune response and the production of PfCSP-
dependent antibodies that can block P. falciparum invasion in liver cells in vitro. The 
PbVac is not fully elucidated yet. 
In previous studies, the immune response in malaria naïve volunteers upon immunization 
with whole sporozoites varied tremendously with variation in the number of elicited 
of studies showed a major contribution of cellular responses (36) for establishment of 
protective immunity after GAP immunization (37), RAS immunization (38-40) and CSP 
immunization (41, 42), whereas in other studies CSP-antibodies were found to play a 
crucial role for establishment of anti-malarial immunity (5, 43-45). All these studies 
focused on cellular and humoral markers as measured in the peripheral blood. However, 
studies in mice showed that resident memory CD8+ T-cells in the liver that can recognize 
Plasmodium spp. (46-48), were responsible for the protective immunity after P. berghei 
PbVac immunization, a decrease in the number of monocytes 
was observed which was associated with Monocyte Chemoattractant Protein-1 (MCP1) 
negatively associated with the prepatent period during challenge. These observations 
suggest a possible recruitment of immune cells to the liver, which may contribute to 
the development of protective tissue-resident immune responses. As liver immunity 
seems to be highly important for the development of protective immunity future studies 
should focus on the contribution of liver immune cells, although this is clearly a major 
challenge. Fine needle biopsy may be used for study purposes and has been found to be 
relatively safe, but given the 0.9% adverse event rate may be not safe enough to perform 
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in healthy volunteers (51). In addition, the number of cells harvested by this technique 
are too low and not representative for the immunological processes going on in the entire 
liver. Development of a proper model which represents the human liver is highly needed 
and currently under research (52, 53). Promising are mice models with humanized livers 
in which P. falciparum can replicate to test immune responses, antimalarial drugs and 
vaccinations. 
Taken together, this novel vaccination strategy of P. berghei as an immunization platform 
is promising and should be explored further. Adding additional P. falciparum genes that 
are expressed during the pre-erythrocytic stages to the P. berghei backbone may elicit 
a broader protective immune response and warrant further investigation. As the level 
of elicited Pf
increasing the number of mosquito bites might be suitable in an experimental setting but 
this is not feasible for commercial production. Questions on upscaling of GAPs need to 
be answered and techniques to produce cryopreserved Plasmodium parasites need to be 
explored. Also, the route of administration of parasites is important to take into account 
as intradermal immunization, but not intravenous infection, has been shown to induce an 
Transmission-blocking vaccines
In addition to vaccines that result in immunity against the malaria parasite in humans, 
vaccines that block transmission from humans to mosquitoes are gaining interest in the 
last decade (54). These transmission blocking vaccines elicit antibodies against proteins 
that are expressed by the sexual parasite stages in the midgut of the mosquito or in 
the human host. These antibodies are taken up by the mosquito when it takes a blood 
meal and subsequently prevent development and maturation of the gametocytes in the 
transmission of parasites of both symptomatic and asymptomatic human Plasmodium 
parasite carriers. To evaluate transmission blocking interventions the current CHMI 
model needs to be adjusted to test transmission of Plasmodium parasites from humans 
to mosquitoes. This model should result in a high number of viable fertile gametocytes 
without compromising the safety of CHMI volunteers. In addition, the transmission rate 
in a small number of healthy volunteers. For this purpose Reuling et al
antimalarial drug regimens after infection of healthy volunteers by mosquito bites to 
induce gametocyte carriage of which a subcurative dose with piperaquine resulted in high 
P. falciparum from humans to mosquitoes and the volunteers already experienced severe 
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clinical symptoms (Chapter 5). The transmission model was adjusted by Collins et al 
(56): healthy volunteers were infected by intravenous inoculation of Plasmodium infected 
erythrocytes instead of by mosquito bites. This resulted in a high asexual parasitaemia, 
gametocytaemia and high transmission rates without severe clinical symptoms. In 
Chapter 3 both methods of infection were compared in a single CHMI study. Additional 
subcurative treatment with piperaquine was given to increase the duration of asexual 
parasitaemia thereby also increasing the gametocytaemia. It was clearly shown that blood 
stage infection induced higher gametocytaemia with only a limited number of adverse 
events. An even higher mosquito infection rate can further optimize the model. As 
asexual blood stage parasitaemia and gametocytaemia correlate with each other, this can 
be established by increasing the asexual parasitaemia during CHMI. However, this will 
also compromise the safety of the healthy malaria naive individuals that participate in 
these trials. Individuals living in malaria endemic areas are known to have a relative mild 
clinical disease despite a high parasite burden (57). Establishing a transmission model 
in these populations is of interest, but, pre-existing immunity on gametocyte generation 
is not completely understood and an immune tolerant response might result in a low 
gametocyte concentration. A study with the current model in individuals from both a high 
and low endemic area may elucidate in what population the gametocyte concentration 
will result in a 100% mosquito infection rate allowing testing of transmission blocking 
interventions in a small sample size. 
The higher number of adverse events after infection by mosquito bites compared to 
infection by an inoculum with infected red blood cells despite a similar level of parasitaemia, 
as described in Chapter 3, is striking. Volunteers experienced headache, fever and 
mosquito bites, whereas these alterations were very limited after blood stage infection. 
by mosquito bites which result in a higher initial parasitaemia. The inoculum contained 
2.800 sporozoites which is 0.5-0.6 parasites/ml after administration (in a human with 
5L blood) whereas after infection by sporozoites thousands of merozoites are released 
into the bloodstream resulting in a much higher parasitaemia at once. This relative high 
initial response upon a relatively low parasitaemia might instead result in an induction of 
Thereby it might imitate the host response in individuals that have experienced multiple 
malaria episodes and are known to have a regulatory immune response upon a malaria 
infection. 
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infected red blood cells in contrast to infection with mosquito bites. The immunological 
processes in the liver after a natural infection are still unclear, but seem to be important 
clinical symptoms and parasitological kinetics should give knowledge on the induction of 
immune tolerance and protective immunity. 
Part II: Heterogeneity in host responses after Plasmodium spp. infection
Malaria patients in endemic areas: a heterogeneous group
immunization (35) or for prediction of disease severity during clinical malaria (62). 
P. falciparum 
in a study comparing malaria patients from areas with high and low P. falciparum 
transmission. Whereas after stimulation with PMA PBMCs of people living in low endemic 
Chapter 4 the problem of using a single marker for prediction of disease outcome or 
showed variability between study populations in malaria endemic areas possible due to 
hospital admission could have consequences for treatment strategies. Such treatment 
strategies are not available yet and multiple promising studies in mice have not resulted in 
a strategy with reduction in mortality or morbidity in humans (64). Most of the studies are 
process (e.g. by an increase of nitric oxide or increase in angiopoietin-1). In my opinion, 
it is questionable whether the complexity of malaria disease is suitable for such a focused 
approach. Interfering with multiple processes that are involved in the pathophysiology of 
malaria (e.g. coagulation, endothelial cell activation, immune paralyses or over-activation) 
seems necessary. 
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CHMI participants: a homogenous group with a heterogeneous host response
Selecting and screening healthy volunteers for a CHMI study, aims to result in a highly 
comparable group. Because of the homogeneity of these groups and the highly controlled 
standardized study protocols, only a small number of volunteers needs to be included 
healthy malaria naïve individuals, in contrast to individuals in malaria endemic areas 
with varying levels of immunity to Plasmodium spp. Chapter 5, 6 and 7 describe the 
host response to the P. falciparum infection which is still heterogeneous despite the 
Chapter 5 
and 6), cytokine responses (Chapter 5, 6 and 7), coagulation (Chapter 6), endothelial 
cell activation (Chapter 6), body temperature (Chapter 6), alterations platelet count 
and liver enzymes (Chapter 5 and 6), parasite growth (Chapter 6) and speed of 
acquisition of immunity (Chapter 7). In general, our CHMI participants can be divided 
activation and laboratory abnormalities such as liver function parameters. The anti-
and limited increase in laboratory abnormalities, for instance, no abnormalities in liver 
responders experience limited clinical symptoms during early disease, but the absence of 
treated in an early phase of disease, no conclusions about causality can be drawn between 
the early host response in CHMIs and disease severity during advanced clinical disease as 
they cannot be compared. However, it can be speculated that the initial lack of parasite 
threshold of parasite density is reached. 
infection
As the initial cytokine response correlates with early clinical pathology (58, 65) and increase 
in parasitaemia (65), the diversity in host response in a homogenous group of CHMI 
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protective immunity after immunization and those who did not (35). Chapter 7 describes 
that this initial immune response upon infection was associated with the baseline immune 
malaria infection whereas a more immune-modulatory immune response is associated 
with a lower baseline immune activation status. The baseline immune activations status 
was associated with the number of immunizations needed for acquisition of protective 
sterile immunity. 
Pre-infection immunity is also known as innate immune memory or trained immunity 
(66). The host immune response is classically divided in an innate and adaptive response 
this paradigm is challenged by relative recent results showing adaptive characteristics 
of the innate immune response. After encountering pathogens or after vaccinations, the 
initial host response shows an increased responsiveness to a secondary stimulus, which 
induced by BCG vaccination which results a long-lasting Th1 skewed immune response 
(67).
a malaria infection is limited (68). One study showed a negative association between 
parasitaemia and an early NK-cell activation in a subset of CHMI participants that received 
a BCG-vaccine before challenge (68), but not in the individuals that did not receive the 
vaccination. In addition, in a malaria endemic area a lower number of malaria episodes 
on left upper arms (69). The BCG-vaccine induces immunological activation (trained 
immunity) results in a decrease in non-tuberculosis mortality in newborns (70). In adults 
stimuli in recent BCG vaccinated adults (71). Remarkably, after CHMI following a BCG-
vaccine, two groups were observed within the BCG-vaccinated individuals similar to the 
groups found in the CHMIs described in Chapter 6 and 7: those with and without an 
P. falciparum
studies are highly interesting and it seems that multiple pro- and immune modulatory 
might force an individual in a more ‘tolerant’ or more ‘memory’ direction (72), thereby 
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Chapter 7 shows that the immune activation status before immunization is associated 
with to the initial cytokine response and to the number of immunizations needed for the 
acquisition of protective immunity. These aspects need to be taken into account in the 
development of vaccine regimens. Multiple malaria episodes result in a tolerant immune 
response against P. falciparum
infection. In addition, areas where helminth infections are prevalent are overlapping 
with countries in which malaria is endemic (73, 74). Consequently, co-infections with 
both parasites occur often and interact. As helminth infections up regulate an Th2-type 
studies are not conclusive on whether the helminth infections have a protective or harmful 
(79, 80) production upon vaccination is decreased during a helminth infection. This 
underlines the importance of further analysis of the relation between helminth infections, 
immune activation status, pre-existing immunity and cytokine response. Especially as 
response upon malaria is made, while it might have major implications. Determination of 
the immune activation status before immunization might lead to a prediction of the host 
can be altered. This might be done by treatment of helminth infections (81), but also 
might lead to an alteration of vaccination schedules and programs in which a part of the 
populations might be selected to receive additional immunizations. 
Determination of the immune activation status
Questions on how immune activation status can be measured are remaining. In Chapter 
7
responders after infection and between fast and slow responders after immunization. 
These individuals have a high level of immune activation status (the immune system 
steady state. A functional read-out in which baseline immune cells are stimulated and 
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immune activation before vaccination in malaria endemic areas or before challenge in a 
CHMI. From these results priming into a direction of higher immune activation or selecting 
individuals that need an adjusted vaccination schedule or adjuvant can be considered. 
Final conclusions and future perspectives 
of the heterogeneity in the host immune response after a P. falciparum infection on the 
disease severity and acquisition of immunity after vaccination. This thesis showed that 
baseline immune activation status and with more clinical symptoms during CHMI and a 
quicker acquisition of immunity after immunization than an initial immune-modulatory 
after administration of e.g. hepatitis B vaccine. In addition, administration of a malaria 
to evaluate as the active immune system after the BCG-vaccination might increase malaria 
in ‘personalized vaccination’ in which an adjusted vaccination schedule can be given 
according to the baseline immune activation status. A second application can be priming 
Additionally, the research described in this thesis showed that the use of P. berghei GAPs 
has high potential as vaccination strategy and should be evaluated for further improvement 
e.g. by inserting more repeats or preserved P. falciparum genes.  
  |  Chapter 
References
controlled human malaria Infection. PLoS computational biology. 2017;13(1):e1005255.
2. Casares S, Brumeanu TD, Richie TL. The RTS,S malaria vaccine. Vaccine. 2010;28(31):4880-
94.
3. Kester KE, Cummings JF, Ockenhouse CF, Nielsen R, Hall BT, Gordon DM, et al. Phase 2a 
trial of 0, 1, and 3 month and 0, 7, and 28 day immunization schedules of malaria vaccine 
RTS,S/AS02 in malaria-naive adults at the Walter Reed Army Institute of Research. Vaccine. 
2008;26(18):2191-202.
4. Kester KE, McKinney DA, Tornieporth N, Ockenhouse CF, Heppner DG, Jr., Hall T, et al. A 
regimen of liquid and lyophilized formulations of the candidate malaria vaccine RTS,S/AS02A 
in malaria-naive adults. Vaccine. 2007;25(29):5359-66.
5. Stoute JA, Slaoui M, Heppner DG, Momin P, Kester KE, Desmons P, et al. A preliminary 
evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum 
malaria. RTS,S Malaria Vaccine Evaluation Group. The New England journal of medicine. 
1997;336(2):86-91.
immune responses following immunization with the RTS,S malaria vaccine. The Journal of 
infectious diseases. 1998;178(4):1139-44.
7. Kester KE, Cummings JF, Ofori-Anyinam O, Ockenhouse CF, Krzych U, Moris P, et al. 
Randomized, double-blind, phase 2a trial of falciparum malaria vaccines RTS,S/AS01B 
protection. The Journal of infectious diseases. 2009;200(3):337-46.
8. Sacarlal J, Aide P, Aponte JJ, Renom M, Leach A, Mandomando I, et al. Long-term safety 
infectious diseases. 2009;200(3):329-36.
9. Agnandji ST, Fendel R, Mestre M, Janssens M, Vekemans J, Held J, et al. Induction of Plasmodium 
RTS,S/AS01(E) and RTS,S/AS02(D). PloS one. 2011;6(4):e18559.
10. Agnandji ST, Lell B, Fernandes JF, Abossolo BP, Methogo BG, Kabwende AL, et al. A phase 3 
trial of RTS,S/AS01 malaria vaccine in African infants. The New England journal of medicine. 
2012;367(24):2284-95.
of RTS,S/AS01E and its interaction with malaria exposure. The New England journal of 
medicine. 2013;368(12):1111-20.
Lancet (London, England). 2015;386(9988):31-45.
of RTS,S/AS01 malaria vaccine among young african children. The New England journal of 
medicine. 2016;374(26):2519-29.
14. Roestenberg M, McCall M, Hopman J, Wiersma J, Luty AJ, van Gemert GJ, et al. Protection 
against a malaria challenge by sporozoite inoculation. The New England journal of medicine. 
2009;361(5):468-77.
15. Roestenberg M, Teirlinck AC, McCall MB, Teelen K, Makamdop KN, Wiersma J, et al. Long-
term protection against malaria after experimental sporozoite inoculation: an open-label 
follow-up study. Lancet (London, England). 2011;377(9779):1770-6.
General discussion  |  
16. Casares S, Richie TL. Immune evasion by malaria parasites: a challenge for vaccine 
development. Current opinion in immunology. 2009;21(3):321-30.
17. Scheller LF, Azad AF. Maintenance of protective immunity against malaria by persistent 
hepatic parasites derived from irradiated sporozoites. Proceedings of the National Academy of 
Sciences of the United States of America. 1995;92(9):4066-8.
18. Mueller AK, Deckert M, Heiss K, Goetz K, Matuschewski K, Schluter D. Genetically attenuated 
Plasmodium berghei liver stages persist and elicit sterile protection primarily via CD8 T cells. 
The American journal of pathology. 2007;171(1):107-15.
19. Nganou-Makamdop K, Sauerwein RW. Liver or blood-stage arrest during malaria sporozoite 
immunization: the later the better? Trends in parasitology. 2013;29(6):304-10.
against sporozoite-induced falciparum malaria. The American journal of the medical sciences. 
1973;266(6):398-403.
21. Seder RA, Chang LJ, Enama ME, Zephir KL, Sarwar UN, Gordon IJ, et al. Protection against 
malaria by intravenous immunization with a nonreplicating sporozoite vaccine. Science (New 
York, NY). 2013;341(6152):1359-65.
22. Epstein JE, Paolino KM, Richie TL, Sedegah M, Singer A, Ruben AJ, et al. Protection against 
Plasmodium falciparum malaria by PfSPZ Vaccine. JCI insight. 2017;2(1):e89154.
23. Lyke KE, Ishizuka AS. Attenuated PfSPZ Vaccine induces strain-transcending T cells and durable 
protection against heterologous controlled human malaria infection. 2017;114(10):2711-6.
vaccine against Plasmodium falciparum via direct venous inoculation in healthy malaria-
exposed adults in Mali: a randomised, double-blind phase 1 trial. The Lancet Infectious 
diseases. 2017;17(5):498-509.
against malaria by immunization with radiation-attenuated Plasmodium falciparum 
sporozoites. The Journal of infectious diseases. 2002;185(8):1155-64.
26. van Schaijk BC, Ploemen IH, Annoura T, Vos MW, Foquet L, van Gemert GJ, et al. A genetically 
attenuated malaria vaccine candidate based on P. falciparum
sporozoites. eLife. 2014;3.
27. Butler NS, Schmidt NW, Vaughan AM, Aly AS, Kappe SH, Harty JT. Superior antimalarial 
immunity after vaccination with late liver stage-arresting genetically attenuated parasites. 
Cell host & microbe. 2011;9(6):451-62.
28. Finney OC, Keitany GJ, Smithers H, Kaushansky A, Kappe S, Wang R. Immunization with 
genetically attenuated P. falciparum 
block hepatocyte invasion by sporozoites. Vaccine. 2014;32(19):2135-8.
29. Vaughan AM, Sack BK, Dankwa D, Minkah N, Nguyen T, Cardamone H, et al. A Plasmodium 
parasite with complete late liver stage arrest protects against preerythrocytic and erythrocytic 
stage infection in mice. Infection and immunity. 2018;86(5).
30. Labaied M, Harupa A, Dumpit RF, Coppens I, Mikolajczak SA, Kappe SH. Plasmodium yoelii 
sporozoites with simultaneous deletion of P52 and P36 are completely attenuated and confer 
sterile immunity against infection. Infection and immunity. 2007;75(8):3758-68.
31. Spring M, Murphy J, Nielsen R, Dowler M, Bennett JW, Zarling S, et al. First-in-human 
evaluation of genetically attenuated Plasmodium falciparum sporozoites administered by bite 
of Anopheles mosquitoes to adult volunteers. Vaccine. 2013;31(43):4975-83.
32. Kublin JG, Mikolajczak SA, Sack BK, Fishbaugher ME, Seilie A, Shelton L, et al. Complete 
attenuation of genetically engineered Plasmodium falciparum sporozoites in human subjects. 
Science translational medicine. 2017;9(371).
33. Mendes AM, Reuling IJ. Pre-clinical evaluation of a P. berghei-based whole-sporozoite malaria 
vaccine candidate. 2018;3:54.
  |  Chapter 
34. Mendes AM, Machado M, Goncalves-Rosa N. A Plasmodium berghei sporozoite-based 
vaccination platform against human malaria. 2018;3:33.
vaccine trials. Seminars in immunology. 2018;39:52-64.
36. Carvalho LH, Sano G, Hafalla JC, Morrot A, Curotto de Lafaille MA, Zavala F. IL-4-secreting 
CD4+ T cells are crucial to the development of CD8+ T-cell responses against malaria liver 
stages. Nature medicine. 2002;8(2):166-70.
37. Tarun AS, Dumpit RF, Camargo N, Labaied M, Liu P, Takagi A, et al. Protracted sterile 
protection with Plasmodium yoelii pre-erythrocytic genetically attenuated parasite malaria 
The Journal of infectious diseases. 2007;196(4):608-16.
interferon, CD8+ T cells and antibodies required for immunity to malaria sporozoites. Nature. 
1987;330(6149):664-6.
39. Rodrigues M, Nussenzweig RS, Zavala F. The relative contribution of antibodies, CD4+ and 
CD8+ T cells to sporozoite-induced protection against malaria. Immunology. 1993;80(1):1-5.
immunity against malaria initiated by CD8+ T cells in the Plasmodium yoelii model. Journal 
of immunology (Baltimore, Md : 1950). 1999;163(2):884-92.
41. Belnoue E, Costa FT, Frankenberg T, Vigario AM, Voza T, Leroy N, et al. Protective T cell 
immunity against malaria liver stage after vaccination with live sporozoites under chloroquine 
treatment. Journal of immunology (Baltimore, Md : 1950). 2004;172(4):2487-95.
42. Bijker EM, Schats R, Visser LG, Sauerwein RW, Scholzen A. Ex vivo lymphocyte phenotyping 
during Plasmodium falciparum sporozoite immunization in humans. Parasite immunology. 
2015;37(11):590-8.
43. Chaudhury S, Ockenhouse CF, Regules JA, Dutta S, Wallqvist A, Jongert E, et al. The biological 
function of antibodies induced by the RTS,S/AS01 malaria vaccine candidate is determined by 
44. Kurtovic L, Behet MC, Feng G, Reiling L, Chelimo K, Dent AE, et al. Human antibodies activate 
complement against Plasmodium falciparum sporozoites, and are associated with protection 
against malaria in children. BMC medicine. 2018;16(1):61.
45. Ubillos I, Ayestaran A, Nhabomba AJ, Dosoo D, Vidal M, Jimenez A, et al. Baseline exposure, 
following RTS,S/AS01E vaccination in African children. BMC medicine. 2018;16(1):197.
46. Cockburn IA, Tse SW, Zavala F. CD8+ T cells eliminate liver-stage Plasmodium berghei 
47. Cockburn IA, Tse SW, Radtke AJ, Srinivasan P, Chen YC, Sinnis P, et al. Dendritic cells and 
hepatocytes use distinct pathways to process protective antigen from Plasmodium in vivo. 
PLoS pathogens. 2011;7(3):e1001318.
48. Fernandez-Ruiz D, Ng WY, Holz LE, Ma JZ, Zaid A, Wong YC, et al. Liver-resident memory 
CD8(+) T cells form a front-line defense against malaria liver-stage infection. Immunity. 
2016;45(4):889-902.
49. Douradinha B, van Dijk M, van Gemert GJ, Khan SM, Janse CJ, Waters AP, et al. Immunization 
Plasmodium berghei sporozoites induces a long-
and vaccines. 2011;9(1):6.
50. Nganou-Makamdop K, Ploemen I, Behet M, Van Gemert GJ, Hermsen C, Roestenberg M, et 
al. Reduced Plasmodium berghei
after intradermal immunization. Parasite immunology. 2012;34(12):562-9.
General discussion  |  
biopsy: a systematic review and meta-analysis. Gastrointestinal endoscopy. 2019;89(2):238-
46.e3.
52. Ng S, March S, Galstian A, Gural N, Stevens KR, Mota MM, et al. Towards a humanized mouse 
53. Siu E, Ploss A. Modeling malaria in humanized mice: opportunities and challenges. Annals of 
the New York Academy of Sciences. 2015;1342:29-36.
54. Vaughan JA, Scheller LF, Wirtz RA, Azad AF. Infectivity of Plasmodium berghei sporozoites 
delivered by intravenous inoculation versus mosquito bite: implications for sporozoite vaccine 
trials. Infection and immunity. 1999;67(8):4285-9.
randomized feasibility trial comparing four antimalarial drug regimens to induce Plasmodium 
falciparum gametocytemia in the controlled human malaria infection model. 2018;7.
56. Collins KA, Wang CY, Adams M, Mitchell H, Rampton M, Elliott S, et al. A controlled human 
malaria infection model enabling evaluation of transmission-blocking interventions. The 
Journal of clinical investigation. 2018;128(4):1551-62.
parasite tolerance vary with malaria transmission intensity. 2017;16(1):145.
58. Hermsen CC, Konijnenberg Y, Mulder L, Loe C, van Deuren M, van der Meer JW, et al. Circulating 
concentrations of soluble granzyme A and B increase during natural and experimental 
Plasmodium falciparum infections. Clinical and experimental immunology. 2003;132(3):467-
72.
59. Kurup SP, Obeng-Adjei N, Anthony SM, Traore B, Doumbo OK, Butler NS, et al. Regulatory T 
cells impede acute and long-term immunity to blood-stage malaria through CTLA-4. Nature 
medicine. 2017;23(10):1220-5.
60. Jagannathan P, Kim CC, Greenhouse B, Nankya F, Bowen K, Eccles-James I, et al. Loss and 
dysfunction of Vdelta2(+) gammadelta T cells are associated with clinical tolerance to malaria. 
Science translational medicine. 2014;6(251):251ra117.
61. Walk J, Stok JE, Sauerwein RW. Can patrolling liver-resident T cells control human malaria 
parasite development? Trends in immunology. 2019;40(3):186-96.
62. Manning L, Davis TM. The mechanistic, diagnostic and prognostic utility of biomarkers in 
severe malaria. Biomarkers in medicine. 2013;7(3):363-80.
63. Bediako Y, Adams R, Reid AJ, Valletta JJ, Ndungu FM, Sodenkamp J, et al. Repeated clinical 
medicine. 2019;17(1):60.
64. White NJ, Turner GD, Medana IM, Dondorp AM, Day NP. The murine cerebral malaria 
phenomenon. Trends in parasitology. 2010;26(1):11-5.
to human malaria: heterogeneous cytokine responses to blood-stage Plasmodium falciparum 
correlate with parasitological and clinical outcomes. Journal of immunology (Baltimore, Md : 
1950). 2006;177(8):5736-45.
66. Netea MG, Joosten LA, Latz E, Mills KH, Natoli G, Stunnenberg HG, et al. Trained immunity: 
a program of innate immune memory in health and disease. Science (New York, NY). 
2016;352(6284):aaf1098.
of BCG vaccination on both heterologous Th1/Th17 responses and innate trained immunity. 
Journal of innate immunity. 2014;6(2):152-8.
68. Walk J, de Bree LCJ, Graumans W, Stoter R, van Gemert GJ, van de Vegte-Bolmer M, et al. 
Outcomes of controlled human malaria infection after BCG vaccination. 2019;10(1):874.
  |  Chapter 
69. Roth A, Gustafson P, Nhaga A, Djana Q, Poulsen A, Garly ML, et al. BCG vaccination scar 
associated with better childhood survival in Guinea-Bissau. International journal of 
epidemiology. 2005;34(3):540-7.
70. Jensen KJ, Larsen N, Biering-Sorensen S, Andersen A, Eriksen HB, Monteiro I, et al. Heterologous 
a randomized-controlled trial. The Journal of infectious diseases. 2015;211(6):956-67.
71. Kleinnijenhuis J, Quintin J, Preijers F, Joosten LA, Ifrim DC, Saeed S, et al. Bacille Calmette-
reprogramming of monocytes. Proceedings of the National Academy of Sciences of the United 
States of America. 2012;109(43):17537-42.
BCG-induced trained immunity and the response to intravesical BCG therapy for bladder 
cancer. PLoS pathogens. 2014;10(10):e1004485.
73. Hotez PJ, Brindley PJ, Bethony JM, King CH, Pearce EJ, Jacobson J. Helminth infections: the 
great neglected tropical diseases. The Journal of clinical investigation. 2008;118(4):1311-21.
74. Salazar-Castanon VH, Legorreta-Herrera M, Rodriguez-Sosa M. Helminth parasites alter 
protection against Plasmodium infection. 2014;2014:913696.
75. Degarege A, Legesse M, Medhin G, Animut A, Erko B. Malaria and related outcomes in patients 
with intestinal helminths: a cross-sectional study. BMC infectious diseases. 2012;12:291.
76. Nacher M, Singhasivanon P, Yimsamran S, Manibunyong W, Thanyavanich N, Wuthisen R, 
et al. Intestinal helminth infections are associated with increased incidence of Plasmodium 
falciparum malaria in Thailand. The Journal of parasitology. 2002;88(1):55-8.
77. Le Hesran JY, Akiana J, Ndiaye el HM, Dia M, Senghor P, Konate L. Severe malaria attack is 
associated with high prevalence of Ascaris lumbricoides infection among children in rural 
Senegal. Transactions of the Royal Society of Tropical Medicine and Hygiene. 2004;98(7):397-
9.
78. Haseeb MA, Craig JP. Suppression of the immune response to diphtheria toxoid in murine 
schistosomiasis. Vaccine. 1997;15(1):45-50.
and humoral responses following tetanus vaccination in human onchocerciasis: a possible 
role for interleukin-10. The Journal of infectious diseases. 1998;178(4):1133-8.
immune responses in humans infected with Schistosoma mansoni. The Journal of infectious 
diseases. 1996;173(1):269-72.
81. Sanchez-Ramon S, Conejero L, Netea MG, Sancho D, Palomares O, Subiza JL. Trained 
immunity-based vaccines: a new paradigm for the development of broad-spectrum anti-
infectious formulations. Frontiers in immunology. 2018;9:2936.
Samenvatting  |  
Samenvatting
Malaria is een infectieziekte met meer dan 200 miljoen nieuwe ziektegevallen en 435.000 
doden per jaar. De ziekte komt vooral voor in sub-Sahara Afrika en het zijn met name 
kinderen jonger dan 5 jaar die aan malaria overlijden. Malaria wordt veroorzaakt door 
Plasmodium parasieten welke worden overgedragen op de mens tijdens een beet van 
besmette vrouwelijke Anopheles muggen. Van de verschillende Plasmodium soorten die 
de mens kunnen infecteren, veroorzaakt P. falciparum het ernstigste ziektebeeld. Door 
klamboes en insecticiden daalde de malaria gerelateerde mortaliteit en morbiditeit in de 
periode 2000 tot 2015. Echter, door de opkomst van resistente Plasmodium parasieten 
en Anopheles muggen wordt er sinds 2015 weer een stijging in de incidentie van malaria 
malaria vaccin zou hierbij een belangrijke rol kunnen spelen. Voor de ontwikkeling van 
een malaria vaccin is goed begrip nodig van de gastheer respons van de mens op de P. 
falciparum parasiet. 
Dit proefschrift bestaat uit twee delen: in deel I staat centraal het ontwikkelen van een 
malaria vaccin en het optimaliseren voor een testmodel voor transmissie blokkerende 
vaccins. Hierbij werd gebruik gemaakt van gecontroleerde humane malaria infectie 
studies (CHMI),  waarbij gezonde vrijwilligers met malaria worden geïnfecteerd 
d.m.v. muggenbeten of door het intraveneus toedienen van P. falciparum geïnfecteerde 
erytrocyten. In deel II wordt ingegaan op hoe en waarom het immuunsysteem van 
vergelijkbare gezonde individuen zeer verschillend kan reageren op een malaria infectie. 
Om deze vragen te beantwoorden, is gebruik gemaakt van bloedsamples verzameld van 
verschillende CHMI studies die eerder waren verricht. 
Deel I - Malaria vaccins
Deel I van dit proefschrift start met de beschrijving van een CHMI waarbij vrijwilligers 
geïmmuniseerd worden met de P. berghei parasiet, een knaagdieren Plasmodium soort 
welke niet pathogeen is voor mensen (hoofdstuk 2). Deze P. berghei parasieten zijn 
circumsporozoite protein (CPS) van P. falciparum zijn toegevoegd aan P. berghei. Op deze 
kan infecteren en immunogeen is maar niet kan resulteren in een infectie van humane 
erytrocyten. Tijdens het eerste deel van deze klinische studie is de veiligheid van het 
product (PbVac) aangetoond. Het tweede deel van deze studie laat zien dat een immunisatie 
met PbVac leidt tot ontwikkeling van antilichamen die resulteren in een daling van 90%-
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99% van de P. falciparum leverinfectie, waardoor veel minder parasieten zich in de lever 
ontwikkelen en een vertraging in het ontwikkelen van de malaria bloedfase optreedt. 
Met het huidige CHMI-model kunnen pre-erytrocytaire malaria vaccins getest worden. 
Echter, voor het testen van vaccins die de transmissie van P. falciparum parasieten van 
mens naar de mug blokkeren is echter nog geen goed model beschikbaar. Voor infectie 
van muggen tijdens een CHMI moeten de geïnfecteerde vrijwilligers hoge aantallen 
geslachtelijke parasieten (gametocyten) ontwikkelen. Deze gametocyten worden 
vervolgens opgenomen door nog niet-geïnfecteerde muggen tijdens een bloedmaal dat zij 
nemen op de huid van de vrijwilliger. Voor het bereiken van een hoog aantal gametocyten, 
is een hoge concentratie van parasieten in het bloed van de vrijwilligers nodig wat leidt 
hoofdstuk 3 is een eerder voorgesteld CHMI-
transmissie model geoptimaliseerd door een groep vrijwilligers te infecteren d.m.v. het 
intraveneus toedienen van geïnfecteerde erytrocyten (bloed inoculum). Infectie met een 
bloed inoculum blijkt te resulteren in alleen milde klinische symptomatologie en in een 
hoger aantal gametocyten en daarmee geïnfecteerde muggen dan na een infectie d.m.v. 
transmissie blokkerende malaria vaccins te testen. 
Deel II - Heterogeniteit in de immuunrespons na een malaria infectie
In een literatuurbespreking in hoofdstuk 4 wordt ingegaan op het gebruik van 
angiopoietine-1 en angiopoietine-2 om het ziektebeloop van malaria te kunnen voorspellen 
en daar therapeutische consequenties aan te verbinden. De markers laten grote verschillen 
van mortaliteit. Mogelijk liggen het verschil in malaria transmissie (e.g. hoog vs. laag 
endemische gebieden) in de studie populaties en daarmee de verschillen in de malaria 
immuniteit hieraan ten grondslag. Het lijkt niet mogelijk om de complexe pathogenese en 
immuunrespons tijdens malaria te voorspellen met één enkele marker. 
Ook bij individuen zonder immuniteit voor malaria verloopt de gastheerrespons zeer 
wisselend blijkt uit de hoofdstukken 5, 6 en 7. In hoofdstuk 5 wordt beschreven hoe 
behandeling met anti-malaria medicatie gestart wordt. Deze afwijkingen correleren met 
volledig. Deze bevindingen zijn belangrijk omdat zij laten zien dat leverenzymstoornissen 
van anti-malaria medicatie waarbij leverenzymstoornissen worden geobserveerd. 
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Tijdens een CHMI kunnen twee groepen vrijwilligers worden onderscheiden (hoofdstuk 
6
symptomen zoals koorts en activatie van de stollingscascade. In de andere groep 
geobserveerd, zij hebben minder klinische symptomen en geen evidente activatie van de 
voor de individuele gastheerreactie op een malaria infectie. In hoofdstuk 7 wordt 
onderzocht wat de mogelijke oorzaak is voor de verschillen in de gastheer reactie tussen 
de vrijwilligers na een malaria infectie. Er wordt aangetoond dat de vrijwilligers voor 
infectie al verschillend zijn in de mate van de activiteit van het immuunsysteem (de mate 
en de samenstelling van de geproduceerde cytokines bij een gelijke prikkel). Een initieel 
vice versa. Ook de snelheid waarmee malaria immuniteit verworven wordt hangt samen 
hangen met de pre-infectie statusvan het immuunsysteem.
Samenvattend presenteert dit proefschrift een nieuwe innovatieve manier van malaria 
immunisatie waarbij een knaagdierenmalaria wordt gebruikt als vector, waaraan een 
belangrijk antigeen van P. falciparum was toegevoegd. Ook al heeft het gebruik van 
deze huidige vector niet geresulteerd in steriele protectie, de mogelijkheid van het 
toevoegen van meer geconserveerde P. falciparum genen maakt dit een veelbelovende 
immunisatiestrategie. Ook laat dit proefschrift een aangepast CHMI-model zien waarin 
Het tweede deel van dit proefschrift laat zeer wisselende gastheerreacties zien bij 
CHMI-vrijwilligers na een malaria infectie welke correleren met de activiteit van het 
immuunsysteem voor infectie. Toekomstige studies zullen zich richten op het meten van 
deze activiteit d.m.v. functionele testen. Op deze manier kan de invloed van de activiteit 
van het immuunsysteem op het verwerven van immuniteit gemeten en mogelijk beïnvloed 
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Rond de eeuwwisseling bouwde een van mijn broers een hut in onze achtertuin met 
2 verdiepingen van ongeveer 5 meter hoog. Waar verschillende schuren in en rondom 
Lekkerkerk instortten tijdens een stormachtige herfst, bleef de hut staan. Het bouwwerk 
kreeg zelfs een geveltekst: ‘met geduld volbracht’. Terugkijkend op de afgelopen 4 jaren, 
onderschrijf ik deze stelling (wellicht in gezelschap van anderen). Echter, in tegenstelling 
tot het eenzame werk van het bouwen van de hut destijds, hebben aan dit werk velen een 
onmisbare bijdrage geleverd.
Mijn promotoren, prof. dr. A. Verbon en prof. dr. R. Sauerwein en co-promotoren dr. 
J. van Hellemond en dr. P. van Genderen: wat een geweldig team heb ik om me heen 
gehad. Annelies, dank voor je goede opbouwende reacties op de vele stukken die me 
weer motivatie en energie gaven om verder aan de slag te gaan. Robert, ik ben dankbaar 
voor de kans die je me geboden hebt tijdens en na de CHMI-trial in Rotterdam. Ik heb 
een fantastische tijd gehad in Nijmegen en heb me bijzonder welkom gevoeld in jouw 
teruggaan naar de essentie van de onderzoeksvraag en het vertellen van een verhaal zijn 
slechts een kleine selectie van zaken die ik mee zal nemen. Jaap, ik bewonder je geduld, 
discipline en structuur in je manier van werken. Ik kon altijd bij je terecht voor vragen en 
advies en kreeg een snelle reactie. Dank voor je goede begeleiding! Perry, direct na mijn 
afstuderen gaf je me de kans om te participeren in mooie onderzoeken. Dank hiervoor aan 
jou en aan de medewerkers van de Travel Clinic. 
Leden van de leescommissie: Prof. dr. P.M. van Hagen, Prof. dr. R.A. de Man en 
Prof. dr. M. van Vugt. Graag wil ik u bedanken voor de interesse in mijn proefschrift en 
het plaatsnemen in de leescommissie. 
een mooie tijd gehad met jullie in de kantoortuin. Dank Maarten en Manon voor jullie 
vriendschap, de pasta staat binnenkort klaar!
Colleagues from the Radboudumc: thanks for the wonderful time during my stay in 
Nijmegen. Manon and Saskia, thanks for the support, friendship, working together in the 
studies and, especially for participating in the silly walk routine. It was a pleasure being 
part of ‘het hok’, Elle and Iris. Also, thanks to Zen and Amanda who helped me, a clumsy 
MD, in the lab. Isaie, it was a pleasure working with you. Jona, thanks for your support 
with the many samples and for teaching me the FACS world! Prof. dr. Bousma, Teun and 
Matthew, thanks for your inspiration, brainstorming on ideas and support. Also, thanks 
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to Matthijs, Geert-Jan, Marga, Taco, Roos, Katharine, Kjerstin, Kartharin, Wouter, Lisette, 
Youri, Annie, Chiara, Meta, Nick, Laura, Roel, Rianne, Felix, Daphne and Annemieke and 
colleagues from the Clinical Research Centre Nijmegen. I enjoyed working in Nimma with 
you very much!  
Ook in de verschillende laboratoria heb ik veel hulp gekregen: Rob, wat een schema’s zijn 
er gemaakt tijdens de klinische studies. Je had altijd scherp inzicht in wat logistiek de 
beste opties waren en mede dankzij jou liggen de samples van de studies gestructureerd 
in de -80 ºC vriezer. Ook tijdens het laboratorium werk heb je me veel geholpen, dank 
hiervoor! Ook Wim Dik en Rolf Urbanus wil ik bedanken voor de hulp bij immunologische 
en hematologische vragen en het beschikbaar stellen van de laboratoria. 
Al zullen weinigen van hen dit boekje onder ogen krijgen, ook dank aan de vrijwilligers 
van de CHMI-studies. Zonder jullie was dit belangrijke onderzoek niet mogelijk. 
Lieve familie en vrienden: bedankt voor jullie steun en interesse. Het is een voorrecht om 
jullie om me heen te hebben. Lieve Edward, dank voor al je support de afgelopen tijd. Nu 
samen op naar een echte berg!
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